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Abstract 
 
The thesis entitled “Design and synthesis of modified Peptide Nucleic Acid (PNAs) with 
improved physico-chemical properties for DNA, RNA and Micro RNA targeting” is 
divided into four chapters. Chapter one deals with the introduction to Peptide Nucleic Acid 
(PNA) its properties and its applications. The second chapter deals with the synthesis of 
modified PNAs with and without fluorescein isothiourea and its kinetic studies by using 
stopped-flow technique. The third chapter deals with the design, synthesis and 
characterization of functionalized PNAs with heterobifunctional linker and their conjugation 
with magnetic nanoparticles (MNPs) for miRNA targeting. The fourth chapter deals with 
design and synthesis of modified thymine monomer PNA and homothymine decamer PNA 
sequence with gold(I) complexes for cellular imaging. 
Chapter 1: Peptide Nucleic Acid (PNA) 
Peptide nucleic acids (PNA) are DNA analogues in which the sugar phosphate backbone is 
replaced by repetitive units of N-(2-aminoethyl) glycine subunits. PNAs exhibit unique 
properties that set them apart from other traditional DNA analogues they are achiral, neutral 
with high chemical and biochemical stability. They hybridize to complementary DNA, RNA 
or PNA sequences according to the Watson-Crick base-pairing rules and leading to PNA-
DNA duplexes are more stable than DNA-DNA duplexes. These favourable features have led 
to application of PNAs in various research areas such as antisense and antigene therapies, 
molecular biology and functional genomics, PNA as a probe for diagnosis and detection and 
PNA as a biosensor (Figure 1) 
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Figure 1: Peptide Nucleic Acid oligomer (a) with its complementary DNA (b) 
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PNA Applications 
The potential applications of PNAs can be divided in three different fields like diagnostics, 
molecular biology and therapy. It is important to notice that new techniques are continuously 
being developed. However, some techniques are very important because they represent 
“historically” steps in the development and use of PNAs. The stability of PNA/DNA 
complexes makes PNAs powerful tools in antisense and antigene applications, and as 
markers in DNA screening assays. The major drawbacks of PNA are like poor water 
solubility, inefficient cell uptake, self-aggregation and uncertainty in directionality of binding 
restricts PNA extensive applications. 
Chemical Modifications of PNA 
The major limitations of the therapeutic applications of PNAs are their poor solubility in 
aqueous media due to self-aggregation and an insufficient cellular uptake. In order to improve 
PNA solubility in aqueous media, the cellular uptake, the binding selectivity towards RNA 
versus DNA, or to stabilise duplex or triplex structures, several analogues of modified PNA 
have been synthesised over the years. 
Aim of the thesis 
This research work concerns with the design, synthesis, characterization and analytical 
studies of newly modified Peptide Nucleic Acids (PNAs), [which is mimic of DNA and 
RNA] in non conventional manner for the applications in DNA interactions, RNA targeting 
and cellular imaging. 
Chapter 2: Design and synthesis of modified peptide nucleic acids (PNAs) with and 
without fluorescein isothiourea and its kinetic studies by using stopped-flow technique.  
Synthesis of aminoethylglycine PNA monomer and PNA decamers 
In the present section, the synthesis of newly modified lysine based Peptide Nucleic Acids 
(PNA) decamer 1, with the TCACTAGATG sequence of nucleobases, and the corresponding 
fluorescent PNA-FITU (fluorescein isothiourea) decamer 2 were synthesized with standard 
manual Boc-based chemistry using MBHA resin loaded with the N(α)-Boc-N(ε)-Fmoc-L-
lysine (Figure 2) The interaction of both decamers 1 and 2 with the complementary parallel 
and antiparallel DNA was followed by steady-state and stopped-flow fluorescence intensity. 
The kinetics of the PNA-DNA duplex formation has been studied. In particular, fluorescence 
stopped-flow technique has been exploited to compare the affinity of two PNA-DNA 
vi 
 
duplexes: using parallel and antiparallel DNA, such data would be very important for the 
evaluation and improvement of antisense reagents and of diagnostic probes based on PNA. 
 
Figure 2: Synthesis of Peptide Nucleic Acids (PNAs) decamer (1) and (2) 
Kinetic studies of PNA: DNA duplexes by fluorescence Stopped-flow technique 
The interaction of both decamers 1 and 2 with the complementary parallel and antiparallel 
DNA was followed by steady-state and stopped-flow fluorescence intensity. The kinetics of 
the PNA-DNA duplex formation has been studied. In particular, fluorescence stopped-flow 
technique has been exploited to compare the affinity of two PNA-DNA duplexes: using 
parallel and antiparallel DNA, such data would be very important for the evaluation and 
improvement of antisense reagents and of diagnostic probes based on PNA. 
Chapter 3: Design, synthesis and characterization of functionalized PNAs with 
heterobifunctional linker and their conjugation with magnetic nanoparticles (MNPs) for 
miRNA targeting. 
Introduction to Magnetic nanoparticles and its properties 
Magnetic nanoparticles (MNPs) are a class of nanoparticles which can be manipulated using 
magnetic fields. The particles are made of magnetic elements such as iron, nickel and cobalt 
or their chemical compounds. During the past decade magnetic nanoparticles have been 
intensively studied, not only for general scientific interest but also due to the large number of 
their possible applications, such as catalysis, biomedicine, magnetic resonance imaging, data 
storage and environmental remediation.  
The physical and chemical properties of magnetic nanoparticles largely depend on the 
synthesis method and on their chemical structure. In most cases, their size range from 1 to 
vii 
 
100 nm, that is the size range necessary for them to display superparamagnetism. In a more 
general way, the properties of the nanocrystals strongly depend upon the dimension of the 
nanoparticles. Therefore it is important to control their proprieties and studies related to fluid 
stability, control of surfactants, particle sizes, materials, and physical behaviour are essential 
to understand ferrofluid behaviour to improve applications or develop new nanoparticles 
(Figure 3). 
 
Figure 3: TEM imaging of iron nanoparticles. 
In the present section we focused our attention on to the design, synthesis and 
characterization of functionalized PNA 3 with heterobifunctional linker and their conjugation 
with magnetic nanoparticles 4 (MNPs) for miRNA targeting. The MNPs bound to PNA can 
be exploited both as contrast agents for magnetic resonance imaging (MRI) and as sources of 
local overheating through the application of an alternating magnetic field (Magnetic Fluid 
Hyperthermia, MFH). Moreover, the microRNAs targeting ability of these tools for 
selectively delivering magnetic nanoparticles and destroying, by hyperthermia, targeted cells 
in multicellular organisms. (Figure 4) 
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Figure 4: Functionalisation of magnetic nanoparticles with PNA through heterobifunctional 
linker. 
Chapter 4: Design and synthesis of modified thymine monomer PNA and homothymine 
decamer PNA sequence with gold(I) complexes for cellular imaging. 
In the present section we focused our attention on to the design and synthesis of modified 
Thymine monomer and PNA decamer with simple organometallic gold(I) complexes which 
is applicable for cellular imaging. Here we introduce Phosphine gold(I) on to the thymine 
monomer 5 and homothymine decamer PNA containing the triple bond 6 at the terminal 
position (Figure 5). The development of gold (I)-acetylide complexes has led to several novel 
compounds. Most notably they have been investigated for their interesting photochemical 
properties or rich luminescence properties. Luminescence from gold-acetylide complexes 
typically results from “aurophilicity”.  
 
Figure 5: Thymine monomer 5 and homothymine 10-mer PNA 6 with gold complex 
Synthesis of modified thymine PNA monomer (5) 
 
Scheme 1: Reagents and conditions: a) 20% TFA, DCM, 0 oC - rt, 12 hr, 96%; b) succinic 
anhydride, DIPEA, DMF, 0 oC - rt, 12 hr, 70%; c) propargyl amine, EDC.HCl, DMF, rt., 12 
hr, 82% ; d) Phosphine gold chloride, KOtBu, MeOH, rt, 12 hr, 24%. 
 
 
 
ix 
 
Synthesis of gold complex with homothymine PNA oligomer (6) on solid support 
 
Scheme 2: Reagents and conditions: a) TFA/m-cresol, 95:5; b) CH2Cl2/DIPEA, 95:5; c) 
thymine monomer, HATU, DIPEA, NMP; d) Ac2O/Pyridine/NMP 1:25:25; e) 12, HATU, 
DIPEA, NMP, 12 hr; f) Cleavage; g) PPh3AuCl, KOtBu, MeOH, rt. 
 
We have successfully synthesized phosphine gold complex of thymine monomer 5 in solution 
phase and studied its photoluminescence emission properties and which are applicable in 
cellular imaging.  
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1.1.1. Introduction 
Peptide nucleic acids (PNAs), first introduced in 1991 by Nielsen and co-workers1 at 
Copenhagen University, are a remarkable example of a simple, neutral and achiral whole 
backbone replacement, that has suppressed, in many ways, other attempts to mimic the native 
nucleic acid structures in terms of molecular recognition properties. PNAs are synthetic 
nucleic acid analogues with an achiral pseudopeptide backbone in which the phosphodiester 
backbone is replaced by repetitive units of N-(2- aminoethyl) glycine. On the backbone the 
purine and pyrimidine bases are attached via a methyl carbonyl linker. Usually, PNA is an 
oligomer of 6-15 monomeric units (Figure 1.1). 
 
Figure 1.1: PNA (blue) versus DNA (black) oligomeric structures and in squared brackets 
         are shown the repeating units 
 
The PNA backbone maintains approximately the same length per repeating unit as in DNA or 
RNA. The appended nucleobases projects from the backbone to form stable double or triple 
helical complexes with target nucleic acids2. The internucleobase distance in PNA is 
conserved, so that it can bind to the target DNA or RNA sequences with high sequence 
specificity and affinity. Therefore, chemical terms they are neither proteins nor nucleic acids. 
The amide (or peptide) bonds in PNA are sufficiently different from the α-amino acid peptide 
bonds present in proteins, resulting that PNA is biologically stable. These non-natural 
characteristics make PNA oligomers highly resistant to protease and nuclease attacks3. 
Because PNAs have a neutral backbone, hybridization with target nucleic acids is not 
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affected by the interstrand negative charge electrostatic repulsions4. In addition, the absence 
of a repetitive charged backbone prevents PNAs from binding to proteins that normally 
recognize polyanions, avoiding a major source of nonspecific interactions and it is also found 
that PNAs are charge-neutral compounds and hence have poor water solubility compared 
with DNA. PNA solubility is also related to the length of the oligomers and to the 
purine/pyrimidine ratio. Some recent modifications, including the incorporation of positively 
charged lysine residues (carboxyl-terminal or backbone modification in place of glycine), 
have shown improvements in solubility while negative charges may also be introduced, 
especially in PNA/DNA chimeras, which will enhance the water solubility5. 
 
1.1.2. PNA interactions with single strand nucleic acids 
a) Duplex 
PNAs are able to hybridize to both complementary DNA and RNA targets in a sequence-
specific manner to form PNA/DNA6 (Figure 1.2) or PNA/RNA duplex structures, according 
to Watson-Crick hydrogen binding rules (Figure 1.3)2, 7, 8 
 
.  
Figure 1.2: PNA/DNA duplex 
 
 
 
Figure 1.3: PNA/DNA duplex Watson-Crick hydrogen bonding paring rules 
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PNAs bind DNA/RNA in either parallel or antiparallel modes, the later being slightly 
preferred over the former. The antiparallel mode refers to the instance when the PNA ‘N’ 
terminus lies towards the 3’-end and the ‘C’ terminus lies towards the 5’-end of the 
complementary DNA/RNA oligonucleotides. Similarly, the parallel mode of binding is said 
to occur when the PNA ‘N’ terminus lies towards the 5’-end and the ‘C’ terminus towards the 
3’-end of the complementary DNA/RNA oligonucleotide (Figure 1.4). 
 
 
Figure 1.4: PNA/DNA binding in parallel (top) and antiparallel (bottom) modes. 
 
b) Triplex 
Homopyrimidinic PNAs strongly bind to target homopurine nucleic acids and sequence 
Specifically, forming of 2:1 PNA2/DNA triplex (Figure 1.5).9 
 
 
Figure 1.5: (PNA)2/DNA triplex 
 
This complex can be formed thanks to the ability of the homopyrimidine strand to bind 
PNA/DNA duplex by Hoogsteen hydrogen bonding scheme (Figure 1.6) 
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Figure 1.6: PNA/DNA triplex Hoogsteen and Watson-Crick hydrogen bonding paring rules. 
 
c) Quadruplex 
G-quadruplexes are four-stranded structures formed from DNA sequences that contain 
stretches of contiguous guanine bases, usually in the presence of alkali metal cations10. G-
quadruplex DNA has been recently in focus because of its putative existence and its 
biological function at telomeres, which affects replication11, 12, and in promoter sites 
influencing transcription13. The guanine bases in G-quadruplexes form G-tetrads where four 
G bases hydrogen bond via the Hoogsteen sites in a cyclic fashion (Figure 1.7) 
 
 
Figure 1.7: G-quadruplex in presence of an alkali metal cation. 
 
In 2003 Prof. Datta reported14 that homologous G-rich PNA and DNA oligomers hybridize to 
form a PNA2-DNA2 quadruplex. The hybrid quadruplex exhibits high thermodynamic 
stability and expands the range of molecular recognition motifs for PNA beyond duplex and 
triplex formation. After this study many research groups have reported the synthesis of PNA 
based G-quadruplex structures with different topologies, 15, 16 for instance a PNA4 G-
quadruplex,17 a structure obtained from PNA-DNA chimeras18 and even a PNA/RNA 
quadruplex.19 
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1.1.3. PNA interactions with double strands nucleic acids   
The interaction of single-stranded PNA with double-stranded DNA is interesting not only 
because of his potential applications in antigene strategy but also for the possible use of PNA 
in different biotechnological applications (as discussed later). Various modes of interaction 
are possible, depending on sequences and conditions. (Figure 1.8) illustrates the triplex and 
duplex invasion modes, in which the targeting PNA breaks up the double helix and 
complexes with the complementary DNA strand.  
 
Figure 1.8: Duplex and triplex invasion modes. 
 
Duplex invasion (Figure 1.8 A) can result if the target DNA is a homopyrimidine and the 
PNA has a homopurine sequence. Instead, if the DNA target is a homopurine sequence, it can 
result a very stable triplex invasion (Figure 1.8 D) complex. Synthesizing pyrimidine-PNAs 
as a palindrome sequence with a flexible linker in the middle creates a so-called bisPNA or 
"PNA clamp", allowing triplex formation in optimal directions with the Watson-Crick base 
pairing in an antiparallel and Hoogsteen bonding in a parallel orientation20, 21. However, the 
triplex invasion complex is very slow to form at neutral pH, unless the cytosine’s in the 
"Hoogsteen-pairing" strand are exchanged to pseudo-isocytosines, also called J bases20. For 
practical applications, the rate of formation can be increased by using cationic PNAs (e.g., 
with extra lysine’s linked) or by linking the PNA to an intercalating molecule such as 9-
aminoacridine22. The most successful method to obtain a double-duplex invasion (Figure 1.8 
B) is to use a pseudo-complementary PNA (pcPNA) in which nucleobases adenine (A) and 
thymine (T) in conventional PNA are replaced with modified bases 2,6-diaminopurine (D) 
and 2-thiouracil (Us)23. 
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1.1.4. Stability of PNAs and PNA complexes 
Compared to normal DNA and RNA oligonucleotides, PNAs are much more stable inside 
cells. PNAs are very resistant to nuclease and protease digestion since nuclease cannot digest 
their altered backbones3. Furthermore, duplexes between PNA and DNA or RNA are in 
general more thermally stable than the corresponding DNA/DNA or DNA/RNA duplexes24, 
25. The stability of PNA/DNA duplexes was studied by differential scanning calorimetry26. 
PNA/DNA duplexes show increased stability when the purines are in the PNA strand. It is 
also observed that the thermal stability of PNA/PNA duplexes exceeds that of PNA/RNA 
duplexes, that are already more stable than PNA/DNA duplexes. As a general rule, the 
Melting Temperature Tm (the temperature at which half of the PNA or DNA strands are in 
the double-helical state and half are in the random coil state) of a PNA/DNA duplex is 1 °C 
higher per base pair than the Tm of the corresponding DNA/DNA duplex. Very important, 
the stability of PNA/DNA duplexes are almost unaffected by the ionic strength of the 
medium.2 PNA/DNA/PNA triplexes exhibit extraordinarily high stability (the thermal 
stability for a decamer is typically up to 70 °C). 
 
1.1.5. Solubility of PNAs 
As it said, PNAs are charge-neutral compounds and hence have poor water solubility 
compared with DNA. Neutral PNA molecules tend to aggregate, depending on the sequence 
of the oligomer. PNA solubility is also related to the length of the oligomer and to the 
purine/pyrimidine ratio24. Some recent modifications, including the incorporation of 
positively charged lysine residues (carboxyl-terminal or backbone modification in place of 
glycine), have shown improvements in solubility27. Negative charges may also be introduced, 
especially in PNA/DNA chimeras, which will enhance the water solubility28. 
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Section 2: PNA applications 
 
The present section deals with brief discussion about some important applications of PNAs. 
The potential applications of PNAs can be divided in three different fields: 
1.2.1 Diagnostics 
1.2.2 Molecular biology 
1.2.3 Therapy 
It is important to notice that new techniques are continuously being developed and that this 
section could not be exhaustive. However, some techniques are very important because they 
represent “historically” step in the development and use of PNAs. These techniques will be 
described more exhaustively than others. 
1.2.1 Diagnostics 
PNAs have found application to detect genetic mutations and to analyse of mismatches in the 
Watson & Creek hydrogen bonding. Their particular affinity towards DNA and RNA, their 
high sequence specificity and their capacity to perform strand displacements make PNAs 
powerful tools for diagnostic purposes. One of the best features of PNAs is the possibility to 
detect the Single Nucleotide Polymorphism (SNP) by measuring the variations of the melting 
temperature. Some techniques have been developed for this target, for example the PCR and 
capillary electrophoresis.1 
1.2.1.1 Single Base Polymorphism: “PCR clamping” 
The Polymerase Chain Reaction (PCR) technique is considered one of the most valuable step 
in the detection of genetic diseases. The high specificity of PNA to bind DNA, the greater 
stability of PNA-DNA duplexes than DNA-DNA ones and the inefficiency of PNA to act as 
primer for DNA polymerases are the bases for this novel techniques.  
This strategy includes a distinct annealing step involving the PNA targeted against one of the 
PCR primer sites. This step is carried out at a higher temperature than that for conventional 
PCR primer annealing where the PNA is selectively bound to the DNA molecule. The 
PNA/DNA complex formed at one of the primer sites effectively blocks the formation of a 
PCR product.2 PNA is also able to discriminate between fully complementary and single 
10 
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mismatch targets in a mixed target PCR. Sequence-selective blockage by PNA allows 
suppression of target sequences that differ by only one base pair. Also, this PNA clamping 
was able to discriminate three different point mutations at a single position.3 
1.2.1.2 Screening for genetic mutations by capillary electrophoresis 
In capillary electrophoresis, the separation is generally carried out using a long, thin fused 
silica capillary (typically 50–80 cm long, inner diameter; 10-300 mm). A portion of the 
coating, closed at one end of the capillary, is removed to allow optical detection of the 
analyte. The analyte passes the detection window during a separation process and can be 
visualized by online, automated UV, or laser-induced fluorescence (LIF) detection systems. 
Capillary electrophoresis is capable of analyzing minute amounts of sample (typically in the 
order of picograms to femtograms). However, it is not possible to analyze more than one 
sample at a time, which is regarded as the major disadvantage compared to slab gel 
electrophoresis.  
A new diagnostic method for the detection of genetic mutations using PNA as a probe for 
capillary electrophoresis has been reported by Carlsson et al.4 The method is sensitive enough 
to detect a single mismatch in the sample DNA. The model system consisted of four 50-mer, 
single-stranded DNA fragments representing a part of the cystic fibrosis transmembrane 
conductance regulator gene, one wild-type and three mutant sequences, and a 15-mer PNA 
probe having a sequence complementary to the wild-type oligomer. 
The probe PNA only binds the fully matched DNA, and the presence of this duplex is 
detected using free solution capillary electrophoresis. Separation of full-match from 
mismatch duplexes was accomplished at a high temperature (70°C) and 50 mM ionic 
strength. At this temperature and ionic strength, only the hybrid duplex carrying the wild-type 
DNA sequences remains stable, while the hybrid complex carrying single mismatch DNA 
will be melted. Free PNA binds to the capillary wall and is not detected.4  
Another application involves the use of fluorescent labelled PNAs. PNA probes with 
fluorescent tags offer sensitive detection and require only a very low concentration of the 
sample. At high temperatures (as described above), the LIF detection system will generate a 
signal for the bound PNAs, since free PNA is efficiently removed. Maybe it will be possible 
in the future to establish a universal screening strategy for any genetic disease with a known 
spectrum of mutations by developing a PNA probe library, possibly using multiple 
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fluorescent tags for multiplex testing of one or more exons. Other electrophoretic techniques 
(also in gel phase) are possible: the RNA binding properties of PNAs have also been 
characterized using capillary gel electrophoresis.5,6 
1.2.1.3 PNA as a probe for nucleic acid biosensor 
The DNA biosensor technology holds promises for a rapid and cost-effective detection of 
specific DNA sequences. A single-stranded nucleic acid probe is immobilized onto optical, 
electrochemical, or mass-sensitive transducers to detect the complementary (or mismatch) 
strand in a sample solution. The response from the hybridization event is converted into a 
useful electrical signal by the transducer. The use of PNAs based probes is a powerful 
alternative to DNAs based ones in different techniques: 
1.2.1.3.1 BIAcore (Biomolecular Interaction Analysis) 
The main background of this technique is the effect called SPR (Surface Plasmon 
Resonance). The PNA hybridization and corresponding mismatch analysis can be studied 
using a BIAcore instrument, which can evaluate a real-time biomolecular interaction analysis 
using optical detection technology. The real-time interactions are monitored on a sensor 
(surface) chip, which constitutes the core part of a BIAcore instrument. The probe molecule 
is attached directly to the surface and the analyte molecule is free in solution. The detection 
principle in BIA uses surface plasmon resonance. The response signal of the BIAcore 
apparatus is proportional to the change in the refractive index at the surface and is assumed to 
be proportional to the mass of substance bound to the chip (Figure 1.9).7 
 
Figure 1.9: Schematic representation of BIAcore. 
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Jensen et al. used this technique to study the interactions between PNA and DNA or RNA. 
The sensor chip used in this case was basically a thin gold surface covered with a layer of 
dextran and containing streptavidin chemically coupled to the dextran. A biotinylated PNA 
probe was immobilized on the surface by using the strong coupling between biotin and 
streptavidin. The amount of bound substance (fully complementary as well as various singly 
mismatched RNA and DNA oligonucleotides) was measured as a function of time when a 
solution containing the complementary strands passed over the chip surface. In this way both 
the association (annealing) and dissociation (melting) kinetics could be studied.8 
1.2.1.3.2 QCM (Quartz Crystal Microbalance) 
The quartz crystal microbalance has been used for some time to monitor the mass or the 
thickness of thin films deposited on surfaces, to study gas adsorption and the deposition on 
surfaces in the monolayer and sub monolayer regimes9. Only recently, this sensitive mass 
measuring device has begun to be used in the area of biochemistry and biotechnology, such 
as for studying the hybridization of nucleic acids on surface. 10,11,12 The resonant frequency of 
the crystal changes due to a minute weight increases on the surface. It is expected that 
immobilized PNA strands (or probes) would show an improved distinction between the 
closely related target sequences compared to an immobilized DNA probe. A recent report by 
Wang and co-workers on quartz crystal microbalance biosensor, based on peptide nucleic 
acid probes, showed that the system can differentiate between a full complementary and 
single mismatch oligonucleotide. A rapid and sensitive detection of mismatch sequences is 
possible by monitoring the frequency/time response of the PNA-QCM biosensor. The PNA 
probes used in the abovementioned study, which formed the monolayer onto the gold QCM 
surface, contained a cysteine attached to the PNA core with the help of an ethylene glycol 
unit.13 The remarkable specificity of the immobilized probe provides a rapid hybridization 
with corresponding oligonucleotides. Such a mismatch sensitivity of PNA-immobilized QCM 
biosensors could be of great importance for diagnostic applications, particularly for genetic 
screening and diagnosis of malignant diseases. 
1.2.1.3.3 MALDI-TOF mass spectrometry 
MALDI-TOF mass spectrometry has been used successfully in PNA-based diagnostic 
research to study discrimination of single-nucleotide polymorphisms (SNPs) in human DNA. 
The human genome and the mitochondrial DNA contain many SNPs that may be linked to 
diseases.14 Rapid and accurate screening of important SNPs, based on high-affinity binding of 
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PNA probes to DNA, is possible by using MALDI-TOF mass spectroscopy. The captured, 
single-stranded DNA molecules are PCR-amplified and thereafter hybridized with PNA 
probes in an allele-specific fashion. MALDITOF can rapidly and accurately detect (identify) 
these hybridized PNA probes. This provides a straightforward, rapid, accurate, and specific 
detection of SNPs in amplified DNA.15 The detection of multiple point mutations using 
allele-specific, mass-labelled PNA hybridization probes is also possible by using a direct 
MALDI-TOF-MS analysis method.16 The mass spectra will show peaks of distinct masses 
corresponding to each allele, and in this way a mass spectral ‘fingerprint’ of each DNA 
sample can be obtained.1 This technique can also be applied to analyse microarrays (Figure 
1.10). 
 
Figure 1.10:  Application of MALDI-TOF in the analysis of microarrays. 
Wang et al.17 have also reported the use of PNA as a recognition probe for the 
electrochemical detection of the hybridization event using chronopotentiometric 
measurements. The method consists of four steps: probe (PNA) immobilization onto the 
transducer surface, hybridization, indicator binding, and chronopotentiometric transduction. 
A carbon paste electrode contains the immobilized DNA or PNA probe. The hybridization 
experiment was carried out by immersing the electrode into the stirred buffer solution 
containing a desired target, followed by measurement of signal. It is important to remember 
that similar techniques could be used to prepare microarray with electrochemical detection 
systems. 
1.2.1.4 Microarray 
Microarrays are small chips carrying on their surface row and column of ordered molecular 
probes (spot). Each of them is able to bind a specific target molecule. The success of 
microarrays in screening mRNA expression profiles of thousands of genes simultaneously 
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has prompted researchers in bioorganic chemistry to explore this format for screening small 
molecules. From an analytical perspective, the prospect of screening thousand of analytes in a 
few micro litres is attractive. Microarrays can be prepared by several techniques including 
photolithography, contact printing and inkjet to generate arrays with densities ranging from 
1000 to 500 000 features per square centimetre. To date, a number of chemistries have been 
developed to derivatize glass surfaces to immobilize proteins, oligosaccharides, and small 
molecules in the microarray format. Many of these methods require the attachment of the 
protein or small molecule to the glass slide and likewise require that screening with the 
biological sample would also be performed on the surface. A supramolecular attachment, 
based on sequence specific hybridization of peptide nucleic acid (PNA), allows the use of the 
libraries as a mixture in solution that can then be converted to an organized microarray in one 
step by a self-sorting process.18  
The microarray could be treated with the sample and the entity of the response of every single 
spot leads to the determination of the sample structure. This technique is already successfully 
applied for nucleic acids sequences screening: in this case the complementary DNA 
sequences of all known polymorphism are spotted on the chip19 (Figure 1.11). 
 
Figure 1.11: Schematic representation of microarrays 
The microarrays technology is very interesting in biochemistry especially because it can be 
miniaturized; this feature makes the microarray the best choice to study the interaction 
between proteins and ligands or to check enzymatic activities in biological unpurified 
mixtures.  
PNAs can represent an useful and advantageous probe, expecially for their peculiar chemical, 
physical and biochemical properties. Different type of PNA based microarrays have been 
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developed, with a variety in terms of its modes of action, especially with respect to 
detection.20 
1.2.2 Tools in molecular biology 
PNAs show good features to be used as new tools in molecular biology. Some examples are 
illustrated in the following sub-sections; 
1.2.2.1 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction (PCR) has been widely used for various molecular genetic 
applications including the amplification of variable number of tandem repeat (VNTR) loci for 
the purpose of genetic typing.1 However, in some cases preferential amplification of small 
allelic products relative to large allelic products may be problematic. This results in an 
incorrect typing in a heterozygous sample.21 PNA has been used to achieve an enhanced 
amplification of VNTR locus D1S80.22 Small PNA oligomers are used to block the template, 
and the latter becomes unavailable for intra and interstrand interaction during re-association. 
On the other hand, the primer extension is not blocked; during this extension, the polymerase 
displaces the PNA molecules from the template and the primer is extended toward 
completion of reaction. This approach shows the potential of PNA application for PCR 
amplification where fragments of different sizes are more accurately and evenly amplified. 
Since the probability of differential amplification is less, the risk of misclassification is 
greatly reduced. Misra et al. demonstrated that PNA-DNA chimera lacking the true 
phosphate backbone are capable of acting as primers for polymerase reactions catalyzed by 
DNA polymerases.23,24  
The chimera (PNA)19-TPG-OH, consisting of a 19 base PNA part linked to a single 
phosphate-containing dinucleotide (TPG-OH) with a free 3’-OH terminus, when annealed 
with a complementary RNA or DNA template strand works as an efficient primer to catalyze 
the addition of nucleotide by polymerase enzymes. The primer is also recognized by reverse 
transcriptase and by the Klenow fragment of E. coli DNA polymerase - I. The results 
suggested that the diameter of the duplex region rather than the presence of phosphate 
backbone of the template primer is the critical factor for a proper template-primer reaction 
and accommodating the enzyme within the binding domain. It also appears that the primer 
phosphate backbone may not be essential, at least not in this case, for the polymerase 
recognition and binding. 
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1.2.2.2 PNA hybridization as alternative to Southern hybridization 
Southern hybridization is perhaps one of the most widely used techniques in molecular 
biology. Despite its great potential to predict both size and sequence information and 
information regarding the genetic context, there are certain disadvantages of this process. It 
requires a laborious multistep washing procedure and sometimes the sequence discrimination 
between closely related species. PNA pre-gel hybridization simplifies the process of Southern 
hybridization by reducing the required time, as the cumbersome post separation, probing, and 
washing steps are eliminated. Labelled (fluoresceinated) PNA oligomers are used as probes 
and allowed to hybridize to a denatured DNA sample at low ionic strength. The mixture is 
thereafter subjected directly to electrophoresis for size separation and single stranded DNA 
fragments separated on the basis of length. The charge-neutral PNA allows hybridization at 
low ionic strength and renders higher mobility to the complex, compared to the excess 
unbound PNA. The DNA-PNA hybrids are blotted (transferred) onto a nylon membrane, 
dried, UV cross-linked, and detected using standard chemiluminescent techniques.25 
Alternatively, the bound PNA can be detected by using capillary electrophoresis (vide infra), 
which uses the direct fluorescence detection method. Under the same conditions, a normal 
DNA-DNA duplex will tend to disrupt, here as the PNA-DNA duplex will remain intact due 
to the strong binding of PNA to DNA. This allows specific sequence detection with 
simultaneous size separation of the target DNA following a simple and straightforward 
protocol. Consequently, the analysis is much faster than conventional the Southern 
hybridization technique.1 
1.2.2.3 PNA-assisted rare cleavage 
The DNAs of bacteria have specific sites that are the target of restriction enzymes and 
methylases. Methylases are particular enzymes that can add a methyl group to a specific 
DNA site to protect that site against the cutting by some endonucleases.  
Peptide nucleic acids, in combination with methylases and other restriction endonucleases, 
can act as rare genome cutters.26 The method is called PNA-assisted rare cleavage (PARC) 
technique. It uses the strong sequence-selective binding of PNAs, preferably bis-PNAs, to 
short homopyrimidine sites on large DNA molecules, e.g., yeast or λ DNA.1 The PNA target 
site is experimentally designed to overlap with the methylation/ restriction enzyme site on the 
DNA, so that a bound PNA molecule will efficiently shield the host site from enzymatic 
methylation whereas the other unprotected methylation/ restriction sites will be methylated. 
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After the removal of bis-PNA, followed by restriction digestions, it is possible to cleave the 
whole DNA by enzymes into limited number of pieces.26 DNA is efficiently protected from 
enzymatic digestion due to methylation in most of the sites except for those previously bound 
to PNA. Thus, short PNA sequences, particularly positively charged bis-PNAs, in 
combination with various methylation/restriction enzyme pairs can constitute an 
extraordinary new class of genome rare cutters. 
1.2.2.4 Artificial restriction enzyme 
S1 nuclease cleaves single-stranded nucleic acids releasing 5’-phosphoryl mono- or 
oligonucleotides. It removes the single-stranded overhangs of DNA fragments and can be 
used in RNA transcript mapping and construction of unidirectional deletions. PNA in 
combination with S1 nuclease can work as an “artificial restriction enzyme” system. 
Homopyrimidine PNA oligomers hybridize to the complementary targets on dsDNA via a 
strand invasion mechanism, leading to the formation of looped-out non complementary DNA 
strands. The enzyme nuclease S1 can degrade this single-stranded DNA part into well defined 
fragments. If two PNAs are used for this purpose and allowed to bind to two adjacent targets 
on either the same or opposite DNA strands, it will essentially open up the entire region, 
making the substrate accessible for the nuclease digestion and thereby increasing the cleavage 
efficiency.27 
1.2.2.5 Determination of telomere size 
The conventional method for the determination of telomere length involves Southern blot 
analysis of genomic DNA and provides a range for the telomere length of all chromosomes 
present. The modern approach uses fluorescein-labelled oligonucleotides and monitor in situ 
hybridization to telomeric repeats. However, a more delicate approach resulting in better 
quantitative results is possible by using fluorescein-labelled PNAs, as shown by Lansdorp et 
al.28 This PNA-mediated approach permits accurate estimates of telomeric length. In situ 
hybridization of fluorescein-labelled PNA probes to telomeres is faster and requires a lower 
concentration of the probe compared to its DNA counterpart. Low photo bleaching and an 
excellent signal-to-noise ratio make it possible to quantitative telomeric repeats on individual 
chromosomes in this way. Experiments suggest that variations of this approach can possibly 
be applied to other repetitive sequences. 
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1.2.2.6 Nucleic acids purification 
Based on its unique hybridization properties, PNAs can also be used to purify target nucleic 
acids. PNAs carrying six histidine residues have been used to purify target nucleic acids 
using nickel affinity chromatography.29 Also, biotinylated PNAs in combination with 
streptavidin-coated magnetic beads may be used to purify Chlamydia trachomatis genomic 
DNA directly from urine samples. However, it appears that this simple, fast, and 
straightforward “purification by hybridization” approach has certain drawbacks. It requires 
the knowledge of the target sequence and depends on a capture oligomer to be synthesized 
for each different target nucleic acid. Such target sequences for the short pyrimidine PNA, 
i.e., the most efficient probe for strand invasion, are prevalent in large nucleic acids. Thus, 
short PNAs can also be used as generic capture probes for purification of large nucleic acids. 
It has been shown that a biotin tagged PNA-thymine heptamer could be used to efficiently 
purify human genomic DNA from whole blood by a simple and rapid procedure.1 
1.2.2.7 Gene expression induction 
Although most of the focuses on PNA applications have revolved around antisense strategies, 
several groups have studied the ability of PNAs to turn on gene expression. When PNA 
triplex structures are formed on one strand of the DNA duplex, the opposing DNA strand is 
displaced to form a D-loop. When sufficiently large, this D-loop resembles a transcriptional 
bubble or an initiation/elongation loop. Using bacterial and rat spleen-cell nuclear extracts 
and triplex-forming PNAs that bound to adjacent sites on a DNA template, Møllegaard and 
colleagues found that transcription was more efficient if two adjacent PNAs were bound to 
the same strand of DNA, thus giving rise to a 26 base D-loop. In this case, transcript initiation 
sites mapped to a site just downstream of PNA binding.30,31  
More recently, the work form the Wang laboratory has extended these findings and has 
shown that PNAs can be used in cultural cells to activate endogenous gene expression.32 
Using promoter-less GFP reporter constructs containing homopurine PNA target sites just 
upstream of the GFP initiation codon, Wang was able to demonstrate specific transcriptional 
initiation in vitro using HeLa cell extracts. In these experiments, designed to explore gene 
therapy approaches for Sickle cell disease (SCD) and Thalassemia, the homopurine target 
sequence was from the 300 region of the human Gγ-globin promoter. As seen by 
Møllegaard30, transcript start sites mapped to the PNA target site and used the D-loop strand 
as template. When the PNAs were hybridized to the reporter plasmid under low salt 
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conditions and microinjected into the nuclei of cells, GFP expression was detected within 20 
hr of injection. By contrast, no GFP expression was detected in cells microinjected with 
plasmid alone. Wang also demonstrated that K562 erythroleukemia cells could be efficiently 
transfected with PNAs using electroporation and inducing the endogenous γ-globin gene 
threefold over background.  
Up regulation of γ -globin gene expression, normally suppressed in adults to <1%, can help in 
the treatment of β-Thalassemia disease, in which it may partially act in place of the mutated 
defective γ-globin. Moreover, this induction was clearly a specific effect of the PNAs since 
the start sites for the transcripts mapped to both the endogenous promoter and to the PNA 
binding sites, 300 bp upstream. 
Thus, despite the presence of physiological salt concentrations and potential chromatin 
structures, the PNAs were able to bind to their target sites in the chromosome and promote 
transcription initiation, providing proof of principle for this approach of gene therapy. It is 
somewhat surprising that γ-globin transcription was induced not only at the PNA binding site, 
but also from its native promoter region.32 Probably the transcription of the γ-globin gene 
from the sequences upstream also makes the native promoter more accessible for RNA 
polymerase. In the cellular context PNA-mediated arrest of transcription is interpreted as an 
inability of the transcription machinery to dissociate PNA/DNA or PNA2/DNA helices, more 
specifically, by the inability of the DNA helicase to unwind these structures. Indeed, specific 
studies show that bis-PNAs can significantly reduce DNA unwinding activity of the UL9 
helicase.33,34 
1.2.3 Gene therapy 
Peptide nucleic acids have promise as candidates for gene therapeutic drugs design. They 
require well identified targets and a well-characterized mechanism for their cellular delivery. 
In principle, two general strategies can be adapted to design gene therapeutic drugs. 
Oligonucleotides or their potential analogs are designed to recognize and hybridize to 
complementary sequences in a particular gene whereby they should interfere with the 
transcription of that particular gene (antigene strategy, Figure 1.12). 
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Figure 1.12: Antigene strategy 
Alternatively, nucleic acid analogs can be designed to recognize and hybridize to 
complementary sequences in mRNA and thereby inhibit its translation (antisense strategy, 
Figure 1.13). PNAs are chemically and biologically stable molecules and have significant 
effects on replication, transcription, and translation processes, as revealed from in vitro 
experiments. Moreover, no sign of any general toxicity of PNA has so far been observed.1a 
 
Figure 1.13: Antisense strategy 
MicroRNAs are short non-coding RNAs expressed in different tissue and cell types that 
suppress the expression of target genes. As such, microRNAs are critical cogs in numerous 
biological processes1b, c and dysregulated microRNA expression is correlated with many 
human diseases.  
Very recently in 2015 Cheng et al reported, MicroRNA (miRNAs) applicable for cancer 
therapy in tumour microenvironment. They introduce a novel antimiR delivery platform that 
targets the acidic tumour microenvironment, evades systemic clearance by the liver and 
facilitates cell entry via a non-endocytic pathway and they find that the attachment of peptide 
nucleic acid antimiRs to a peptide with a low pH-induced transmembrane structure (pHLIP) 
produces a novel construct that could target the tumour microenvironment, transport antimiRs 
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across plasma membranes under acidic conditions such as those found in solid tumours (pH 
~6), and effectively inhibit themiR-155 oncomiRin a mouse model of lymphoma. This study 
introduces a new model for using antimiRs as anti-cancer drugs, which can have broad 
impacts on the field of targeted drug delivery.1d 
The blood disorder, β-thalassaemia, is considered an attractive target for gene correction. 1e 
Site-specific triplex formation has been shown to induce DNA repair and thereby catalyse 
genome editing. In 2016 Bahal et al reported that triplex-forming peptide nucleic acids 
(PNAs) substituted at the γ position plus stimulation of the stem cell factor (SCF)/c-Kit 
pathway yielded high levels of gene editing in haematopoietic stem cells (HSCs) in a mouse 
model of human β-thalassaemia. Injection of thalassemic mice with SCF plus nanoparticles 
containing γPNAs and donor DNAs ameliorated the disease phenotype, with sustained 
elevation of blood haemoglobin levels into the normal range, reduced reticulocytosis, reversal 
of splenomegaly and up to 7% β-globin gene correction in HSCs, with extremely low off-
target effects. The combination of nanoparticle delivery, next generation γPNAs and SCF 
treatment may offer a minimally invasive treatment for genetic disorders of the blood that can 
be achieved safely and simply by intravenous administration. 
 
1.2.3.1 Antigene strategy 
Peptide nucleic acids should be capable of arresting transcriptional processes thanks to of 
their ability to form a stable triplex structure or a strand-invaded or strand displacement 
complex with DNA. Such complexes can create a structural hindrance to block the stable 
function of RNA polymerase and thus are capable of working as antigene agents. Evidence 
from in vitro studies supports the idea that such complexes are indeed capable of affecting the 
process of transcription involving both prokaryotic and eukaryotic RNA polymerases. PNA 
targeted against the promoter region can form a stable PNA–DNA complex that restricts the 
DNA access of the corresponding polymerase. PNA strand displacement complexes, located 
far downstream from the promoter, can also efficiently block polymerase progression and 
transcription elongation and thereby produce truncated RNA transcripts; the PNA (DNA 
poly-purine) target must be present in the gene of interest.,35 Nielsen et al. have demonstrated 
that even an 8-mer PNA (T8) is capable of blocking phage T3 polymerase activity.36 The 
presence of a PNA target within the promoter region of IL-2Ra gene has been used to 
understand the effect of PNA binding to its target on this gene expression.37,38 The 
PNA2/DNA triplex arrests transcription in vitro and it is capable of acting as an antigene 
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agent. Unfortunately one of the major obstacles to use PNA as an antigene agent is that the 
strand invasion or the formation of strand displacement complex is rather slow at 
physiological salt concentrations.39 Several modifications of PNA have shown improvements 
in terms of binding. Modifications of PNA by chemically linking the ends of the Watson- 
Crick and Hoogsteen PNA strands to each other, introducing pH-independent 
pseudoisocytosines into the Hoogsteen strand,40 incorporating intercalators,41 or positively 
charged lysine residues 40,42 in PNA strands can drastically increase the association rates with 
dsDNA. Lee et al. have demonstrated that PNA, as well as the PNA–DNA chimera, 
complementary to the primary site of the HIV-I genome can completely block priming by 
tRNA3Lys.43 Consequently, in vitro initiation of the reverse transcription by HIV-1 RT is 
blocked. Thus, oligomeric PNAs targeted to various critical regions of the viral genome are 
likely to have a strong therapeutic potential for interrupting multiple steps involved in the 
replication of HIV-1.43 It has been found that under physiological salt conditions, binding of 
PNA to super coiled plasmid DNA is faster compared to linear DNA.42  This result is relevant 
to the fact that the transcriptionally active chromosomal DNA usually is negatively 
supercoiled, so it can be better target for PNA binding in vivo. It has also been found that the 
binding of PNA to dsDNA is enhanced when the DNA is being transcribed. This 
transcription-mediated PNA binding occurs about threefold as efficiently when the PNA 
target is situated on the nontemplate strand instead of the template strand. As transcription 
mediates template strand-associated (PNA)2/DNA complexes, which can arrest further 
elongation, the action of RNA polymerase results in repression of its own activity, i.e., 
suicide transcription.44 These findings are highly relevant for the possible future use of PNA 
as an antigene agent. We wish to refer to reports describing the ability of PNA to activate 
transcription, although this is not actually related to its antigene effect. Møllegaard et al.30 
have efficiently demonstrated that the looped-out single-stranded structure formed as a result 
of strand invasion is also capable of acting as efficient initiation sites for Escherichia coli and 
mammalian RNA polymerases in which the polymerase might start transcription using the 
single-stranded loop as a template.38 This is consistent with the affinity of RNA polymerase 
for single-stranded DNA and its ability to transcribe single-stranded DNA. 
The nuclear localisation signal (NLS) of SV40 has been shown to translocate 17-mer anti-
myc PNA over the plasma membrane into the cytosol and further convey into nuclei of 
Burkitt’s lymphoma derived cell-lines. A 17-mer antigene PNA, that is complementary to a 
unique sequence located at the start of the second exon of c-myc, was delivered into BRG 
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and BJAB cells by both NLS peptide and peptide with a scrambled NLS sequence. However, 
the nuclear transport of PNA was achieved only with a PKKKRKV peptide that corresponds 
to the active/wild type NLS (NLSwt).45 Inside the nuclei the rhodamine-labelled PNA–NLS 
was visualised as a small number of highly fluorescing bright spots associated with clumped 
chromatin material. Twenty four hours after application of 10 μM antimyc- NLSwt–PNA 
constructs, MYC expression was inhibited by 75% and cell viability decreased by 25%, 
respectively. MYC expression in treated cells decreased progressively and after 72 h the 
protein concentration was below the level of detection. The level of myc mRNA was reduced 
by 35% after 7 h of treatment and by 60% after 18 h, suggesting that MYC expression was 
also inhibited at the level of transcription. However, reduction of protein concentration upon 
PNA-NLSwt construct treatment seems to slightly precede the decrease in the mRNA 
concentration. This discrepancy can be explained by general difficulties in quantifying 
exactly the Western and Northern blot analyses. On the other hand, this hints that antimyc- 
PNA–NLSwt acts not only on a transcriptional, but on a translational level as well. 
The potential applicability of receptor mediated intracellular translocation of PN (from 
cytosol into the nucleus) was demonstrated in prostatic carcinoma cells. Dihydrotestosterone 
coupled to anti-gene PNA induced nuclear uptake in LNCaP cells that express the androgen 
receptor gene (AR), but not in DU145 cells where its receptor gene is silent. The 
cellular/cytoplasmic uptake of rhodamine labelled anti-myc PNA is, however, detectable in 
both cell-lines, but in DU145 cells the uptake is strictly cytoplasmic only.46 Coupling of 
dihydrotestosterone adds hydrophobicity to PNA oligomer molecules and that seems to 
facilitate the uptake of PNA by cells, as compared to unmodified PNA. 
1.2.3.2 Antisense strategy 
In the antisense strategy the target of the PNA strand is the mRNA (instead the antigene 
where the target is the DNA double strand). The basic mechanism of the antisense effect by 
oligodeoxynucleotides is considered to be either a ribonuclease H (RNase H) - mediated 
cleavage of the RNA strand in oligonucleotide-RNA heteroduplex or a steric blockage in the 
oligonucleotide - RNA complex of the translation machinery.47 Oligodeoxynucleotide 
analogs such as phosphorothioates activate RNase H and thus hold promise of working as 
antisense agents.48 However, they also exhibit some non-specificity in their action. 
PNA/RNA duplexes, on the other hand, cannot act as substrates for RNase H. Normally; the 
peptide nucleic acid antisense effect is based on the steric blocking of either RNA processing, 
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transport into cytoplasm, or translation. It has been concluded from the results of in vitro 
translation experiments involving rabbit reticulocyte lysates that both duplex- (mixed 
sequence) and triplex-forming (pyrimidine-rich) PNAs are capable of inhibiting translation at 
targets overlapping the AUG start codon.47 Triplex-forming PNAs are able to hinder the 
translation machinery at targets in the coding region of mRNA. However, the translation 
elongation arrest requires a (PNA)2–RNA triplex and thus needs a homopurine target of 10-
15 bases. In contrast, duplex-forming PNAs are incapable of doing the same. Triplex-forming 
PNAs can inhibit translation at initiation codon targets and ribosome elongation at codon 
region targets. 
Mologni et al. showed effects of three different types of antisense on the in vitro expression 
of PML/RARα gene.62 The first one was complementary to the first AUG (initiation) site. 
The second could bind to a sequence in the coding region that includes the second AUG, the 
starting site for the synthesis of an active protein. The third PNA was targeted against the 59-
untranslated region (UTR) of the mRNA, the point of assembly of the translation machinery. 
Together, these three PNAs could efficiently inhibit translation even at a concentration much 
below the critical concentration used for each individual. The result suggests that the PNA 
targeting of RNA molecules like PML/RARα requires the effective blocking of different 
sequences on the 59 part of the messenger. A 59-UTR PNA target can also be used as 
efficiently as an initiation (AUG) target to achieve an antisense activity of PNA, and a more 
effective translation inhibition can be achieved by combining PNA directed toward 59-UTR 
and AUG regions.  
Triple helix-forming PNAs can also hinder the translation process. Bis-PNA or clamp-PNA 
structures are capable of forming internal triple helical constructs. In principle, if targeted 
against the coding region of mRNA, PNA2/RNA triple helix-forming derivatives can also 
cause a stop in translation, which can be easily verified by the detection of a truncated 
protein.47 However, this methodology, requires a sequence optimization for each new target. 
Recent studies show that E. coli cells are somewhat permeable for PNA molecules. Good and 
Nielsen 50a-b have shown that it is possible to achieve PNA antisense effects in the ‘leaky’ 
mutant strains of E. coli. PNAs targeted against the AUG region of the mRNA corresponding 
to β-galactosidase and β-lactamase genes were indeed capable of down-regulating the 
expression of these two genes.50a Another study demonstrated the effect of two bis-PNAs, 
targeted against the homopurine stretches in rRNA, either in the peptidyl transferase center or 
in the α-sarcin loop, in inhibiting the ribosome function in a cell-free system.50b The 
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translation was arrested at submicromolar range of PNA concentration. The growth of a 
mutant strain of E. coli, namely, AS19, was also inhibited by using the same PNAs at low 
micromolar concentration. 
1.2.3.3 Inhibition of replication 
It is also possible by using PNA to inhibit the elongation of DNA primers by DNA 
polymerase. Further, the inhibition of DNA replication should be possible if the DNA duplex 
is subjected to strand invasion by PNA under physiological conditions or if the DNA is single 
stranded during the replication process. Efficient inhibition of extra chromosomal 
mitochondrial DNA, which is largely single-stranded during replication, has been 
demonstrated by Taylor et al.51 The PNA-mediated inhibition of the replication of mutant 
human mitochondrial DNA is a novel (and also potential) approach toward the treatment of 
patients suffering from ailments related to the heteroplasmy of mitochondrial DNA. Here 
wild-type and mutated DNA are both present in the same cell. Experiments have shown that 
PNA is capable of inhibiting the replication of mutated DNA under physiological conditions 
without affecting the wild-type DNA in mitochondria. 
1.2.3.4 Interaction of PNA with enzymes 
It was observed that PNAs are able to interact with several enzymes. 
¾ RNase H  
Despite their remarkable nucleic acid binding properties, PNAs are not generally 
capable of stimulating RNase H activity on duplex formation with RNA. However, 
recent studies have shown that DNA/PNA chimeras are capable of stimulating RNase 
H activity. On formation of a chimeric RNA double strand, PNA/DNA can activate 
the RNA cleavage activity of RNase H. Cleavage occurs at the ribonucleotide parts 
base paired to the DNA part of the chimera. Moreover, this cleavage is sequence 
specific in such a way that certain sequences of DNA/PNA chimeras are preferred 
over others.52 They are also reported to be taken up by cells to a similar extent as 
corresponding oligonucleotides. Thus, PNA/DNA chimeras appear by far the best 
potential candidates for antisense PNA constructs. 
 
¾ Polymerase and reverse transcriptase  
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In general, there is no direct interaction of PNA with either DNA polymerase or 
reverse transcriptase. However, different groups have shown indirect involvement of 
PNA in inhibiting these enzyme functions (activity) under in vitro conditions. For 
example, PNA oligomers are capable of terminating the elongation of oligonucleotide 
primers by either binding to the template strand or directly competing with the primer 
for binding to the template. Primer extension by MMLV reverse transcriptase has 
been shown to be inhibited by introducing a PNA oligomer.37 In another experiment, 
Nielsen et al.53 demonstrated that the primer extension catalyzed by Taq-polymerase 
can be terminated by incorporating a PNA oligomer [PNA-H (t) 10] into the system. 
The latter can bind to a (dA)10 sequence in the template and thereby terminate the 
primer extension. Moreover, uncharged PNA primers with only a single 59-amino-
29,59- dideoxynucleoside at the carboxyl terminus can be recognized by the Klenow 
fragment for DNA pol I and VentDNA polymerase (Thermococcus litoralis), and a 
linear amplification is possible with the use of an excess of PNA-DNA primer and 
suitable thermo stable polymerases.54 Moreover, the reverse transcription of gag gene 
of HIV I is also inhibited in vitro by PNAs.55 The inhibition has been achieved by 
using a bis-PNA construct, which is more efficient than the corresponding mono PNA 
construct.51 Also, the reverse transcription can be completely inhibited by a 
pentadecameric antisense PNA, using a molar ratio of 10:1 (PNA/RNA), without any 
noticeable RNase H cleavage of the RNA.55 
 
¾ Telomerase 
Human telomerase, a ribonucleoprotein complex consisting of a protein with DNA 
polymerase activity and an RNA component, synthesizes (TTAGGG)n repeats at the 
39 end of DNA strands. PNA oligomers that are complementary to the RNA primer 
binding site can inhibit the telomerase activity. Studies have shown that the 
telomerase inhibition activity of PNA is better than that of corresponding activity of 
phosphorothioate oligonucleotides. This is mainly due to a higher binding affinity of 
PNA compared to phosphorothioates.56 Corey and co-workers have demonstrated an 
efficient inhibition of telomerase after lipid mediated delivery of template- and non 
template- directed PNA into the cell.57 
1.2.3.5 Mutagen action of PNA 
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One consequence of the tight binding of triplex-forming oligonucleotides and PNAs to 
cellular homopurine DNA targets is that they can induce DNA repair pathways within the 
cell. Thus, the PNA2/DNA complex can be interpreted by the cell to be a DNA lesion in need 
of repair. One possible outcome of this is the production of site-specific mutants at, or 
proximal to, the site of PNA binding.58 Faruqi ad co-workers reported that PNAs with 
binding affinities of around 10-7 M were able to be taken up by streptolysin- O permeabilized 
murine fibroblast, bind to their target sites within SupF1 reporter gene integrated into the 
genome, and induce point mutations or single base deletions or insertions in the target 
sequence or within 5 bp of the site.59 The frequency of mutagenesis observed with the PNAs 
was 8 × 10-4, compared to a background mutagenesis frequency of 9 × 10-5. Similar results 
have been obtained with tightly binding triplex-forming phosphorothioates, leading to the 
prediction that triplex complexes in general can induce transcription-coupled DNA repair 
pathways.60 Presently, this mutagenic capacity is being developed as a technique to 
selectively mutagenize and repair single point mutations that are crucial in certain genetic 
diseases, including sickle cell disease.31 
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Section 3: Chemical modifications of PNA 
The major limitations of the therapeutic applications of PNAs are their poor solubility in 
aqueous media due to self-aggregation and an insufficient cellular uptake. In order to improve 
PNA solubility in aqueous media, the cellular uptake, the binding selectivity towards RNA 
versus DNA, or to stabilise duplex or triplex structures, several analogues have been 
synthesised over the years.1 
1.3.1. PNAs with Modified Nucleobases 
Inhibition of gene expression by antisense or antigene approaches relies on the formation of 
stable duplex and triplex structures.2, 3 In this context, the use of modified nucleobases 
represents an obvious way to control recognition between nucleic acids. The non-standard 
nucleobases employed so far with PNA are limited, compared with the repertoire of backbone 
modifications described. Structures of nucleobase-modified PNA are illustrated in Figure 
1.14. 
 
Figure 1.14: Structures of nucleobase-modified PNA. 
Substitution of natural bases for analogues can be used for interfering with the hybridisation 
process; for example, N4-benzoyl cytosine (Figure 1.14a) has been shown to cause inhibition 
of triplex formation, whereas E-base (Figure 1.14b), rationally designed to recognise T-A 
base pair, stabilises a triplex even when the target strand contains one or two pyrimidine 
residues.4, 5 In fact, triplex formation is generally restricted to oligopurine strands whereas a 
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substantial destabilisation is observed when pyrimidine residues are introduced. However, the 
binding affinity of E●T-A triplet is far from optimal, which might partially be due to 
excessive flexibility of the linker between the backbone and the nucleobase. In order to 
address the issue of flexibility, a conformationally constrained E-base analogue (Figure 
1.14c), was synthesised6. Surprisingly, no improvement was found, a result that could mean 
that local flexibility has only little influence on the thermodynamics of oligonucleotide 
hybridisation. As said, 2-Thiouracil (Figure 1.14d) along with 2, 6-diaminopurine (Figure 
1.14e) was used as a non-natural base pair in PNA-DNA recognition and was shown, for the 
first time, to lead to a phenomenon termed as “double duplex invasion”. Pyrimidines which 
have extended aromatic moieties as a means of increasing the stacking energy and hence the 
stability of the hybridised complexes represent another class of modified nucleobases. 
Incorporation of tricyclic phenothiazine (Figure 1.14f) as a substitute for cytosine and 
bicyclic/tricyclic naphthyridinones (Figure 1.14g and h) as substitutes for thymine showed a 
modest affinity increase, whereas tricyclic cytosine analogues based on the phenoxazine gave 
the highest increase in affinity and sequence specificity towards targets7. This result 
demonstrates that factors other than mere molecular stacking overlap, such as electronic 
factors, contribute to base pair stacking stabilities.  
Interesting modification on nucleobases have also been carried out to yield fluorescent PNA 
monomers and oligomers (Figure 1.15). 
 
Figure 1.15: Structures of fluorescent nucleobase-modified PNA. 
2-Aminopurine, being intrinsically fluorescent, can be used to study PNA–DNA interaction 
dynamics8. O4-(o-nitrophenyl) thymine (Figure 1.15-k) PNA monomer was reported as 
valuable intermediate for the introduction of fluorescent compounds into PNA oligomers9. 
Thiazole orange (Figure 1.15-l) is the first base to fulfil the demands desired for a fluorescent 
universal base10. Thanks to its remarkable base stacking ability, it pairs well against all four 
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canonical DNA bases maintaining duplex stability. In addition to this, the sensitivity of its 
fluorescence to a neighbouring base mismatch, it is suitable for homogeneous single-
nucleotide-polymorphism detection11. 
1.3.2. PNAs with modified backbone 
Since the first report of aegPNA, many research groups have started the synthesis of 
backbone modified peptide nucleic acids in order to improve or modify the chemico-physical 
properties, in particular the solubility, and the binding affinity of classical PNA. 
Improvement of the aqueous solubility of PNAs has been achieved by the introduction of 
charges in the molecule, or by the introduction of ether linkages in the backbone. PNAs are 
endowed of positive charges by linking a terminal lysine residue12 (Figure 1.16a) or by the 
introduction of a positive charge in the backbone, or by replacing the acetamide linker to the 
nucleobase by a flexible ethylene linker (Figure 1.16b) 13. 
 
Figure 1.16: Positively charged modified backbone. 
Cationic guanidinium linkages (Figure 1.17) have also recently been introduced into PNA 
and were found to improve its binding affinity with complementary nucleic acid sequences14. 
 
Figure 1.17: Positively charged guanidinium modified backbone. 
Making the PNA anionic also aided in increasing its water-solubility as in the case of the 
phosphonate analogues (Figure 1.18), but was accompanied by a decrease in the binding 
affinity to complementary nucleic acid sequences 15-20. 
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Efimov et al.15 have described the synthesis of homopyrimidine pPNA oligomers containing 
N-(2-hydroxyethyl) phosphonoglycine (pPNA-O), or N-(2-aminoethyl) phosphono glycine 
(pPNA-N). These oligomers did form complexes with complementary DNA/RNA, but with a 
much lower stability than PNA. 
 
Figure 1.18: Anionic charged modified backbone. 
Increased water solubility was also achieved by putting an ether linkage in the PNA 
backbone20, 21 (Figure 1.19). 
 
Figure 1.19: O-ether modified backbone. 
In the attempt to make the backbone rigid, alkyl and cyclic substituents have been 
introduced22,23. 3-, 5- and 6-member rings have been appended in various position of the 
backbone. The rationale behind the design of such constrained PNA is to obtain a 
preorganised structure with high selectivity in the binding of DNA/RNA. As the presence of 
rotamers around the tertiary amide bond in aegPNA interferes with the hybridisation process, 
it was postulated that connecting the nucleobase to the cycle inhibits the rotation, overcoming 
the problem of the rotamers. Examples of conformationally blocked PNA (Figure 1.20) are 
represented by the aminoprolyl PNA (ap-PNA), aminoethylprolyl PNA (aep-PNA), 
aminoethylpyrrolidinone PNA (aepone-PNA), pyrrolidine PNA, cyclopropane (cpr), 
cyclopentyl (cp) and cyclohexyl (ch) PNA. 
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Figure 1.20: Rigid modified backbone. 
Introduction of a single ap-PNA in a PNA sequence results in a stabilisation of the 
PNA/DNA duplex, whereas homothymine ap-PNA do not bind to the target sequence; 
stereochemistry affects the preference for parallel or antiparallel binding24. Aep-PNAs are 
obtained protecting the hydroxyproline carboxyl as an ester, derivatising the nitrogen with an 
ethylamine moiety and then replacing the OH with the nucleobase. These derivatives bear a 
positive charge; homothymine decamer binds polyadenilic acid to form 2:1 hybrids, with 
high affinity and specificity. When hybridised to DNA, they show higher affinity for the 
antiparallel hybridisation than for the parallel25.Aepone-PNAs also stabilise formation of 
triple helical structures with DNA partners, while destabilise triplexes formed with polyA26. 
(2R, 4S) Pyrrolidine-PNA oligomers form very stable hybrids with complementary DNA and 
RNA; protonation of the nitrogen does not affect the stability of the hybrids. On the contrary, 
(2S, 4S) isomers do not stabilise the formation of hybrids with DNA and RNA.27 Cp-PNAs 
show higher affinity towards RNA than DNA; the (1R, 2S) enantiomers form higher affinity 
complexes with DNA than the (1S, 2R) enantiomers. Both stabilise PNA2: DNA and PNA2: 
RNA triplexes.28 Cyclohexyl PNAs were synthesised in the forms (1S,2S), (1R,2R), (1S,2R), 
(1R,2S); although the presence of S,S isomers does not affect the thermal stability of DNA 
and RNA hybrids, introduction of R,R isomers results in a destabilisation of the PNA/DNA 
or RNA complexes. PNA including the (1R, 2S) isomer exhibits higher hybrid stability and 
ability to discriminate between DNA and RNA.29 
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1.3.3. PNAs with Fluorescent Probes 
The introduction of fluorescent probes in biomolecules may constitute a valuable tool to 
study their structures and biological activity, opening the possibility to design new 
fluorescent bioactive molecules that can exploit their peculiar properties for diagnostics or 
therapeutic applications. For more than thirty years, the conjugation of fluorescent marker to 
DNA or proteins have been successfully applied and more recently also with PNAs. 
In literature are now reported different examples of fluorescent PNAs and their cellular 
uptake, as well as their capability to hybridize specific DNA or RNA sequences, have been 
widely studied. 
The introduction of a fluorescent molecule in the PNA oligomer can be achieved or by 
classical reaction in solution, or by solid phase reactions while the oligomer is still attached to 
the resin support. 
In 1996 Kremsky et al30 reported the Functionalisation of PNA oligomers with biotin and a 
fluorescein derivative, with the aim to set up a synthetic protocol to support specific markers 
in solid phase synthesis. Fluorescein is one of the most used fluorescent probe and finds wide 
applications in bio analytical chemistry, 31 molecular biology and pharmacokinetic studies.32 
As shown in (Figure 1.21), fluorescein itself cannot be directly used in solid phase synthesis 
(SPS), while its derivatives bearing a carboxylic group are suitable for classical peptide bond 
formation. 
 
Figure 1.21: Fluorescein and its carboxy-derivatives. 
Carboxy fluorescein derivatives, as pure isomer, are commercially available but are quite 
expensive; thus a mixture of the two isomers 5- and 6- carboxyfluorescein (61:39) were 
practically used in SPS.33 
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It’s also commercially available the isothiocyanate derivative (FITC, Figure 1.22), that allows 
the outstanding reaction with free amino groups, by formation of stable thiourea bond. 
 
Figure 1.22: Fluorescein isothiocyanate (FITC) 
In molecular biology, also rhodamine and its derivatives were widely used, as an alternative 
to fluorescein (Figure 1.23). 
 
Figure 1.23: Rhodamine and Rhodamine B 
More recently, Englund et al34. Have introduced in the PNA backbone a lysine-based 
monomer, exploiting the terminal ε-amino group to bind the 9-fluorenacetic acid as a 
fluorescent probe. 
1.3.4. PNA Synthesis 
1.3.4.1. Synthesis of PNA monomers  
Although PNA monomers are commercially available, they are also relatively easy to 
synthesize from inexpensive starting materials (Scheme1.1). 
As previously mentioned, PNA consists of repeating N-(2-aminoethyl) glycine units with a 
nucleobases attached on to it. The synthesis of the backbone unit can be achieved either via 
reductive amination of glycine ester with an N-protected amino acetaldehyde35 or via an 
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alkylation’s of mono-protected ethylenediamine with a bromoacetic acid ester36. Either route 
gives high yields of the desired intermediate. 
 
 
 
Scheme 1.1: Synthesis of protected (2-aminoethyl) glycine 
 
In the next step, protected nucleobases viz., adenine, guanine, cytosine, thymine or uracil are 
attached via an amide bond using a coupling agent, e.g., DCC37 or HBTU38 (Scheme 1.2). 
 
 
 
Scheme 1.2: Synthesis of aeg PNA monomers 
 
PNA monomers can be assembled using synthetic methods developed for the peptide 
synthesis both in solid phase and in solution. Different synthetic strategies have been reported 
in the literature35-38, but the most used are based on: 
¾ Boc/Cbz protected monomers (Figure 1.24) 
¾ Fmoc/Bhoc protected monomers 
In our laboratories the first strategy is routinely used for the synthesis of PNA oligomers, 
both by manual as well as automated SPS, starting from commercially available aegA (1), 
aegC (2) and aegG (3) monomers, while aegT (4) one is generally synthesized by ourselves 
in lab and its synthesis we will see in next chapter 2. 
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Figure 1.24: Aminoethylglycine A, C, G and T monomers with Boc/Cbz and Fmoc/Bhoc 
protections 
1.3.4.2. Solid phase PNA synthesis 
The assembly of PNA using the above described monomers is usually performed on a solid 
support, preferably via by manually or by automated synthesis 
The solid support is usually functionalized polystyrene with a cleavable linker. The choice of 
the linker is very important and depends on the protecting group strategy used. For the 
Boc/Cbz strategy, the best linker is the MBHA (Figure 1.25-9), an acid labile linker that can 
be cleaved with a mixture of trifluoroacetic acid and trifluoromethanesulfonic acid. In the 
Fmoc/Bhoc strategy, an acid labile linker can be used, for example the Rink Amide (Figure 
1.25-10). Best results in the Fmoc chemistry are achieved using a polyethylene glycol 
derivatized polystyrene resin (PEG-PS) that provides a “solution like” environment for the 
synthesis. The typical linkers used with this resin are the PAL or XAL linkers (Figure 1.25-
11 and 12). The loading of the solid support can range from 30 μM/g to >1mM/g. Low 
loading resins are usually used in the synthesis of PNA-DNA chimera36a. 
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Figure 1.25:  Most used solid phase supports for the synthesis of PNAs. 
Independently from the strategy, the solid phase oligomers synthesis (Scheme 1.3) proceeds 
with the following standard synthetic steps: 
1) Downloading: this step consists in the coupling of the first monomer or a properly 
protected-amino acid (e.g. PG1-Lysine-Nε-PG2, generally used to improve the solubility in 
water of the final oligomer), to the resin. This reaction is performed using a smaller amount 
of the monomer with respect to the loading of the resin, in order to avoid the interaction 
among the oligomer chains on a bead. A typical loading used in the PNA oligomers synthesis 
is 0.2 mmol/g. 
2) Deprotection: to build the oligomer is necessary to remove the protecting group on the 
PNA monomer (or amino acid) attached on the resin. For the Boc/Cbz strategy, the Boc 
group is removed using trifluoroacetic acid (TFA) in presence of m-cresol (ratio 95:5). The 
m-cresol was added to function as a scavenger for the tert-butyl cations in order to avoid 
alkylation of the nucleobases. 
3) Coupling: this step is the key step of the chain elongation. Using typical condensing agent 
(HBTU or HATU gave best results) the carboxylic acid function of a monomer is coupled 
with the amino group of the monomer attached on the resin and previously deprotected. 
4) Capping: this step is performed in order to avoid that unreacted amino groups can react in 
the next coupling steps giving mistaken sequence that are more difficult to purify. The 
preferred capping reagent is acetic anhydride, which reacts very fast with the free amino 
groups. 
Once the oligomer synthesis is completed, the chain is cleaved using the more appropriate 
reagent (for MBHA resin, TFA and trifluoromethanesulfonic acid (TFMSA) mixture in 
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presence of m-cresol and thioanisole). Usually, in the final cleavage also the protecting group 
of the exocyclic amino moieties of the nucleobases are also removed. At last, semi 
preparative HPLC purification were done to isolate the desired PNA oligomer. 
 
 
Scheme 1.3: Schematic representation of the solid phase PNA synthesis 
The final acetylation is very useful in order to avoid undesired intramolecular side reaction 
(Scheme 1.4 and 1.5), because of the basicity of the terminal amino moiety and a favourable 
geometry for rearrangement, acyl migration of the nucleobase acetyl moiety to the N-terminal 
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Position (Scheme 1.4) is a common side reaction. 
 
Scheme 1.4: undesired intramolecular side reaction 
Another intramolecular side reaction in PNA synthesis is the attack of the primary amine at 
the N-terminal on the carbonyl group of the amide bond. In this case the N-terminal unit is 
lost and cleaved off in the form of a ketopiperazine derivative (Scheme 1.5). 
 
Scheme 1.5: undesired intramolecular side reaction 
As mentioned above, HBTU and HATU gave the highest coupling yields in PNA synthesis. 
However, uronium salts react with primary amines to form guanidinium salts, and this 
reaction has been shown to cap free α-amines in peptide synthesis efficiently. The capped 
products are easily identified by mass spectroscopy by the presence of M+100 masses. The 
higher pKa value of the 2-ethyl amine in PNA and the fact that it is less steric hindered makes 
PNA monomers even more prone to this reaction (Scheme 1.6). Therefore, pre-activation of 
the monomers and a slight excess or monomer over HATU are employed in the protocol. 
 
Scheme 1.6: Side reaction between condensing agent and aegPNA monomer 
1.3.5. Binding Affinity Evaluation of PNAs  
Like other non-covalent structures, the DNA complexes (duplex or triplex) are unstable at 
high temperatures. When the temperature is increased gradually, this process of heat 
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denaturation, also called melting, begins in areas with a high A-T content. A-T base pairs can 
be separated more easily than G-C base pairs. The Melting Temperature (Tm) is defined as 
the temperature at which half of the DNA strands are in the double-helical state and half are 
in the single strand states (Figure 1.26). 
 
Figure 1.26: Thermal denaturation process of dsDNA 
The best ways to determine the melting temperature and to evaluate the PNA/DNA 
interactions are by spectroscopic techniques, as described in the following paragraph, or by 
Differential Scanning Calorimetry (DSC). 
1.3.7. Bibliography 
1. Pensato, S.; Saviano, M.; Romanelli, A. Expert Opin Biol Ther. 2007, 7, 1219-32. 
2. Uhlmann, E.; Peyman, A. Chem. Rev. 1990, 90, 543-584. 
3. Doronina, S. O.; Behr, J. Chem. Soc. Rev. 1997, 26, 63-71. 
4. Christensen, L.; Hansen, H. F.; Koch, T.; Nielsen, P. E. Nucleic. Acids. Res. 1998,  
 26, 2735-2739. 
5. Eldrup, A.; Dahl, O.; Nielsen, P. J. Am. Chem. Soc. 1997, 119, 11116-11117. 
6. Olsen, A. G.; Dahl, O.; Nielsen, P. E. Bioorg Med Chem Lett. 2004, 14, 1551-4. 
7. a) Eldrup, A.; Nielsen, B.; Haaima, G.; Rasmussen, H.; Kastrup, J.; Christensen, C.; 
 Nielsen, P. Eur. J. Org. Chem. 2001, 1781-1790. b) Eldrup, A. B.; Christensen, C.; 
 Haaima, G.; Nielsen, P. E. J. Am. Chem. Soc. 2002, 124, 3254-62. c) Rajeev, K.; 
 Maier,  M.; Lesnik, E.; Manoharan, M. Org. Lett. 2002, 4, 4395-4398. 
8. Gangamani, B. P.; Kumar, V. A. Chem. Commun. 1997, 1913-1914 
45 
 
Chapter 1 Section 3…….  
9. De la Torre, B. G.; Eritja, R. Bioorg. Med. Chem. Lett. 2003, 13, 391-393 
10. Kohler, O.; Seitz, O. Chem. Comm. 2003, 2938-9. 
11. a) Kohler, O.; Jarikote,  D. V.; Seitz, O. Chem Bio Chem. 2005, 6, 69-77. b) Jarikote, 
 D. V.; Kohler, O.; Socher, E.; Seitz, O. Eur. J. Org. Chem. 2005, 3187-3195. 
12. a) Nielsen, P. E.; Haaima, G.; Lohse, A.; Buchardt, O. Angew. Chem. Int. Ed. 1996, 
 35, 1939-1942. b) Sforza, S.; Haaima, G.; Marchelli, R.; Nielsen, P. E. Eur. J. Org. 
 Chem. 1999, 197-204. 
13. Hyrup, B.; Egholm, M.; Buchardt, O.; Nielsen, P. E. Bioorg. Med. Chem. Lett. 1996, 
 6, 1083-1088. 
14. Barawkar, D. A.; Bruice, T. C. J. Am. Chem. Soc. 1999, 121, 10418-10419. 
15. Efimov, V. A.; Choob, M. V.; Buryakova, A. A.; Chakhmakhcheva, O. G. 
 Nucleosides, Nucleotides & Nucleic Acids. 1998, 17, 1671 - 1679. 
16. Efimov, V. A.; Buryakova, A. A.; Choob, M. V.; Chakhmakhcheva, O. G. 
 Nucleosides, Nucleotides & Nucleic Acids. 1999, 18, 1393 - 1396. 
17. Van der Laan, A. C.; Stromberg, R.; van Boom, J. H.; Kuyl-Yeheskiely, E.; Efimov, 
 V. A.; Chakhmakhcheva, O. G. Tetrahedron Lett. 1996, 37, 7857-7860. 
18. Peyman, A.; Uhlmann, E.; Wagner, K.; Augustin, S.; Breipohl, G.; Will, D. W.; 
 Schafer, A.; Wallmeier, H. Angew. Chem. Int. Ed. 1996, 35, 2636-2638. 
19. Kehler, J.; Henriksen, U.; Vejbjerg, H.; Dahl, O. Bioorg. Med. Chem. 1998, 6, 315-
 322. 
20. Garcia-Echeverria, C.; Husken, D.; Chiesi, C. S.; Altmann, K. Bioorg. Med. Chem. 
 Lett. 1997, 7, 1123-1126. 
21. Kuwahara, M.; Arimitsu, M.; Sisido, M. J. Am. Chem. Soc. 1999, 121, 256-257. 
22. Kumar, V.; Ganesh, K. Acc. Chem. Res. 2005, 38, 404-412. 
23. Kumar, V. Eur. J. Org. Chem. 2002, 2002, 2021-2032. 
46 
 
Chapter 1 Section 3…….  
24. Gangamani, B. P.; Decosta, M.; Kumar, V. A.; Ganesh, K. N. Nucleosides, 
 Nucleotides & Nucleic Acids. 1999, 18, 1409-1411. 
25. a) D'Costa, M.; Kumar, V.; Ganesh, K. Org. Lett. 1999, 1, 1513-1516. b)  D'Costa, 
 M.; Kumar, V.; Ganesh, K. Org. Lett. 2001, 3, 1281-1284. 
26. Sharma, N. K.; Ganesh, K. N. Chem Commun (Camb). 2003, 2484-5. 
27. Puschl, A.; Tedeschi, T.; Nielsen, P. Org. Lett. 2000, 2, 4161- 4163. 
28. a) Govindaraju, T.; Kumar, V.; Ganesh, K. J. Org. Chem. 2004, 69, 5725-5734 b) 
 Govindaraju, T.; Kumar, V. A.; Ganesh, K. N. Chem. Commun. 2004, 860-861 c) 
 Myers, M. C.; Witschi, M. A.; Larionova, N. V.; Franck, J. M.; Haynes, R. D.; Hara, 
 T.; Grajkowski, A.; Appella, D. H. Org Lett. 2003, 5, 2695-8. d) Englund, E. A.; Xu, 
 Q.; Witschi, M. A.; Appella, D. H. J. Am. Chem. Soc. 2006, 128, 16456-7 e) 
 Lagriffoule, P.; Eriksson, M.; Jensen, K. K.; Nielsen, P. E.; Wittung, P.; Norden, B.; 
 Buchardt, O. Chem. Eur. J. 1997, 3, 912-919. 
29. Corradini, R.; Sforza, S.; Tedeschi, T.; Marchelli, R. Chirality. 2007, 19, 269-294. 
30. J.N. Kremsky, M. Pluskal, S. Casey, H. Perry-O’Keefe, S.A. Kates, N.D. Sinha, 
 Tetrahedron Lett. 1996, 37(25), 4313-4316. 
31. a) F.V. Bright, Anal. Chem. 1988, 60, 1031A-1039A; b) R.P. Haughland, Handbook 
 of Fluorescent Probes and Research Chemicals 1992, Molecular Probes, Eugene, OR; 
 c) M. Miki, Eur. J. Biochem. 1987, 164, 229-235. 
32. M. Lu-Steffes et al,. Clin. Chem. 1982, 28, 2278-2282. 
33. Adamczyk, M., Fishpaugh, J. R., Heuser, K. J. Bioconjugate Chem. 1997, 8, 253-255. 
34. Englund, E.A., Appella, D. A, Org. Lett. 2005, 7, 3465-3467. 
35. a) Salvi, J-P., Walchofer, N., Paris, J., Tetrahedron Lett., 1994, 35, 1181-1184 b) 
 Farese, A, Patino, N., Condom, R., Dalleu, S., Guedj, R. Tetrahedron Lett., 1996, 37, 
 1413-1416 c) Falkiewicz, B., Kolodziejczyk, A. S, Lieberek, B, Wisniewski, K., 
 Tetrahedron 2001, 57, 7909. 
36. a) Van der Lann, A.C., Brill, R., Kuimelis, R.G., Kuyl-Yeheskiely, E., van Boom, J. 
 H., Andrus, A., Vinayak, R., Tetrahedron Lett. 1997, 38, 2249-2252 b) Fader, L.D., 
47 
 
Chapter 1 Section 3…….  
48 
 
 Boyd, M., Tsantrizos, Y.S., J. Org. Chem., 2001, 66, 3372-3379 c) Clivio, P., 
 Guillaume, D., Adeline, M-T., Hamon, J., Riche, C., Fourrey, J-L., J. Am. Chem. Soc., 
 1998, 120, 1157-1166 d) Efimov, V. A., Buryakova, A. A., Choob, M., 
 Chakhmakhcheva, O. G., Russ. J. Bioorg. Chem (Engl. Transl) 1998, 24, 618-630. 
37. Egholm, M., Nielsen, P.E., Buchardt, O., J. Am. Chem. Soc, 1992, 114, 9677-9678. 
38. Thomson, S. A., Josey, J. A., Cadilla, R., Gaul, M.D., Hassman, C., Fred, 
 Tetrahedron, 1995, 51, 6179-6194. 
 
 
Chapter 1 Section 4…… 
 
 
 
 
 
 
 
 
 
Chapter 1: Peptide Nucleic Acid (PNA) 
 
Section 4: Aim of the thesis 
 
 
 
 
 
 
 
49 
 
Chapter 1 Section 4…… 
1.4.1. Present Work 
The preceding section has given an overview on the concept of peptide nucleic acids (PNAs) 
which are among the most interesting and versatile artificial structural mimic of nucleic acid 
(DNA). These are having the properties of natural oligonucleotides. The stability of 
PNA/DNA complexes makes PNAs powerful tools in antisense and antigene applications, 
and as markers in DNA screening assays. The major drawbacks of PNA are like poor water 
solubility, inefficient cell uptake, self-aggregation and uncertainty in directionality of binding 
restricts PNA extensive applications. Hence various modifications of PNA for improving the 
activity were attempted by different research groups, and these methods were described in 
section 3 of this chapter. 
This research work concerns with the design, synthesis, characterization and analytical 
studies of newly modified Peptide Nucleic Acids (PNAs), [which is mimic of DNA and 
RNA] in non conventional manner for the applications in DNA interactions, RNA targeting 
and cellular imaging. 
Moreover, in this thesis we introduce a very innovative and new technique for the interaction 
between PNA and DNA by using Stopped-flow spectroscopy. This technique has never been 
used so far to study the interaction between PNA/DNA strands in the formation of hybrids. 
Normally the affinity of PNA for DNA were detected by using melting temperature but 
sometimes this technique is not appropriate, especially if PNA contain some thermal sensitive 
functional groups. So, to overcome these obstacles we started this ingenious study of PNA-
DNA interaction by using stopped-flow spectroscopy. We also design and synthesized PNA 
oligomers having magnetic and luminescent properties by the conjugation of iron oxide 
magnetic nanoparticles (MNPs) and by organometallic gold complexes which are, in 
principle, applicable for diagnostic and therapeutic purposes, miRNA targeting and cellular 
imaging. 
Chapter 2 deals with the design and synthesis of newly modified lysine based Peptide 
Nucleic Acids (PNAs) decamer (A), with the standard TCACTAGATG sequence of 
nucleobases and the corresponding fluorescent PNA-FITU (fluorescein isothiourea) decamer 
(B). All these decamers were manually synthesized by SPPS using standard Boc-based 
chemistry (Figure 1.27) 
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Figure 1.27: Synthesis of Peptide Nucleic Acids (PNAs) decamer (A) and (B) 
The interaction of both decamers (A) and (B) with the complementary parallel and 
antiparallel DNA was followed by steady-state and stopped-flow fluorescence intensity. The 
kinetics of the PNA-DNA duplex formation has been studied. In particular, fluorescence 
stopped-flow technique has been exploited to compare the affinity of two PNA-DNA 
duplexes: using parallel and antiparallel DNA, such data would be very important for the 
evaluation and improvement of antisense reagents and of diagnostic probes based on PNA. 
Chapter 3 deals with the design, synthesis and characterization of Peptide Nucleic Acids 
(PNA) and their conjugation with magnetic nanoparticles (MNPs) for the treatment in 
diagnostic and therapeutic purposes and the synthesis of Heterobifunctional Linker for the 
conjugation of PNA (Figure 1.28) 
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Figure 1.28: Functionalisation of magnetic nanoparticles with PNA through 
heterobifunctional linker. 
However, MNPs-DMSA with functionasalizaion strategies for the specific purpose with 
polymers, antibodies, and cytokines has been reported. In order to take all these advantages, 
so we have been synthesised MNPs subsequently coated with DMSA with functionasalizaion 
strategies with PNA through heterobifunctional linker (D). MNPs surface with amine 
(isocyanate) or carboxylic acid functional groups have been modified with heterobifunctional 
molecule and further reacted with Peptide nucleic acid (PNA). Taking the advantage of this 
approach here is the use of a linker molecule with PNA that anchored to MNPs. Amine-
functionalized PNA were covalently attached to MNP-DMSA via an ethyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) or NHS mediated coupling reaction or by 
Michael addition of free thiol group attached to MNP-DMSA, on to the maleimide group (G). 
 
Chapter 4 deals with design and synthesis of modified Thymine monomer and PNA with 
simple organometallic Gold (I) complexes which is applicable for cellular imaging. Here we 
introduce Phosphine gold (I) on to the Thymine monomer (K) and homothymine decamer (L) 
(PNA) containing the triple bond at the terminal position (Figure 1.30). The development of 
gold (I)-acetylide complexes has led to several novel compounds. Most notably they have 
been investigated for their interesting photochemical properties or rich luminescence 
properties. Luminescence from gold-acetylide complexes typically results from 
“aurophilicity”. 
 
Figure 1.30: Thymine monomer (K) and homothymine 10-mer PNA (L) with gold complex 
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Taking all these advantages, we have successfully synthesized phosphine gold complex of 
thymine monomer in solution phase and studied its photoluminescence emission properties 
and which are applicable in cellular imaging. gold (I) complex which is never carried out in 
the field of conjugation with PNA. 
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2.1.1. Introduction 
Peptide nucleic acid (PNA) is one of the most studied and interesting DNA mimic with great 
potential for biomedical applications, both in diagnostics and therapy1. The chemical 
structure of PNA is quite different with respect to that of natural nucleic acids in that its 
backbone is composed of N-(2-aminoethyl)glycine repeating units forming a pseudopeptide 
chain on which the four nucleobases like adenine or A, cytosine or C, guanine or G and 
thymine or T (Fig. 2.1). The neutral character of PNA molecules and the distance between 
two adjacent nucleobases (the same as that found in DNA and RNA) confer them stronger 
and more selective binding affinity for complementary nucleic acid (DNA and RNA) strands 
than natural nucleic acids2. 
 
Figure 2.1: Peptide Nucleic Acid oligomer (a) with its complementary DNA (b) 
Though in DNA-DNA duplexes the two strands are always in an antiparallel orientation (with 
the 5′-end of one strand opposed to the 3′- end of the other), PNA:DNA adducts can be 
formed in two different orientations, termed parallel (in which the terminal amino group of 
PNA is opposed to the 5′ end of DNA) and antiparallel (where, on the contrary, the amino 
group is opposed to the 3′ end of DNA). However, the antiparallel binding is favoured over 
the parallel one3. The binding of PNAs to DNA and RNA targets is stronger than that of 
DNA-DNA or RNA-RNA bindings4. This enhanced binding affinity is partially due to the 
uncharged property of the PNAs. Since PNAs are neutral in charge, the duplexes formed by 
PNA-DNA or PNA-RNA hybrids lack the electrostatic repulsion formed by DNA-DNA or 
RNA-DNA duplexes, resulting in a very stable duplex formation even at a relatively high 
temperature and a very high binding affinity.  
One of the most popular, easy and reliable method to measure the stability of PNA-DNA 
hybrid systems is the melting temperature (Tm), that is the monitoring of the changes in UV 
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absorption at about 260 nm as a function of temperature5. The higher affinity of PNA-DNA 
binding is expressed by the larger melting temperature values of PNA-DNA hybrids with 
respect to those of DNA-DNA ones. In addition to melting temperature measurements, 
isothermal titration Calorimetry (ITC) 6 and atomic force microscopy (AFM) have been 
proposed as suitable methods7.But the thermodynamic data are obtained using a big quantity 
of materials failing to provide information on the kinetics of the interaction. Surface Plasmon 
Resonance (SPR)8 and SPR-enhanced fluorescence spectroscopy9 have been used to 
investigate also the kinetics of DNA-DNA and PNA-DNA interactions but every technique 
shows some advantages along with some drawbacks and a detailed description of the 
phenomenon is thus limited. 
The stopped-flow absorbance spectroscopy and fluorescence intensity method10 offers a 
powerful tool for a detailed kinetic analysis of interactions since it can monitor reactions 
continuously in real time and in a real physiological medium11. It has been used in the past to 
obtain a detailed understanding of locked nucleic acid (LNA) 11a and PNA12 as a trapping 
strand in helicase-catalyzed unwinding of oligonucleotide substrates. But fluorescence 
stopped-flow spectroscopy has never been used for a detailed PNA interaction study with 
parallel and antiparallel DNA with the aim of measuring the different affinities of the formed 
duplexes. Moreover, Gangamani et al. have previously demonstrated that intrinsic fluorescent 
PNA analogues can be used to monitor PNA self-melting and PNA-DNA duplex transitions 
without affecting or perturbing their structures.13 
2.1.2. Objective 
In the present work, the synthesis of newly modified lysine based Peptide Nucleic Acids 
(PNA) decamer 1, with the TCACTAGATG sequence of nucleobases, and the corresponding 
fluorescent PNA-FITU (fluorescein isothiourea) decamer 2 were synthesized with standard 
manual Boc-based chemistry using MBHA resin loaded with the N(α)-Boc-N(ε)-Fmoc-L-
lysine (Figure 2.2) The interaction of both decamers 1 and 2 with the complementary parallel 
and antiparallel DNA was followed by steady-state and stopped-flow fluorescence intensity. 
The kinetics of the PNA-DNA duplex formation has been studied. In particular, fluorescence 
stopped-flow technique has been exploited to compare the affinity of two PNA-DNA 
duplexes: using parallel and antiparallel DNA, such data would be very important for the 
evaluation and improvement of antisense reagents and of diagnostic probes based on PNA. 
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Figure 2.2: Synthesis of Peptide Nucleic Acids (PNAs) decamer (1) and (2) 
The specific objectives of this chapter are 
 1. Solid phase synthesis of oligomers (PNAs) decamer 1 and corresponding 
 fluorescent PNA-FITU decamer 2 by using standard manual Boc-based chemistry, 
 using MBHA resin loaded with the N(α)-Boc-N(ε)-Fmoc-L-lysine (loading 0.2 
 mmol/g) and also synthesis of aminoethylglycine PNA monomer (Thymine 
 monomer). 
 2. Cleavage from the solid support, purification and characterization of the oligomers 
 3. Kinetic studies of PNA oligomers 1 and corresponding fluorescent PNA-FITU 
 decamer 2 with its complementary parallel and antiparallel DNA by steady-state and 
 stopped-flow fluorescence instrument. This technique has never been used to study 
 the interaction between Peptide Nucleic Acids (PNA) and DNA strands in the 
 formation of hybrids. 
2.1.2.1. Synthesis of aminoethylglycine PNA monomer (aeg T monomer) 
The synthesis of unmodified aegPNA monomers were carried out following the literature 
procedures14. The synthesis was started from the easily available ethylene diamine 3, 
(Scheme 2.1). This was treated with di-tert-butyl dicarbonate to give the mono-protected 
derivative 4 and was obtained by using a large excess of ethylene diamine over the di-tert-
butyl dicarbonate in high dilution conditions. The di-Boc derivative which was obtained as a 
minor product. The N-Boc-ethylenediamine 4 was then subjected to N-alkylation using 
methyl bromoacetate 5 and Triethyl amine in dry acetonitrile to yield the corresponding 
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methyl N-(2-Boc aminoethyl) glycinate 6, which is the common intermediate or backbone for 
the preparation of all the PNA monomers in good yield. This methyl N-(2-Boc aminoethyl) 
glycinate 6 was further treated with thymine acetic acid 7 in presence of N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC.HCl) as a coupling agent 
in anhydrous acetonitrile, gives the corresponding N-(Boc-aminoethylglycyl)-thymine methyl 
ester 8 which was purified by using column chromatography with an excellent yield. The 
methyl ester 8 was hydrolyzed very efficiently with lithium hydroxide in methanol at rt 
followed by acidification by using 1M solution of KHSO4 to give the corresponding acid 9 
which was further used for solid phase synthesis and all the compounds exhibited 1H and 13C 
NMR spectra consistent with the reported data.14  
 
Scheme 2.1: Reagents and conditions: a) (Boc)2O, THF, 0 oC - rt, 12 hr, 95% b) methyl 
bromoacetate (5), NEt3, CH3CN, rt, 3 hr, 40% c) Thymine acetic acid (7), EDC.HCl, CH3CN, 
rt, 3 hr, 82% d) LiOH.H2O, MeOH, rt, 3 hr, 86%. 
2.1.3. General principle of Solid Phase Peptide Synthesis (SPPS) 
The solid phase peptide synthesis method introduced by Merrifield, 15 offers great advantages 
in contrast to solution phase method. The fundamental promise of this technique involves the 
incorporation of N-α-amino acids into a peptide of any desired sequence with one end of the 
sequence remaining attached to a solid support matrix. After the desired sequence of amino 
acids has been obtained, the peptide can be removed from the polymeric support (Scheme 
2.2). The solid support is a synthetic polymer that bears reactive groups such as -NH2. These 
groups are made so that they can react easily with the carboxyl group of an N-α-protected 
amino acid, thereby covalently binding it to the polymer. The amino protecting group can 
then be removed and a second N-α-protected amino acid can be coupled to the attached 
amino acid. These steps are repeated until the desired sequence is obtained. At the end of the 
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synthesis, a different reagent is applied to cleave the bond between the C-terminal amino acid 
and the polymer support; the peptide is then released into solution and can be obtained from 
the solution. 
 
Scheme 2.2: General protocol for solid phase peptide synthesis. 
2.1.3.1. Synthesis of PNA decamer (1) 
As in the case of solid phase peptide synthesis, PNA synthesis is also done conveniently from 
the C- terminus to the N- terminus. For this, the monomeric units must have their amino 
functions suitably protected, with their carboxylic acid functions free. In present work the 
PNA decamer 1 (Scheme 2.2), with the TCACTAGATG sequence of nucleobases, and the 
corresponding fluorescent PNA-FITU decamer 2 (Scheme 2.3) were synthesized with 
standard manual Boc-based chemistry by using MBHA resin (4-methyl-benzhydryl amine) 3. 
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Scheme 2.2: Reagents and conditions: a) HATU, DIPEA, NMP, 24 hr, rt; b) TFA/m-cresol, 
95:5, 2 × 4 min, rt; c) CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; d) PNA monomer, HATU, DIPEA, 
NMP, 2 hr, rt; e) Ac2O/Pyridine/NMP,1:25:25, 2 × 1 min, rt; f) 20% Piperidine in DMF, 2 × 
20 min, rt; g) TFA/TFMSA/thioanisole/m-cresol 6:2:1:1 (v/v), 1 hr, rt. 
The synthesis was performed with standard manual Boc-based chemistry using MBHA resin 
3 loaded with the N(α)-Boc-N(ε)-Fmoc-L-lysine monomer 4 by using HATU as a coupling 
reagent in order to obtain functionalized resin 5 with loading 0.2 mmol/g (Scheme 2.2). Then 
the tert-butyloxycarbonyl (Boc) group of the loaded lysine 5 was removed by treatment with 
5% m-cresol in TFA to get an amine TFA salt which was neutralized by 5% DIPEA in 
dichloromethane. Then the free amine on resin was coupled with thymine monomer with 
DIPEA and HATU in NMP as a solvent. After coupling step resin were washed with NMP, 
and then treated with a solution of Ac2O/pyridine/NMP (1:25:25, v/v). The cycles were 
repeated using the monomers like cytosine, adenine and guanine with the same protocol to 
afford the corresponding supported PNA 10-mer on resin 6. Then, the Fmoc group was 
removed by treatment with a solution of 20% piperidine in DMF to give resin 7, for which 
the presence of the free amino group was confirmed by the Kaiser test. Then the resin were 
cleaved by washing with TFA, and subsequently stirred with a mixture of 
TFA/TFMSA/thioanisole/m-cresol (6:2:1:1 v/v). The reaction mixture was filtered, and the 
filtrate were concentrated to by the addition of diethyl ether to afford white coloured crude 
PNA decamer 1, which was purified by receive phase HPLC and analyzed by mass. 
2.1.3.2. Purification of decamer (1) by reverse phase HPLC 
The crude decamer 1 was purified by reverse phase semi preparative HPLC by column (tR = 
6.2 min). The purity of the 1 was checked by LC-MS (Figure 2.3 and 2.4) 
Figure 2.3: HPLC of decamer 1, retention time 6.2 min. 
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Figure 2.4: ESI-Mass analysis of decamer 1, found m/z:  C114H149N60O31+: 2855.9 
2.1.3.3. Synthesis of fluorescent PNA-FITU decamer (2) 
The MBHA resin 7, with the free amine group on lysine monomer was directly reacted with 
fluorescein isothiocyanate [FITC] with DIPEA in DMF to give resin 8, (Scheme 2.3), which 
were tested by Kaiser Test.  
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Scheme 2.3: Reagents and conditions: g) FITC, DIPEA, DMF, 12 hr, rt; h) 
TFA/TFMSA/thioanisole/m-cresol 6:2:1:1 (v/v), 1 hr, rt. 
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Then the resin were cleaved by washing with TFA and stirred with a mixture of 
TFA/TFMSA/thioanisole/m-cresol (6:2:1:1 v/v). The reaction mixture was filtered, the 
filtrate were concentrated and the residue taken up with diethyl ether to afford a yellow 
coloured crude fluorescent PNA-FITU decamer 2 which was purified by reverse phase HPLC 
and characterized by MALDI-TOF. 
2.1.3.4. Purification of fluorescent PNA-FITU decamer (2) by reverse phase HPLC 
The fluorescent PNA-FITU decamer 2 was purified by reverse phase semi preparative HPLC 
(tR = 12.9 min). The purity of 2 was checked by LC-MS (Figure 2.4 and 2.5) 
 
Figure 2.4: HPLC of fluorescent PNA-FITU decamer 2, retention time 12.9 min. 
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Figure 2.5: ESI-Mass analysis of fluorescent PNA-FITU decamer 2, found m/z:  
C135H160N61O36S+: 3245.7 
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2.2.1. Introduction to Fluorescence Stopped-flow spectroscopy 
Fluorescence spectroscopy has been widely used to study ligand-protein interaction because 
of its simplicity and sensitivity. Fluorescence methods are particularly popular because they 
are well suited for protein-ligand interactions with dissociation constants in the range of 10
-4
 
to 10
-8
 M, where some protein-nucleic acid dissociation constants fall. Many fluorescence 
parameters, such as anisotropy, intensity and energy transfer efficiency, are sensitive to 
formation of protein-ligand complexes and can be utilized to derive binding isotherms
1
. The 
change in fluorescence intensity on formation of a protein ligand complex is one of the 
simplest ways to measure binding of a ligand to a protein. 
Stopped flow: 
Stopped-flow technique is useful for studying fast reactions that have half-lives as short as a 
few milliseconds
2
. Many methods are available for measuring the equilibrium binding 
constant of a protein with a ligand, where the ligand can be a small molecule or another 
macromolecule such as a protein or nucleic acid. However, many biological processes are 
controlled not by equilibrium constants but by the kinetics of the interaction between protein 
and ligand and for this reason it is necessary to measure the association and dissociation rate 
constants in order to fully understand a system. Although this can be done using surface 
plasmon resonance techniques, and in certain cases by NMR measurements, rapid-reaction 
methods are generally the method of choice if a suitable intrinsic optical probe exists in the 
system or an extrinsic probe can be introduced. 
In the stopped-flow technique
3
, two solutions are rapidly mixed together and at any given 
point the age of the solution is defined by the flow rate and the volume between mixing and 
observation. However, by the use of a back syringe, the flow of mixed reactants is suddenly 
stopped and the reaction is followed in real time with a suitable detection system (Figure 2.l) 
 
 
 
 
Figure 2.1: The stopped-flow instrument and its diagrammatic representation. 
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The stopped-flow absorbance spectroscopy and fluorescence intensity method
4
 offers a 
powerful tool for a detailed kinetic analysis of interactions since it can monitor reactions 
continuously in real time and in a real physiological medium
5
. It has been used in the past to 
obtain a detailed understanding of locked nucleic acid (LNA)
 6
 and PNA
7
 as a trapping strand 
in helicase-catalyzed unwinding of oligonucleotide substrates. But fluorescence stopped-flow 
spectroscopy has never been used for a detailed PNA interaction study with parallel and 
antiparallel DNA with the aim of measuring the different affinities of the formed duplexes. 
Moreover, Gangamani et al. have previously demonstrated that intrinsic fluorescent PNA 
analogues can be used to monitor PNA self-melting and PNA-DNA duplex transitions 
without affecting or perturbing their structures
8
.  
The objective of this work is to study PNA-DNA interaction from a kinetic point of view 
with a non-consuming and fast spectroscopic method. With this technique, with respect to 
steady-state spectroscopy, in a single experiment, the data that can be collected are many: a 
complete kinetic profile can be obtained as well as a thermodynamic description of the 
interaction. 
2.2.2. Results and Discussion 
PNA decamer 1 and fluorescein isothiocyanate (FITC) labelled PNA decamer 2 (PNA-FITU) 
were synthesized with a standard manual Boc-based chemistry (Section 1, Scheme 2.2 and 
2.3). N(α)-Boc-N(ε)-Fmoc-L-lysine loaded MBHA resin (loading 0.2 mmol/g) was used to 
build the TCACTAGATG PNA decamer sequence. The (ε) amino group of the lysine was 
used as anchoring point for the FITC. Therefore, in decamer 1 the (ε) amino group of the 
lysine residue is present as a free amino moiety, while in decamer 2 it is conjugated with the 
FITC, becoming PNA-FITU (Fluorescein isothiourea). 
The interaction of both decamers 1 and 2 with the complementary parallel and antiparallel 
DNA was followed by steady-state and stopped-flow fluorescence intensity. 
2.2.2.1. Steady-state experiment 
Preliminary UV-Vis and steady-state fluorescence experiments were performed in order to 
check the complex formation between PNA and DNA. The steady state experiment was 
performed by keeping PNA-FITU 2 concentration constant (0.2 μM) and titrating an 
increasing concentration of antiparallel DNA in the concentration range 1.6-16 μM in order 
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to reach saturation (Figure 2.2a). The fluorescence intensity maxima of the spectra were 
plotted against DNA concentration and the data were fitted to a rectangular hyperbola (Figure 
2.2b) to get the thermodynamic binding constants
9, 10
 and the spectra were obtained by 
exciting at 480 nm and collecting the spectra in the 480-650 nm range. 
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Figure 2.2: (a) Titration curves of the PNA-FITU vs antiparallel DNA interaction followed 
by steady-state fluorescence and (b) plot of the fluorescence intensity maxima (black squares) 
against DNA concentration and nonlinear fitting to hyperbole (red curve) to get the 
thermodynamic binding constants. 
2.2.2.2. Stopped Flow experiment 
However from the UV-Vis and steady-state fluorescence experiments conclude that 
fluorescent biolabeling did not interfere in the binding, so by taking this advantage we were 
studied the kinetic binding experiment by stopped flow fluorescence. The binding was 
investigated under pseudo-first order condition
11
 ([DNA] ≫ [PNA-FITU]) by monitoring the 
fluorescence changes after the formation of the complex. The two interactions (PNA-FITU 
versus both parallel and antiparallel DNA) were studied by keeping PNA-FITU concentration 
fixed at 0.12 μM and changing the DNA concentration over the range 0.8-8 μM. Figure 2.3 
shows that on mixing 0.12 μM PNA-FITU with 4 μM DNA (cell concentration) there is a 
decrease of the signal which reaches a plateau after few ms. 
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Figure 2.3: The stopped-flow fluorescence intensity record of the binding of 0.2 μM PNA-
FITU to (a) 4 μM antiparallel DNA and (b) 4 μM parallel DNA. The reported concentrations 
are real cell concentrations. 
Raw data were analyzed and plotted to a single exponential function providing the so called 
observed rate constant (kobs). Figure 2.4 shows the dependence of the kobs of DNA (both 
parallel and antiparallel) binding to PNA. The different behaviour when comparing parallel 
and antiparallel DNA is evident: in the case of antiparallel DNA binding to PNA-FITU, the 
kobs evaluation is reproducible and the dependence with concentration is pronounced. 
Moreover, the repeatability is very good with a standard deviation for each concentration 
point being extremely small. A completely different scenario is recorded for parallel DNA 
where the fitting of the single curves to get kobs is more difficult and the fitting to get any 
insight on the association and dissociation constants of the overall interaction results nearly 
impossible (Figure 2.4b). This suggests a weaker interaction of PNA-FITU with parallel 
DNA in agreement with the Tm measurements. 
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Figure 2.4: kobs dependence for antiparallel DNA (a) and parallel DNA (b). 
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In any case, we can observe that kobs dependence from (DNA) is, in term of slope of the line, 
comparable for both parallel and antiparallel DNA. The fact that the antiparallel DNA 
interaction is stronger and more reproducible is in agreement with the Tm measurements. For 
the PNA-FITU/antiparallel DNA interaction, the values of the kinetic parameters (kon and 
koff) can be calculated from the slopes and intercepts of the linear plots of kobs versus 
increasing concentration of DNA (equation 2.1)
4a
. 
    kobs = kon [DNA] + koff   -----(2.1) 
The slope of the straight line is the kon (second-order rate constant or rate constant of 
association process; units, M
-1
 s
-1
) and the intercept on the ordinate is the koff (first-order rate 
constant or rate constant of dissociation process; units, s
-1
). For the PNA-FITU interacting 
with antiparallel DNA, the second-order rate constant kon is 2.27·10
6 
± 1.12·10
5
 M
-1
 s
-1
. As it 
can be seen, the intercept on the ordinate has a very small value (2.62 ± 0.56 s
-1
). This means 
that the interaction is nearly completely shifted toward the formation of the complex. This 
interaction was also studied at higher concentrations of antiparallel DNA (up to 15 μM) to 
further monitor the interaction (Figure 2.5) and we are getting almost the same kinetic 
constants. 
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Figure 2.5: kobs dependence for anti-parallel DNA in the 0.8-15 µM range. 
2.2.2.3. Displacement experiment 
Since the dissociation rate constant value seems to be small, the koff obtained from the 
intercept cannot be consistent. To gain more information and to measure koff value accurately, 
a displacement experiment was executed as proposed previously for a protein-protein 
interaction.
5a
 Briefly, in the displacement experiment (Scheme 2.1), a solution containing 
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fluorescent PNA-FITU (PNA-fL) and DNA were mixed together. The concentration of PNA 
FITU chosen to get a saturation of DNA, and then a high concentration of unlabeled PNA 
(PNA-nfL) was added so that PNA-FITU dissociates from DNA and cannot re-associate. 
 
Scheme 2.1: Scheme of the displacement experiment 
In this way the rate constant of the observed process were determined only by the k-1 in 
Scheme 2.1 which was measure directly by the displacement of PNA-FITU from its complex 
with DNA using an excess of unlabeled PNA. Experimentally, the increasing fluorescence 
intensity was monitored during the process and the corresponding record was fitted to give 
directly an average rate constant koff value of 32.2 s
-1
 (Figure 2.6). 
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Figure 2.6: Displacement experiment: 50 μM of unlabelled PNA (PNA-nfL) is used to 
displace antiparallel DNA (1 μM) to PNA-FITU (PNA-fL, 1 μM). 
This koff value together with that obtained for the kon allowed us to calculate the 
thermodynamic dissociation constant Kd (i.e. koff/kon) value of 14.2 μM for PNAFITU/ 
antiparallel DNA interaction, being in the same order of magnitude compared to the Kd 
obtained by steady-state fluorescence in the same buffer (2.5 μM) (Figure 2.2). 
2.2.2.4. Temperature dependence experiment (Tm)  
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We also studied the temperature dependence experiment for the binding constants on our 
PNA-FITU 2 with its complimentary parallel and anti-parallel DNA. The same interaction 
experiments were repeated at 50 °C for both DNAs. The dependence of kobs on parallel and 
antiparallel DNA concentration was again investigated in the range 0.8-8 μM (Figure 2.7). 
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Figure 2.7: Temperature dependence of kobs for (a) antiparallel DNA and (b) parallel DNA. 
As is evident, in the case of parallel DNA, there is no temperature dependence of the 
interaction. On the contrary, the behaviour of PNA/antiparallel DNA interaction is different 
when working at 25 or 50 °C. In this case, it is possible to express numerically the strength of 
the two interactions (Table 2.1). As expected, the binding constant increases by increasing the 
working temperature. 
Temperature (°C) 
K
a
 (∙10
4
) M K
d
 (∙10
-6
) M
-1
 K
on
 (∙10
6
) M
-1
s
-1
 K
off
 s
-1
 
25 7.05 14.18 2.27 32.2 
50 17.69 5.65 4.67 26.4 
 
Table 2.1: Thermodynamic and kinetic binding constants for PNA-FITU vs antiparallel DNA 
interaction at different temperatures. 
2.2.3. Conclusion 
In the present chapter, the PNA decamer 1, with the TCACTAGATG sequence of 
nucleobases and the corresponding fluorescent PNA-FITU (fluorescein isothiourea) decamer 
2 were synthesized with standard manual Boc-based chemistry. 
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The interaction of both decamers 1 and 2 with the complementary parallel and antiparallel 
DNA was followed by steady-state and stopped-flow fluorescence intensity and this has 
never been used or studied so far. In particular, fluorescence stopped-flow technique has been 
exploited to compare the affinity of two PNA-DNA duplexes: using parallel and antiparallel 
DNA, such data would be very important for the evaluation and improvement of antisense 
reagents and of diagnostic probes based on PNA. 
Stopped-flow fluorescence showed the poor binding of PNA with its parallel DNA but was 
very useful for the determination of the binding constants for the PNA-antiparallel DNA 
interaction. The kinetic and thermodynamic constants obtained by stopped-flow fluorescence 
were in complete agreement with those obtained by steady-state measurements. 
To conclude the stopped-flow has proved to be a reliable, non-consuming, in terms of time 
and sample, and fast method to discriminate the different behaviour between the parallel and 
antiparallel DNA. In the case of the interaction between PNA and antiparallel DNA, stopped-
flow fluorescence has revealed its power, with respect to the melting temperature, in the 
possibility of working in a physiological environment with a real mimic of the interaction. 
All these kinetic studies with stopped-flow instrument have been done in collaboration with 
the University of Torino, Italy. 
2.2.4. Experimental Section 
2.2.4.1. General Materials and Methods 
The thymine monomer aeg-(T) PNA-COOH was synthesized according to the literature
12
. 
The other three monomers containing the nucleobases C, G and A were purchased from ASM 
Research Chemicals and were used as such without further purification. 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxidhexafluoro phos -
phate (HATU), fluorescein isothiocyanate isomer I (FITC), N(α)-Boc-N(ε)-Fmoc-L-lysine, 
trifluoroacetic acid (TFA), trifluoromethanesulfonic acid (TFMSA) and m-cresol were 
purchased from Aldrich. N-methyl-2-pyrrolidone (NMP), N, N-diisopropylethylamine 
(DIPEA) and thioanisole were purchased from Fluorochem. Polystyrene bead carrying 4-
methylbenzhydrylamine hydrochloride salt groups (MBHA resin, 0.63 mmol/g) was 
purchased from VWR International. Parallel DNA (5′-3′ sequence: CATCTAGTGA) and 
antiparallel DNA (5′-3′ sequence: AGTGATCTAC) were purchased from Eurofins 
Genomics, Germany. 
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2.2.4.2. Experimental Techniques 
UV-Vis measurements for the evaluation of the PNA-FITU concentration and the FITC 
labelled and unlabelled PNA-DNA interaction studies were recorded using a Varian cary 300 
Bio UV-Visible Spectrophotometer. Steady state fluorescence measurements were recorded 
using a Fluorolog 2 from Jobyn Ivon. As a preliminary analysis for the stopped flow binding 
experiments, steady-state fluorescence spectra were recorded in the range of 495-650 nm 
upon excitation at 480 nm, at 25 °C, in order to investigate the binding of PNA-FITU to 
DNA.  
Fluorescence kinetics measurements were recorded using an Applied Photophysics SX20 
stopped-flow spectrometer fitted with a 515 nm cut-off filter between the cell and 
fluorescence detector and equipped with a thermostat bath. The excitation wavelength was 
480 nm and slits widths of the excitation monochromator were 1.0 mm. Data acquisition, 
visualisation and analysis were provided by Pro-Data software from Applied Photophysics 
Ltd. 
1
H and 
13
C NMR spectra were recorded on Bruker 300 MHz and 70 MHz respectively. 
Chemical shifts (δ) are reported in parts per million relative to solvent peak. Many of the 
compounds described below showed many rotamers and consequently exhibit complex 
1
H 
NMR patterns. Some of the signals in the 
1
H NMR are therefore described as major (ma.) and 
minor (mi.) components; however, in many cases, some minor signals were obscured by the 
major signal of another proton. In such cases, only the major signal is reported or a range 
containing two or more CH2. In some cases, the 
13
C spectrum shows many peaks that cannot 
be distinguished in a small range: ov. Means ‘overlapped’. Melting points of samples were 
determined in open capillary tubes with a Büchi Melting Point B-540 apparatus and (dec) 
indicates decomposition. The IR spectra were recorded on a Perkin-Elmer FTIR 4100. Mass 
spectra were obtained by LCMS techniques (a Thermo Scientific LCQ Advantage). TLC was 
performed using TLC glass plates pre-coated with silica gel (Merck). TLCs were visualized 
with UV light and/or either by charring in Ninhydrine solution or developing in I2 chamber. 
Silica gel 60-120 and 100-200 mesh was used for column chromatography using ethyl 
acetate/hexane and dichloromethane/methanol mixture as elution solvent depending upon the 
compound polarity and chemical nature. Commercial reagents were generally used as 
received. Solvents used in organic reactions were distilled under an inert atmosphere. Unless 
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otherwise noted, all reactions were carried out at room temperature. Oligomers were 
characterized by RP HPLC, using C18 column and MALDI-TOF mass spectrometry. 
All weightings of reagents were carried out with analytical balance Mettler Toledo AB135- 
S/FACT. Vials ALLTECH of 1.5 ml, 4 ml and 8 ml with frits of PTFE were used as reactor 
for manual solid phase synthesis. The downloading of the MBHA resin 3 was performed 
using the standard manual Boc-based chemistry and reported here: 
1. Wash 0.1 gm MBHA resin twice in DCM and swell for 30 min. 
2. Wash the resin with 5% DIPEA in DCM for 3 minutes. 
3. Wash the resin twice in DCM. The resin is now neutralized. 
4. Dissolve 0.20 mmol (amino acid or PNA monomer) in 0.5 mL NMP. 
5. Add 0.4 mmol DIPEA to the monomer solution. 
6. Dissolve 7.79 mg (0.19 mmol) HBTU in 0.5 mL NMP, and add this to the monomer 
 solution. 
7. Activate the monomer for 2 minutes. 
8. Add the activated monomer solution to the neutralized resin. 
9. Allow the reaction to proceed for 24 hour. 
10. Filter the resin. 
11. Wash the resin with 2 x NMP 
12. Make 5 mL of capping solution using a 1:2:2 ratios of acetic anhydride, pyridine and 
 NMP 
13. Add the capping solution to the resin and allow the reaction to proceed for 1 hour. 
 Successful capping will produce a negative Ninhydrine test. 
14. Wash the resin with 2 x NMP 
15. Wash the resin with 4 x DCM. 
16. Wash the resin with2 mL of 5% DIPEA in DCM. 
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17. Wash the resin with 4 x DCM. 
18. Dry the resin in vacuum. 
The cleavage procedure to remove PNA oligomers from the MBHA resin is the following: 
1. Wash the resin 2 x with TFA. 
2. Make 1 mL of cleavage solution TFA/TFMSA/m-cresol/thioanisole 6:2:1:1. 
3. Add the cleavage solution to the resin and allow the reaction to proceed for 1 hr on 
 an orbital shaker. 
4. Filter the resin and recover the solution in a centrifuge tubes 
5. Wash the resin with TFA 
6. Filter the resin and add this solution to the one recovered at point 4. 
7. Repeat point 5 and 6 three times 
8. Remove volatiles by nitrogen stream to afford black/brown oil. 
9. Add cold diethyl ether to the tube and mix. A white precipitate forms. 
10. Put the tube at -20°C for 1 hr to complete the precipitation. 
11. Centrifuge and remove the solvent by pipetting the ether. 
12. Wash the solid with fresh ether, mix, centrifuge and remove the solution. 
13. Repeat point 12 four/five times 
14. Dry the crude PNA first by nitrogen stream and then in vacuum. 
HPLC of PNA oligomers were performed with a HPLC AGILENT 1100 Series, using an 
analytical column DISCOVERY
®
 BIO WIDE PORE C18 (15 cm x 4.6 mm, 5 μM) and a 
semi preparative column DISCOVERY
® 
BIO WIDE PORE C18 (25 cm x 10 mm, 10 μM). 
MALDI-TOF spectra were recorded with a Bruker Daltonics Omniflex. Pulsed nitrogen 
lasers (337 nm) were used to generate ions that have been accelerated in a 20 kV field. The 
instrument was calibrated in the range from 0 to 20 KDa. Generally, Sinapinic acid and 2, 5- 
dihydroxybenzoic acid (DHB) matrixes were used. 
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A lyophilizer Telstar Cryodos were used to isolate pure PNA oligomers from aqueous 
solutions. 
2.2.4.3. Experimental Procedures 
Tert-butyl (2-aminoethyl) carbamate (4) 
A solution of di-tert-butyl dicarbonate (0.5 g, 2.29 mmol) in THF 
(10 mL) was added over 30 min to a stirred, cooled solution of 
ethylene diamine 3 (0.46 mL, 6.87 mmol) in THF (10 mL) at 0 
o
C. 
After addition was complete, the reaction mixture was stirred in an 
ice bath for 30 min and then at room temperature for 12 h. After completion of reaction 
(monitored by TLC), solvents were removed under reduced pressure, the reaction mixture 
was diluted with brine (5 mL) and extracted with ethyl acetate (3 X 10 mL). The combined 
organic extracts were dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure to afford compound 4 (0.350 gm, 95%) as a oily product, which were used without 
further purification. 
Molecular formula: C7H16N2O2 
Rf: 0.2 (ethyl acetate) 
1
H NMR (300 MHz, CDCl3): δ 1.42 (s, 9H), 2.77 (t, 2H), 3.15 (m, 2H), 5 (bs, 1H). 
13
C NMR (75 MHz, CDCl3): δ 28.30, 41.67, 43.12, 79.09, 156.19 
MS (ESI) (m/z): 160 monoboc. + 260 diboc.[M+Na]
+
  
 
methyl (2-((tert-butoxycarbonyl)amino)ethyl)glycinate (6) 
N-Boc-ethylene diamine 4 (8.5 gm, 55.31 mmol) was 
dissolved in acetonitrile (10 mL) to that solution 
triethylamine (5.9 gm, 58.64 mmol) were added dropwise, 
and then Methyl bromoacetate 5 (8.9 gm, 58.64 mmol) was 
added under vigorous stirring over 30 min. The reaction mixture was allowed to stir for 
another 2 hr. The progress of the reaction mixture was monitored by TLC. After completion 
of the reaction, mixture were reduced in on rota vapour to afford an yellow residue, which 
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was diluted in water (10 mL), The solution was cooled to 0-5 °C and the pH was adjusted to 
10 – 10.5 with 2 M NaOH solution. The solution was extracted with DCM (2 X 10 mL). 
Again the pH of the water phase was adjusted to 11.2 with 2 M NaOH solution and then 
extracted with ethyl acetate (3 X 20 mL). The combined organic extracts were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford crude 
compound 6. The crude product was purified on flash chromatography (SiO2, 3:7 EtOAc: 
Hexane) to 6 as a pale yellow oil in 40% yield. 
Molecular formula: C10H20N2O4 
Rf: 0.3 (ethyl acetate) 
1
H NMR (300 MHz, CDCl3): δ 1.42 (s, 9H), 2.72 (t, 2H), 3.18 (q, 2H), 3.40 (s, 2H), 3.71 (s, 
3H), 5.07 (bs, 1H). 
13
C NMR (75 MHz, CDCl3): δ 28.24, 39.93, 48.62, 50.04, 51.67, 77.00, 78.97, 156.00, 
172.63 
MS (ESI) (m/z): 255 [M+Na]
 + 
 
 
Methyl-N-(2-((tert-butoxycarbonyl)amino)ethyl)-N-(2-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)acetyl)glycinate (8) 
To a stirred solution of the compound 6 (0.74 g, 32.17 
mmol) in acetonitrile (10 mL), Thymine acetic acid 7 (0.65 
gm, 35.39 mmol) was added under nitrogen atmosphere and 
stir the reaction at room temperature for about 10 min., then 
EDC.HCl (0.7 g, 35.39 mmol) were added in portion-wise 
over a period of 30 min. The reaction mixture was allowed 
to stir for another 3 hr at room temperature. The progress of 
reaction was monitored by TLC. After completion of reaction solvent was removed under 
reduced pressure, the reaction mixture was diluted with brine (10 mL) and extracted with 
ethyl acetate (3 X 20 mL). The combined organic extracts were dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure to afford crude compound 8, which 
was purified on flash column chromatography (SiO2) using ethyl acetate as a eluent to afford 
compound 8 as a white solid (1.02 gm, 82% yield); M.P.: 158 
o
C. 
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Molecular formula: C17H26N4O7 
Rf: 0.75 (ethyl acetate: methanol, 70:30)  
IR (CHCl3): 3421, 2360, 1756, 1698, 1666, 1474, 1426, 1255, 1210, 1016 cm
-1
. 
1
H NMR (300 MHz, CDCl3): δ 1.45 (s, 9H), 1.91 (s, 3H), 3.35 (q, 2H), 3.54 (t, 2H), 3.76 (s, 
3H), 4.07 (d, 2H), 4.58 (d, 2H), 5.56 (t, 1H), 6.97 (s, 1H), 8.81 (s, 1H)  
13
C NMR (75 MHz, CDCl3: mix of rotamers): δ 12.30, 28.40, 38.83, 47.74, 48.98, 50.30, 
52.49, 77.00, 80.07, 110.79, 140.87, 151.00, 156.00, 164.01, 167.41, 170.11 
MS (ESI) (m/z): 398 [M+Na]
 + 
 
 
N-(2-((tert-butoxycarbonyl)amino)ethyl)-N-(2-(5-methyl-2,4-dioxo-3,4-hydropyrimidin-
1 (2H)-yl)acetyl)glycine (9) / [Boc-T-OH]  
To a stirred solution of the compound 8 (1 gm, 26.35 mmol) 
in Methanol (10 mL), LiOH (0.55 gm, 13.18 mmol) was 
added and stir the reaction at room temperature for 3 hr. The 
progress of reaction was monitored by TLC. After 
completion of reaction solvent were removed under reduced 
pressure, to afford an yellow residue which was diluted with 
brine (10 mL) and extracted with DCM (3 X 10 mL). The 
solution was cooled to 0-5 °C and the pH was adjusted to 2 with 2 M KHSO4 solution. The 
solution was extracted with ethyl acetate (3 X 20 mL). The combined organic extracts were 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford an 
crude acid (9). To that acid add about 10 mL of diethyl ether and stir it for about 1 hr at room 
temperature, then filter the acid and wash it with diethyl ether 10 mL, and dried it on vacuum 
to afford 9 (0.9 gm, 86%) as a white solid. M.P.: 118-120 
o
C. 
Molecular formula: C16H24N4O7 
Rf: 0.02 (ethyl acetate: methanol, 80:20) 
IR (Nujol): 3420, 2361, 1653, 1541, 1456, 1251, 1006 cm
-1
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1
H NMR (300 MHz, DMSO-d6: mix of rotamers): δ 1.38 (s, 9H), 1.75 (s, 3H), 3.17 (m, 2H), 
3.38 (t, 2H), 3.97 (d, 2H), 4.64 (d, 2H), 6.62 (s, 1H), 11.27 (s, 1H), 12.67 (bs, 1H) 
13
C NMR (75 MHz, DMSO-d6: mix of rotamers): δ 11.93, 28.17, 38.05, 39.51, 46.77, 47.54, 
49.07, 78.05, 108.13, 142.02, 151.00, 155.75, 164.39, 167.17, 170.48 
MS (ESI) (m/z): 384 [M+Na]
 + 
 
 
Loading (0.2 mmol/gm) of N(α)-Boc-N(ε)-Fmoc-L-lysine monomer 4 on MBHA resin (5) 
The MBHA resin 3 (0.4 gm) was washed with CH2Cl2 
(2 x 5 mL) and activated by treatment with 5% DIPEA 
in CH2Cl2 for 5 min for 3 times; and then washed with 
CH2Cl2 (2 x 5 mL). In a vial, DIPEA (27 μL, 0.16 
mmol) was added to a solution of N(α)-Boc-N(ε)-
Fmoc-L-lysine monomer 4 (37.5 mg, 0.08 mmol) in NMP (1 mL); then, a solution of HBTU 
(30.3 mg, 0.08 mmol) in NMP (1 mL) in another vial and add this solution into the monomer 
solution, and activate the monomer solution for 2 minutes. This mixture was then added to 
the neutralized resin and at rt for 12 hr. The resin was washed with NMP (3 x 5 mL). A 
solution of Ac2O/Py/NMP 1:2:2 (5 mL) was added to the resin (capping of unreacted amino 
groups) and left under stirring at rt for 1 h. After this time, the resin was washed with NMP (3 
x 5 mL), CH2Cl2 (4 x 5 mL), 5% DIPEA in CH2Cl2 (2 x 5 mL) and again with CH2Cl2 (4 x 5 
mL); and finally dried in vacuum to afford the MBHA resin downloaded with lysine 
monomer 5 (0.492 g); Kaiser Test: negative. 
 
Synthesis of the resin supported TCACTAGATG sequence of nucleobases aeg-PNA 
decamer (6) 
Solid phase synthesis was done by using 
standard manual Boc-based chemistry; resin 5 
(100 mg, substitution with 0.2 mmol/gm) was 
placed in a reaction vessel (volume; 8 mL) and 
which was swollen with CH2Cl2 for 30 minutes, 
the Boc group of the loaded monomer was removed by treatment with TFA/m-cresol (95:5), 
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(3 mL, 2 x 4 min). The resin was washed with CH2Cl2 (2 x 5 mL) and then treated with 
CH2Cl2/DIPEA (95:5), (3 mL, 2 x 2 min). Then the resin was washed thoroughly with 
CH2Cl2 (2 x 5 mL). In a vial, DIPEA (35 μL, 0.2 mmol, 10 eq.) was added to a solution of 
aeg-(T) PNA-COOH monomer 9 (40.7 mg, 0.106 mmol, 5.3 eq.) in NMP (500 μL); then, a 
solution of HATU (38 mg, 0.1 mmol, 5 eq.) in NMP (500 μL) in another vial and add this 
solution into the monomer solution, and activate the monomer solution for 2 minutes. This 
mixture was then added to the neutralized resin and shaken for 2 hr at rt. After coupling step 
the resin was filtered, washed with NMP (3 x 5 mL) and CH2Cl2 (3 x 5 mL). Then resin 
treated with Ac2O/Py/NMP; 1:25:25 capping solution twice for 1 min. and again washed the 
resin with CH2Cl2 (3 x 5 mL), NMP (3 x 5 mL) and CH2Cl2 (3 x 5 mL). The cycle was 
repeated using the required monomers like cytosine (53.4 mg), adenine (56 mg) and guanine 
(57.6 mg) with the same protocol and after the last coupling and capping the resin was 
washed with several times with NMP and CH2Cl2 and finally dried the resin under vacuum to 
afford the corresponding supported PNA decamer on resin 6 (146 mg). 
 
Synthesis of the resin supported TCACTAGATG sequence of nucleobases aeg-PNA 
decamer (7) 
The Fmoc-L-lysine TCACTAGATG-NHBoc 
MBHA resin 6 (100 mg) was swollen with 
CH2Cl2 for 30 minutes. Then the Fmoc group 
was removed by treatment with a solution of 
20% piperidine in DMF (2 mL, 3 x 20 min) the 
resin was filtered, washed with DMF (3 x 5 mL, 3 min) and CH2Cl2 (3 x 5 mL, 3 min) to 
afford an resin 7, for which the presence of the free amino group was confirmed by the Kaiser 
test. 
Synthesis of PNA Decamer (1) 
 
Chapter 2 Section 2…….   
82 
 
Cleavage: The resin 7 (100 mg) was washed with TFA (2 × 200 μL) and subsequently stirred 
for 1 hr with a mixture of TFA/TFMSA/thioanisole/m-cresol [6:2:1:1 v/v] (500 μL). The 
reaction mixture was filtered, and the resin washed with TFA (4 × 200 μL). The filtrate was 
concentrated under nitrogen flow and Et2O (5 mL) was added to precipitate PNA as a white 
solid. Centrifugation of the slurry gave the product, which was washed with Et2O (8 x 5 mL) 
and dried to afford the crude decamer 1 (28 mg). Purification of the crude PNA by RP-HPLC 
afforded the PNA 10-mer 1 (7.4 mg) as a white solid. 
Retention time (analytic column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
AcCN/TFA 0.1%) = 6.2 min. 
Maldi Tof MS: found m/z: 2855.9 [M] +, calculated for C114H149N60O31
+
: 2855.83. 
 
Synthesis of fluorescent PNA-FITU decamer (8) 
The MBHA resin 7 (100 mg) was washed with 
CH2Cl2 (2 x 5 mL), the free amine group on 
lysine, was directly reacted with fluorescein 
isothiocyanate [FITC]. In particular, a solution 
of DIPEA (34 μL, 0.2 mmol, 8 eq.) and FITC 
(38.60 mg, 0.099 mmol, 4 eq.) in DMF was added to the resin and shaken at room 
temperature for 12 h. Then the resin was washed with DMF (3 x 5 mL) and CH2Cl2 (3 x 5 
mL) to afford resin 8. 
 
Synthesis of fluorescent PNA-FITU decamer (2) 
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Cleavage: The resin 8 (100 mg) was washed with TFA (2 × 200 μL) and subsequently stirred 
for 1 hr with a mixture of TFA/TFMSA/thioanisole/m-cresol [6:2:1:1 v/v] (500 μL). The 
reaction mixture was filtered, and the resin washed with TFA (4 × 200 μL). The filtrate was 
concentrated under nitrogen flow and Et2O (5 mL) was added to precipitate PNA as a white 
solid. Centrifugation of the slurry gave the product, which was washed with Et2O (8 x 5 mL) 
and dried to afford the crude decamer 2 (26 mg). Purification of the crude PNA by RP-HPLC 
afforded the PNA-FITU decamer 2 (7 mg) as a yellow solid. 
Retention time (analytic column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
AcCN/TFA 0.1%) = 12.9 min. 
Maldi Tof MS: found m/z: 3245.7 [M]
 +
, calculated for C135H160N61O36S
+
: 3245.22. 
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3.1.1. Rationale 
In the past decade, the non-coding microRNAs (miRNA) have emerged as a novel class of 
potent regulatory molecules that are found in a wide variety of organisms, able to modulate 
gene expression at the post-transcriptional level. They are responsible for regulating many 
biological processes including differentiation, apoptosis, proliferation and cell-fate 
determination. miRNAs are highly conserved in different animals, suggesting an early 
recruitment and a conserved role of these molecules in animal development. The 
dysregulation of miRNAs has been implicated in a variety of pathologies, such as 
inflammatory and autoimmune diseases, neurological disorders, as well as several types of 
cancer. Anti-miRNA platforms highly effective in in-vitro cell assays have been reported, but 
translation to the clinic is hampered by poor in-vivo stability of nucleic acids and ineffective 
uptake of nucleic acids by target cells. 
The aim of this research is to overcome these obstacles by designing, producing and in-vivo 
testing new miRNA targeting materials constituted by chemically modified Peptide Nucleic 
Acids (PNAs, synthetic mimics of natural DNA and RNA)1. PNAs allow combining the 
versatility of synthetic materials with the effectiveness of the natural nucleic acids targeting, 
arising from the Watson-Crick base-pairing scheme. Moreover, PNAs are insensitive to 
enzymatic biodegradation by nucleases or peptidases and have outstanding chemical and 
thermal stability.  
3.1.2. Scientific background: MicroRNAs 
MicroRNAs (miRNAs or miRs) are a family of small (19-25 nucleotides in length) 
noncoding RNAs, which in the past decade have emerged as a novel class of potent 
regulatory molecules that are found in a wide variety of organisms, able to modulate gene 
expression at the post-transcriptional level2. They are responsible for regulating many 
biological processes including differentiation, apoptosis, proliferation and cell-fate 
determination. The dysregulation of miRNAs has been demonstrated to be associated with a 
variety of pathologies, such as inflammatory and autoimmune diseases, neurological 
disorders, as well as several types of cancer3. The inhibition of miRNAs using antisense 
oligonucleotides is an effective technique for the characterization and subsequent therapeutic 
targeting of miRNA function. 
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Moreover, PNAs are resistant to nucleases, which is an essential characteristic for a miRNA 
inhibitor that will be exposed to serum and cellular nucleases. A few reports on the inhibition 
of the function of some miRNAs have been published4, 5. However, in vivo applications of 
PNAs are hindered by poor cellular uptake, endosomal entrapment6 and poor solubility in 
aqueous media due to the neutral chemical structure and self-aggregation. In order to solve 
these drawbacks many modifications of the original PNA backbones have been proposed, in 
particular by linking PNA to a polylysine or a polyarginine tail5. 
MNPs provide biocompatible and biodegradable nanovectors, which can be functionalized 
with proper drugs or targeting molecule, to obtain a theranostic nano-device for clinical uses. 
A great interest is at present devoted to multifunctional nanostructured magnetic particles in 
different areas of biomedicine7.  
3.1.3. Introduction to magnetic nanoparticles (MNPs) 
Magnetic nanoparticles (MNPs) are a class of nanoparticles which can be manipulated using 
magnetic fields. The particles are made of magnetic elements such as iron, nickel and cobalt 
or their chemical compounds. During the past decade magnetic nanoparticles have been 
intensively studied, not only for general scientific interest but also due to the large number of 
their possible applications, such as catalysis8, biomedicine9, magnetic resonance imaging10, 
data storage11 and environmental remediation. 
The physical and chemical properties of magnetic nanoparticles largely depend on the 
synthesis method and on their chemical structure. In most cases, their size range from 1 to 
100 nm, that is the size range necessary for them to display superparamagnetism12. In a more 
general way, the properties of the nanocrystals strongly depend upon the dimension of the 
nanoparticles. Therefore it is important to control their proprieties and studies related to fluid 
stability, control of surfactants, particle sizes, materials, and physical behaviour are essential 
to understand ferrofluid behaviour to improve applications or develop new nanoparticles 
(Figure 3.1). 
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Figure 3.1: TEM imaging of iron nanoparticles. 
MNPs possessing appropriate physicochemistry and tailored surface properties have been 
extensively investigated for various applications such as drug delivery, hyperthermia, 
magnetic resonance imaging (MRI), tissue engineering and repair, biosensing, biochemical 
separations, and bioanalysis. In the field of disease therapy, the development of 
“theranostics”, which facilitates simultaneous drug delivery and imaging, represents an 
important breakthrough of MNP technology.13 Currently, various clinical trials are in 
progress to investigate the potential of different magnetic nanosystems for pharmaceutical 
and biomedical applications.14, 15, 16 
3.1.3.1. Synthesis 
Several chemical methods can be used to synthesize magnetic nanoparticles for medical 
applications: micro emulsions, sol-gel syntheses, sonochemical reactions, hydrothermal 
reactions, hydrolysis and thermolysis of precursors, flow injection syntheses, and 
electrospray syntheses.17 Iron oxides (either Fe3O4 or γ Fe2O3) are usually prepared by an 
aging stoichiometric mixture of ferrous and ferric salts in aqueous medium. The chemical 
reaction of Fe3O4 formation may be written as scheme 3.1. 
 
Scheme 3.1 
According to the thermodynamics of this reaction, complete precipitation of Fe3O4 should be 
expected at a pH ranging between 8 and 14, with a stoichiometric ratio of 2:1 (Fe3+/Fe2+) in a 
non-oxidizing oxygen environment.18 
3.1.3.2. Stabilization of Magnetic Nanoparticles 
The stabilization of the iron oxide particles is crucial to obtain magnetic colloidal ferrofluids 
that are stable against aggregation in a biological medium as in a magnetic field. The stability 
of a magnetic colloidal suspension results from the equilibrium between attractive and 
repulsive forces. Theoretically, four kinds of forces can contribute to the interparticle 
potential in the system. Van der Waals forces induce strong short-range isotropic attractions. 
For magnetic suspensions, magnetic dipolar forces between two particles must be added. 
These forces induce anisotropic interactions, which are found to be globally attractive if the 
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anisotropic interparticle potential is integrated over all directions. Finally, steric repulsion 
forces have to be taken into account for non-naked particles. 
In iron oxide, the surface iron atoms act as Lewis acids and coordinate with molecules that 
donate lone-pair electrons. Therefore, in aqueous solutions, the Fe atoms coordinate with 
water, which dissociates readily to leave the iron oxide surface hydroxyl functionalized. 
These hydroxyl groups are amphoteric and may react with acids or bases.19  
 
Figure 3.2: Stabilization of iron nanoparticles. 
Depending on the pH of the solution, the surface of the magnetite will be positive or negative. 
The isoelectric point is observed at pH 6.820 around this point [point of zero charge (PZC)], 
the surface charge density (Ʃ) is too small and the particles are no longer stable in water and 
flocculate.  
The main ways used to stabilize the iron oxide nanoparticles use to build around the particles 
a secondary core-shell made of small molecules, polymers or a second metal (Figure 3.2). 
3.1.3.3. Surface Functionalization 
The design of improved and multifunctional nanoparticles is a huge challenge. A very 
intensive investigation has been conducted to search for new strategies to prepare magnetic 
nanoparticles with tailor-made properties for pharmaceutical applications, especially for 
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targeted drug delivery, biomedical imaging, biosensing, hyperthermia, or nanothermometry. 
DMSA coated nanoparticles have also been used as a basic core for further 
functionalizations.  
There are several ways and methods to conjugate some drug to the MNPs. In the last decade 
functionalization have mainly be made using amine, carboxylic acid, thiol, carbonyl group 
etc linked by covalent bonds. The best procedure is to stabilize the nanoparticles with some 
ligands having with a specific functional group in the end and then to use this group to form 
the bioconjugates with the specific drug (Figure 3.3). 
SPDP
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Figure 3.3: Post-synthesis functionalization of iron nanoparticles. 
In this way, one peptide or protein could be attached to the nanoparticles thanks to a simple 
chemical interaction with the surface anime of the nanoparticles. 
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Figure 3.4: Thiol chemistry: post-synthesis functionalization of iron nanoparticles. 
Another using the thiol chemistry or the well know reaction call click-chemistry (Figure 3.4 
and 3.5). 
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Figure 3.5: Click-chemistry, post-synthesis functionalization of iron nanoparticles. 
3.1.3.4. Biomedical applications 
Magnetic nanoparticles are already applied in biotechnology and nanomedicene. Some 
formulations have been clinically approved for medical imaging and therapeutic applications. 
Some of them include formulations of iron oxide nanoparticles like for liver and spleen 
imaging 21. 
3.1.3.4.1. Disease therapy 
MNPs are promising stimuli-sensitive drug carriers because of their magnetic field 
responsiveness, an applied extracorporeal magnetic field can concentrate these nano devices 
at the desired site, keeping them in place for a given period of time until the encapsulated 
drug is released, thereby minimizing the drug-associated side effects due to nonspecific 
distribution.22 Alternatively, the heat generation property of the MNPs under the influence of 
an external AMF may contribute to an additional therapeutic mechanism called hyperthermia. 
In vitro 
In vitro use of MNPs has proven to be very useful tools for magnetic separation techniques in 
clinical use and have replaced other separation technologies. This is particularly true 
concerning immunomagnetic cell separation and purification, as solid phase for 
immunoassays for isolation, purification and recognition of proteins23. In addition they are 
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used for molecular biology, where they were shown to be useful for the isolation, 
purification, hybridization, synthesis and as markers for DNA/RNA.24 The isolation and 
detection of microorganisms is easily possible using MNPs23, as well as an efficient gene 
transfer of nucleotides or gene sequences into cells. 
In vivo 
Magnetic nanoparticles (usually Fe2O3 and Fe3O4) are quite useful for in vivo applications, as 
they do not retain any magnetism after removal of the magnetic field. They are specially 
suitable for therapy. One major hurdle that underlies the use of nanoparticles therapy is the 
problem of getting the particles to a particular site in the body. A potential benefit of using 
magnetic nanoparticles is the use of localized magnetic field gradients to attract the particles 
to a chosen site, to hold them there until the therapy is complete and then to remove them. 
This involves some fairly advanced design of systems for producing these fields. 
Additionally, such equipment should ideally contain other molecules to show that the 
particles have been actually located in the appropriate region of the body.25 The particles may 
be injected intravenously, and then blood circulation would be used to transport the particles 
to the region of interest for treatment. Alternatively, in many cases the particles suspension 
would be injected directly into the general area when treatment is desired. Either of these 
routes has the requirement that the particles do not aggregate and block their own spread. 
Nanoparticles of about 5-10 nm diameter should form the ideal particles for most forms of 
therapy but that there will also be problems of formulating the particle concentrations and 
suspending media to obtain best distributions. Nanotechnology has reached a stage that 
makes it possible to produce, characterize and specifically tailor the functional properties of 
nanoparticles for clinical applications. 
3.1.3.4.2. Magnetic resonance imaging 
Magnetic Resonance Imaging (MRI), or nuclear magnetic resonance imaging (NMRI), is 
primarily a medical imaging technique commonly used in radiology to visualize the internal 
structure and function of the body. Clinical diagnostics with MRI (magnetic resonance 
imaging) has become a popular non-invasive method for diagnosing many pathologies, 
because of the different relaxation times of hydrogen atoms in different tissue. The increase 
the diagnostic sensitivity and specificity many contrast agent are used, one of most used are 
the MNPs and SPIONs because they ability to modify the relaxation time of the protons.26  
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3.1.2. Objective: 
In the present work we focused our attention on to the design, synthesis and characterization 
of functionalized Peptide Nucleic Acids 9 (PNAs) with heterobifunctional linker and their 
conjugation with magnetic nanoparticles 10 (MNPs) for miRNA targeting. The MNPs bound 
to PNA can be exploited both as contrast agents for magnetic resonance imaging (MRI) and 
as sources of local overheating through the application of an alternating magnetic field 
(Magnetic Fluid Hyperthermia, MFH). Moreover, the microRNAs targeting ability of these 
tools for selectively delivering magnetic nanoparticles and destroying, by hyperthermia, 
targeted cells in multicellular organisms. However, synthesis of MNPs has been done by in 
collaboration with Dr. Daniela Maggioni & group (CARIPLO Project), University of Milan, 
Italy. 
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Figure 3.6: (9) PNA with Heterobifunctional Linker and (10) Fe3O4 on DMSA-PNA.  
3.1.5. Results and discussion 
We planned to synthesized (p-Maleimido) phenyl isocyanate (PMPI) 15 as a 
heterobifunctional linker, because it contains highly reactive isocyanate functional group 
which could be useful for the formation of urea bond with terminal free amino group from 
PNA oligomer and other is activated alkene which were used as Micheal acceptor, free thiol 
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groups from DMSA coated MNP. So, (PMPI) 15 were easily synthesized as reported in 
literature27 and its synthesis is shown in Scheme 3.2.  
3.1.5.1. Synthesis of heterobifunctional linker 
So for this we started our synthesis from cheap and commercially available p-amino benzoic 
acid 11. (p-Maleimido) benzoic acid (PMBA) 12 was synthesized by the condensation 
reaction of maleic anhydride with p-amino benzoic acid 11 (PABA) followed by 
cyclodehydration using acetic anhydride and sodium acetate in three step procedure with 60% 
yield. This (p-Maleimido) benzoic acid (PMBA) 12 is directly converted into the 
corresponding (p-maleimido)benzoyl chloride (PMB-Cl) 13 by refluxing in thionyl chloride 
to obtained acyl chloride almost a quantitative yield, which was reacted with sodium azide in 
order to form the PMB-azide 14 in 67% yield after chromatographic purification. Then, the 
labile PMB-azide 14 undergoes a Curtius rearrangement in anhydrous toluene affording the 
desired (p-Maleimido) phenyl isocyanate (PMPI) 15 in quantitative yield. 
 
Scheme 3.2: Reagents and conditions: a) maleic anhydride, Acetone/MeOH, 20 mins, rt; b) 
Ac2O, NaOAc, 2 hr, 50 oC; c) H2O, 2.5 hr, 70 oC, 50%; d) SOCl2, DCM, reflux, 2 hr, quant.; 
e) NaN3, Acetone, 0 oC - rt, 4 hr, 70%; f) Toluene, reflux, 1.5 hr, quant. 
After successfully synthesized heterobifunctional linker, next job was link this linker 15 
having isocyanate group as a electrophile with free amino group as a nucleophile at the 
terminal position of the decamer (PNA) 16. So accordingly we plan to synthesize PNA 
decamer 16.  
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3.1.5.2. Synthesis of PNA decamer (16) 
PNA decamer 16, with the TCACTAGATG sequence of nucleobases were synthesized. The 
synthesis was performed with standard manual Boc-based chemistry using MBHA resin 3, 
firstly loaded with Thymine monomer 9 by using HBTU as a coupling reagent in order to 
obtain functionalized resin 17 with loading 0.2 mmol/g (Scheme 3.3). Then the tert-
butyloxycarbonyl (Boc) group of the loaded monomer 17 was removed by treatment with 5% 
m-cresol in TFA to get an amine TFA salt which was neutralized by 5% DIPEA in 
dichloromethane. Then the free amine on resin was coupled with next cytosine monomer with 
DIPEA and HATU in NMP as a solvent. After coupling step resin were washed with NMP, 
and then treated with a solution of Ac2O/pyridine/NMP (1:25:25, v/v). The cycles were 
repeated using the monomers like adenine, cytosine, thymine and guanine (TCACTAGATG 
sequence) with the same protocol to afford the corresponding supported PNA 10-mer on resin 
16, which were tested by Kaiser Test. Then small amount (~5 mg) of the resin were cleaved 
by washing with TFA, and subsequently stirred with a mixture of 
TFA/TFMSA/thioanisole/m-cresol (6:2:1:1 v/v). The reaction mixture was filtered, and the 
filtrate were concentrated to by the addition of diethyl ether to afford white coloured crude 
PNA decamer 18, which was analyzed by mass. 
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Scheme 3.3: Reagents and conditions: a) HBTU, DIPEA, NMP, 24 hr, rt; b) TFA/m-cresol, 
95:5, 2 × 4 min, rt; c) CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; d) PNA monomers, HATU, DIPEA, 
NMP, 2 hr, rt; e) Ac2O/Pyridine/NMP 1:25:25, 2 × 1 min, rt; f) TFA/TFMSA/thioanisole/m-
cresol 6:2:1:1 (v/v) 1 hr, rt. 
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3.1.5.3. Synthesis of PNA-linker for the conjugation to magnetic nanoparticle (MNP) 
After synthesizing heterobifunctional linker (PMPI) 15, our next target is to attached this 
linker 15 to the standard sequence of decamer (PNA) 16 [Figure 3.7]; through the reaction of 
isocyanate group from linker with the terminal amino group of PNA decamer. 
 
Figure 3.7: Standard sequence of decamer (PNA) 
For this, firstly we tried reaction of PMPI 15 on single adenine monomer 20 (which were 
loaded on MBHA resin) by using solid phase methodology, through the Boc-strategy to 
afford urea 21, which on after classical cleavage conditions afford 22. We performed several 
coupling reactions but unfortunately, we are getting only 10 to 12% yield of compound 22, 
which means compound 22 was never obtained as a pure single product, and which were 
confirmed by HPLC and mass (Scheme 3.4). 
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Scheme 3.4: Reagents and conditions: a) HBTU, DIPEA, NMP, 24 hr, rt; b) TFA/m-cresol, 
95:5, 2 × 4 min, rt; c) CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; d) PMPI (15), DIPEA, NMP; 2 hr, 
rt; e) TFA/TFMSA/thioanisole/m-cresol 6:2:1:1 (v/v), 1 hr, rt. 
Here we performed several coupling reaction conditions based on similar types of literature 
reports28, with downloading of monomer on MBHA resin like 0.2 and 0.67 mmol/gm and 
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also screened solvents like NMP and DMF, but unfortunately we are not getting desired 
product 22 instead we get complex compound which were characterized by NMR and mass 
(Table 3.1) 
Table 3.1: Coupling conditions for the synthesis of urea 22 by using SSPS, through the Boc-
strategy. 
Entry 
 
aeg-A monomer (20) PMPI (15) Base Solvent Result (%) 
 
1 
 
 
 (0.02 mmoles) 
 
 (1.5 eq.) 
 
DIPEA 
(10 eq.) 
 
NMP 
 
 
Not well characterized 
 
2 
 
 
 (0.67 mmoles) 
 
 (5 eq.) 
 
 
DIPEA 
(10 eq.) 
 
NMP 
 
 
10%  product 
formation (22) 
 
3 
 
 
 (0.67 mmoles) 
 
 (5 eq.) 
 
 
DIPEA 
(10 eq.) 
 
DMF 
 
 
12%  product 
formation (22) 
 
We are also tried the same reaction in solution phase. Accordingly, the synthesis began with 
the esterification of the commercially available adenine monomer 19 with K2CO3 and MeI in 
acetone to afford an ester 23 in 92% yield. This compound 23 was then subjected with TFA 
in dichloromethane for the deprotection of -Boc group to afford a crude 24 which were used 
for the next reaction without further purification. This compound 24 was treated with PMBI 
15 in dichloromethane but unfortunately here also we are getting only 30% of compound 25 
(Scheme 3.5). 
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Scheme 3.5: Reagents and conditions: a) DMAP, DCC, DCM, 0 oC-rt, 3 hr, 60%; b) K2CO3, 
MeI, Acetone, 0 oC-rt, 12 hr, 92%; c) TFA, DCM, 0 oC-rt, 2 hr, 85%; d) PMPI (15), DIPEA, 
DCM, rt, 12 hr, 34%. 
In both the cases means in solid phase (Scheme 3.4) as well as in solution phase (Scheme 3.5) 
we are getting a desired products 22 and 25 with low yields. 
So we planned and designed new strategy for the conjugation of linker to PNA 16, and 
prepared the more simple linker, for this we used (p-maleimido) benzoic acid (PMBA) 12, 
which is the precursor of the PMPI 15 and equally economically also important. So in the test 
reaction acid 12 was coupled with the terminal amino group of PNA monomer 19 in presence 
of HATU as a coupling agent in NMP to afford monomer 26 which, after cleavage gave the 
maleimido modified PNA monomer 27. Finally, the structure of compound 27 was confirmed 
by mass analysis (Scheme 3.6). 
 
Scheme 3.6: Reagents and conditions: a) TFA/m-cresol, 95:5, 2 × 4 min, rt; b) 
CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; c) PMBA (12), HATU, DIPEA, NMP; 2 hr, rt; d) 
TFA/TFMSA/thioanisole/m-cresol 6:2:1:1 (w/w), 1 hr, rt. 
We got the desired product 27 by using this new strategy. We implement the same strategy 
with the standard sequence of decamer 16 (synthesized in lab by manually using Boc 
strategy) with PMBA 12 by using HATU as a coupling agent in presence of DIPEA in NMP 
to afford 28, which was confirmed by Kaiser Test. After cleavage from the resin, PNA 
oligomer 9 (Scheme 3.7) was obtained as white solid and its MW was confirmed by Q-Tof 
mass analysis. 
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Scheme 3.7: Reagents and conditions: a) TFA/m-cresol, 95:5, 2 × 4 min, rt; b) 
CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; c) PMBA (12), HATU, DIPEA, NMP; 2 hr, rt; d) 
TFA/TFMSA/thioanisole/m-cresol 6:2:1:1 (w/w), 1 hr, rt. 
3.1.5.4. Purification of decamer (9) by reverse phase HPLC  
The crude decamer 9 was purified by reverse phase semi preparative HPLC by column (tR = 
12.2 min). The purity of the 9 was checked by LC-MS (Figure 3.8 and 3.9) 
 
Figure 3.8: HPLC of decamer 9, retention time 12.2 min. 
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Figure 3.9: ESI-Mass analysis of decamer 9, found m/z: C119H141N59O33: 2926.00 
3.1.5.5. Functionalisation of nanoparticles with PNA-maleimide-(MNP-DMSA-PNA: 10) 
Once we have successfully synthesized and characterized oligomer 9, Michael addition of 
free thiol groups from DMSA-MNP 29 (Figure 3.10) onto the PNA-malemide (oligomer 9) 
was realized in the presence of water, under sonication for 6 hr (Scheme 3.8). The loading of 
PNA onto MNP was confirmed by elemental analysis and zeta potential (Figure 3.11)  
 
Figure 3.10: MNP surface functionalized with meso-2,3-dimercaptosuccinic acid (MNP-
DMSA) 
(16)
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Scheme 3.8: Reagents and conditions: a) H2O, sonication, r.t., 4 hr.  
Zeta potential measurements in acetone, showed a decrease in negative superficial charge, 
from -34.2 ± 0.3 mV to -20.1 ± 1.4 mV. This change is coherent with the bonding of PNA 
oligomer. 
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Fe3O4@DMSA 
Fe3O4@DMSA‐PNA 
 
Figure 3.11: Zeta potential distribution of the two nanoparticles 
Finally, ζ-potential measurements on the Fe3O4@DMSA-Mal-PNA colloid (Fig.3.11) 
showed a decrease of the negative surface charge with respect to Fe3O4@DMSA, from -34.2 
± 0.3 mV to -20.1 ± 1.4 mV, in line with the bonding of a positively charged species such as 
PNA to the negatively charged native nanoparticles. 
We also tried another strategy for the functionalisation of nanoparticle with PNA 18 (without 
linker). DMSA-MNP 29 is having free thiol and carboxylic group. 
3.1.5.6. Functionalisation of nanoparticles with PNA by EDC/NHS coupling 
By taking advantage of the presence of  the free carboxylic group in DMSA, we planned to 
coupled it with free the amino group on PNA decamer 18 by using EDC.HCl as a coupling 
reagent under sonication (Scheme 3.9) 
PN
A
PN
A
PN
A
PN
A
PN
A
 
Scheme 3.9: Reagents and conditions: a) EDC.HCl, NHS, CH3CN, sonication, rt., 2 hr.  
Unfortunately, after addition of the EDC.HCl the nanoparticles become a colloid and loses its 
stability, likely due to the shielding of the nanoparticle negative surface charge by the 
positively charged EDC. From the FT-IR spectra of the obtained MNP, we found bands not 
attributable to those of PNA (1645 vs 1685 and 1130-1054 vs 1207-1140),  which suggest 
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that they can come from EDC. (Figure 3.12). Also elemental analysis confirmed this 
hypothesis (Table 3.2). 
PNA-NH2 + MNP EDC/NHS mediated 
400 900 1400 1900 2400 2900 3400 3900 
PNA 
 
1685 
1421 
1140 
3383 
1207 
1054 
1386 
1130 
3454 
2931 
3092 
1645 
1385 
586 
478 
2981 
3104 
(a) 
(b) 
Wavenumbers (cm-1) 
3900               3400               2900              2400              1900              1400               900                400  
 
Figure 3.12: FTIR spectra of (a) MNP with PNA; (b) PNA in solid (KBr pellets). 
Table 3.2: Elemental analysis of the MNP  
 MNP@DMSA MNP@PNA (30) PNA (18) 
C% 3.36 8.03 47.57 
H% 0.75 1.73 5.03 
N% --- 2.16 29.79 
C/N --- 2.16 1.60 
 
Synthesis of DMSA-MNP 29, MNP 10 and MNP 30 has been done by our collaborator Dr. 
Daniela and co-workers, University of Milan, Italy. 
3.1.6. Conclusion 
A novel and effective strategy for binding PNA oligomers onto the surface of magnetic iron 
oxide nanoparticles has been developed. All the requirements that stimulated this work have 
been fulfilled, and some of the drawbacks shown by previous literature reports have been 
overcome. The control of the size of the magnetic core for the diagnostic and therapeutic 
applications is ensured by the use of thermal decomposition synthetic route. The desired 
water solubility and the colloidal stability are provided by the coating with DMSA. The 
stable linking of MNP to PNA oligomers is given by the efficient Michael addition of 
102 
 
Chapter 3 Section 1…….   
maleimide-functionalized PNAs to the SH groups of DMSA grafted to the nanoparticle 
surface. 
The approach here described, therefore, produces multimodal hybrid organic-inorganic 
nanomaterials, that can act as dual (T1 and T2) MRI contrast agents, as efficient hyperthermia 
promoters and as PNA carriers. To fully exploit the theranostic potential of these 
nanohybrids, future work will explore the replacement of the standard PNA sequence, here 
used for setting the method, with PNA oligomers designed for targeting specific non-coding 
microRNAs (miRNA), 2 whose dysregulation has been implicated in a variety of pathologies, 
such as inflammatory and autoimmune diseases, neurological disorders, as well as several 
types of cancer.3 
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3.2.1. Experimental Section 
3.2.1.1. General Materials and Methods 
The monomers containing the nucleobases C, G and A were purchased from ASM Research 
Chemicals and were used for the synthesis of PNA decamer, as such without further 
purification. The thymine monomer aeg-(T) PNA-COOH was synthesized in lab. (Chapter 2, 
section 2). 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxidhexafluoro phos- phate (HATU), trifluoroacetic acid (TFA), trifluoromethanesulfonic 
acid (TFMSA), m-cresol and p-amino benzoic acid were purchased from Aldrich. N-methyl-
2-pyrrolidone (NMP), N, N-diisopropylethylamine (DIPEA) and thioanisole were purchased 
from Fluorochem. Polystyrene bead carrying 4-methylbenzhydrylamine hydrochloride salt 
groups (MBHA resin, 0.63 mmol/g) was purchased from VWR International.  
3.2.1.2. Experimental Techniques 
1H and 13C NMR spectra were recorded on Bruker 300 MHz and 70 MHz respectively. 
Chemical shifts (δ) are reported in parts per million relative to solvent peak. Many of the 
compounds described below showed many rotamers and consequently exhibit complex 1H 
NMR patterns. Some of the signals in the 1H NMR are therefore described as major (ma.) and 
minor (mi.) components; however, in many cases, some minor signals were obscured by the 
major signal of another proton. In such cases, only the major signal is reported or a range 
containing two or more CH2. In some cases, the 13C spectrum shows many peaks that cannot 
be distinguished in a small range: ov. Means ‘overlapped’. Melting points of samples were 
determined in open capillary tubes with a Büchi Melting Point B-540 apparatus and (dec) 
indicates decomposition. The IR spectra were recorded on a Perkin-Elmer FTIR 4100. Mass 
spectra were obtained by LCMS techniques (a Thermo Scientific LCQ Advantage). TLC was 
performed using TLC glass plates pre-coated with silica gel (Merck). TLCs were visualized 
with UV light and/or either by charring in Ninhydrine solution or developing in I2 chamber. 
Silica gel 60-120 and 100-200 mesh was used for column chromatography using ethyl 
acetate/hexane and dichloromethane/methanol mixture as elution solvent depending upon the 
compound polarity and chemical nature. Commercial reagents were generally used as 
received. Solvents used in organic reactions were distilled under an inert atmosphere. 
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Unless otherwise noted, all reactions were carried out at room temperature. Oligomers were 
characterized by RP HPLC, using C18 column and MALDI-TOF mass spectrometry. 
All weightings of reagents were carried out with analytical balance Mettler Toledo AB135- 
S/FACT. Vials ALLTECH of 1.5 ml, 4 ml and 8 ml with frits of PTFE were used as reactor 
for manual solid phase synthesis. 
HPLC of PNA oligomers were performed with a HPLC AGILENT 1100 Series, using an 
analytical column DISCOVERY® BIO WIDE PORE C18 (15 cm x 4.6 mm, 5 μm) and a 
semi preparative column DISCOVERY® BIO WIDE PORE C18 (25 cm x 10 mm, 10 μm). 
MALDI-TOF spectra were recorded with a Bruker Daltonics Omniflex. Pulsed nitrogen 
lasers (337 nm) were used to generate ions that have been accelerated in a 20 kV field. The 
instrument was calibrated in the range from 0 to 20 kDa. Generally, Sinapinic acid and 2, 5- 
dihydroxybenzoic acid (DHB) matrixes were used. 
A lyophilizer Telstar Cryodos were used to isolate pure PNA oligomers from aqueous 
solutions. 
3.2.1.3. Experimental Procedures 
4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoic acid (12) 
Commercially available p-aminobenzoic acid, PABA 11 (4.36 
gm, 31 mmol, 1 eq.) was suspended in 30 ml of acetone and 
solubilized by the addition of 5 ml of methanol. A solution of 
maleic anhydride (3.66 gm, 37 mmol, 1.2 eq.) in 10 ml of 
acetone was added dropwise and the resulting precipitate stirred 
for 20 min. The material was suction filtered, washed with 
acetone and vacuum-dried to afford a yellow powder (5.9 gm). This material was dissolved in 
acetic anhydride (13 mL), treated with sodium acetate (1.1 gm), and then heated with stirring 
at 50 °C for 2 hr. The volatiles were then removed in vacuo, and the resulting residue was 
taken up in 150 mL of water and heated at 70 °C for 2.5 hr. The resulting white precipitate 
was suction filtered, washed with water and vacuum-dried to afford compound 12 crude 
product, which was purified on flash column chromatography (SiO2) using 10% MeOH in 
DCM as a eluent to afford compound 12 as a white solid (3.5 gm, 50%); M.P.: 234 oC. 
N
O
O
O
OH
12
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Molecular formula: C11H7NO4 
Rf: 0.7 (DCM: Methanol, 90:10) 
IR (CHCl3): 3583, 3178, 2360, 1710, 1603, 1516, 1420 cm-1. 
1H NMR (300 MHz, CDCl3 + DMSO-d6): δ 6.82 (s, 2H), 7.36 (d, J = 9 Hz, 2H), 8.02 (d, J = 
9 Hz, 2H) 
13C NMR (75 MHz, CDCl3+ DMSO-d6): δ 118.88, 126.28, 130.05, 130.51, 134.92, 135.58, 
166.88, 169.67 
MS (ESI) (m/z): 218 (M+1)+ 
 
4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoyl chloride (13) 
p-Maleimidobenzoic acid, PMBA 12 (500 mg, 2.30 mmol) 
was suspended in 2 mL of DCM and then 10 mL of thionyl 
chloride were added, leading to a yellowish solution. After 
refluxing for 2 hr and the progress of the reaction was 
monitored by TLC, the solution were vacuum dried to afford 
a yellow powder as desired product 13 (540 mg, quantitative 
yield), which were used without further purification. M.P.: 158 oC. 
N
O
O
O
Cl
13
Molecular formula: C11H6ClNO3 
Rf: 0.6 (ethyl acetate: Hexane, 50:50) 
IR (CHCl3): cm-1 3473, 3107, 1772, 1713, 1599.  
1H NMR (300 MHz, CDCl3+DMSO-d6): δ 6.93 (s, 2H), 7.65 (d, J = 8.7 Hz, 2H), 8.25 (d, J 
= 8.7 Hz, 2H),  
13C NMR (75 MHz, CDCl3+DMSO-d6): δ 120.00, 127.20, 130.95, 131.39, 135.53, 143.31, 
164.89, 168.07, 170.55 
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4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoyl azide (14) 
To a stirred suspension of compound 13 (500 mg, 2.12 mmol, 1 
eq.) in 5 mL of acetone at 0 °C, solid NaN3 (690 mg, 10.60 
mmol, 5 eq.) was added in three portions. The suspension was 
stirred at 0 °C and then raised to room temperature. The 
progress of the reaction was monitored by TLC. After stirring at 
rt for 4 hr, the solvent were removed in vacuo, and the resulting 
orange/reddish residue was chromatographed with DCM as eluent. The product 14 is isolated 
upon evaporation of solvent to afford an pale yellow fluffy needles (359 mg, 70%). 
N
O
O
O
N3
14
Molecular formula: C11H6N4O3 
Rf: 0.6 (ethyl acetate: Hexane, 50:50) 
IR (CHCl3): cm-1 3111, 2137, 1717, 1692, 1604, 1509, 1460, 1376.  
1H NMR (300 MHz, CDCl3): δ 6.91 (s, 2H), 7.55 (d, J = 8 Hz, 2H), 8.15(d, J = 8 Hz, 2H) 
13C NMR (75 MHz, CDCl3+DMSO-d6): δ 124.76, 128.66, 129.68, 134.06, 136.29, 168.30, 
171.02 
 
1-(4-isocyanatophenyl)-1H-pyrrole-2, 5-Dione (15) 
A solution of compound 14 (300 mg, 1.24 mmol) in dry 
toluene (10 mL) is refluxed under nitrogen for 1.5 hr. The 
progress of the reaction was monitored by TLC, after 
completion of the reaction evaporate the reaction mixture on to 
the rota vapour. This quantitatively affords compound 15 as a 
yellow solid (265 mg). [This compound should be stored in a 
sealed vial, protected from light and moisture, in a freezer]; M.P.: 121-123 °C. 
N
N
O
O 15
C O
Molecular formula: C11H6N2O3 
Rf: 0.5 (ethyl acetate: Hexane, 40:60) 
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1H NMR (300 MHz, CDCl3): δ 6.87 (s, 2H), 7.17-7.20 (d, J = 9 Hz, 2H), 7.33-7.36 (d, J = 9 
Hz, 2H) 
13C NMR (75 MHz, CDCl3): δ 125.34, 127.04, 128.67, 132.93, 134.25, 169.19 
MS (ESI) (m/z): 215 (M+1). 
 
Loading (0.2 mmol/gm) of Thymine monomer 9 on MBHA resin (17) 
The MBHA resin 3 (0.3 gm) was washed with CH2Cl2 (2 x 5 
mL) and activated by treatment with 5% DIPEA in CH2Cl2 for 
5 min for 3 times; and then washed with CH2Cl2 (2 x 5 mL). In 
a vial, DIPEA (21 μL, 0.12 mmol) was added to a solution of 
Thymine monomer 9 (23.06 mg, 0.06 mmol) in NMP (1 mL); 
then, a solution of HBTU (22.78 mg, 0.06 mmol) in NMP (1 
mL) in another vial and add this solution into the monomer solution, and activate the 
monomer solution for 2 minutes. This mixture was then added to the neutralized resin and at 
rt for 12 hr. The resin was washed with NMP (3 x 5 mL). A solution of Ac2O/Py/NMP 1:2:2 
(5 mL) was added to the resin (capping of unreacted amino groups) and left under stirring at 
rt for 1 hr. After this time, the resin was washed with NMP (3 x 5 mL), CH2Cl2 (4 x 5 mL), 
5% DIPEA in CH2Cl2 (2 x 5 mL) and again with CH2Cl2 (4 x 5 mL); and finally dried in 
vacuum to afford the MBHA resin downloaded with Thymine monomer 17 (0.352 gm); 
Kaiser Test: negative. 
17
N
H
O
N
O
N
NH
NHBoc
O
O
 
Synthesis of the resin supported TCACTAGATG sequence of nucleobases aeg-PNA 
decamer (16) 
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Solid phase synthesis was done by using standard manual Boc-based chemistry; resin 17 (100 
mg, substitution with 0.2 mmol/g) was placed in a reaction vessel (volume; 8 mL) and which 
was swollen with CH2Cl2 for 30 minutes, the Boc group of the loaded monomer was removed 
by treatment with TFA/m-cresol (95:5), (3 mL, 2 x 4 min). The resin was washed with 
CH2Cl2 (2 x 5 mL) and then treated with CH2Cl2 /DIPEA (95:5), (3 mL, 2 x 2 min). Then the 
resin was washed thoroughly with CH2Cl2 (2 x 5 mL). In a vial, DIPEA (35 μL, 0.2 mmol, 10 
eq.) was added to a solution of aeg-(C) PNA-COOH monomer (53.37 mg, 0.106 mmol, 5.3 
eq.) in NMP (500 μL); then, a solution of HATU (38 mg, 0.1 mmol, 5 eq.) in NMP (500 μL) 
in another vial and add this solution into the monomer solution, and activate the monomer 
solution for 2 minutes. This mixture was then added to the neutralized resin and shaken for 2 
hr at rt. After coupling step the resin was filtered, washed with NMP (3 x 5 mL) and CH2Cl2 
(3 x 5 mL). Then resin treated with Ac2O/Py/NMP; 1:25:25 capping solution twice for 1 min. 
and again washed the resin with CH2Cl2 (3 x 5 mL), NMP (3 x 5 mL) and CH2Cl2 (3 x 5 mL). 
The cycle was repeated using the required monomers like cytosine (53.4 mg), adenine (56 
mg) and guanine (57.6 mg) with the same protocol and after the last coupling and capping the 
resin was washed with several times with NMP and CH2Cl2 and finally dried the resin under 
vacuum to afford the corresponding supported PNA decamer on resin 16 (146 mg). 
 
Synthesis of PNA Decamer (18) 
 
Cleavage: The resin 16 (5 mg) was washed with TFA (2 × 100 μL) and subsequently stirred 
for 1 hr with a mixture of TFA/TFMSA/thioanisole/m-cresol [6:2:1:1 v/v] (500 μL). The 
reaction mixture was filtered, and the resin washed with TFA (2 × 100 μL). The filtrate was 
concentrated under nitrogen flow and Et2O (5 mL) was added to precipitate PNA as a white 
solid. Centrifugation of the slurry gave the product, which was washed with Et2O (5 x 5 mL) 
and dried to afford the crude decamer 18.  
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Retention time (analytic column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
AcCN/TFA 0.1%) = 10.2 min. 
Maldi Tof MS: found m/z: 2726 [M] +, calculated for C108H137N58O30+: 2726.10 
 
Loading (0.67 mmol/gm) of Adenine monomer 19 (aeg-A-PNA) on MBHA resin 3. 
The MBHA resin 3 (200 mg) was washed with CH2Cl2 (2 x 5 
mL) and activated by treatment with 5% DIPEA in CH2Cl2 
for 5 min for 3 times; and then washed with CH2Cl2 (2 x 5 
mL). In a vial, DIPEA (47 μL, 0.268 mmol) was added to a 
solution of Adenine monomer 19 (70.7 mg, 0.134 mmol) in 
NMP (1 mL); then a solution of HBTU (51 mg, 0.134 mmol) 
in NMP (1 mL) in another vial and add this solution into the monomer solution, and activate 
the monomer solution for 2 minutes. This mixture was then added to the neutralized resin and 
at rt for 12 hr. The resin was washed with NMP (3 x 5 mL). A solution of Ac2O/Py/NMP 
1:2:2 (5 mL) was added to the resin (capping of unreacted amino groups) and left under 
stirring at rt for 1 hr. After this time, the resin was washed with NMP (3 x 5 mL), CH2Cl2 (4 x 
5 mL), 5% DIPEA in CH2Cl2 (2 x 5 mL) and again with CH2Cl2 (4 x 5 mL); and finally dried 
in vacuum to afford the MBHA resin downloaded with Adenine monomer 20 (263 mg); 
Kaiser Test: negative. 
N
H
O
N
O
NHBoc
N
NN
N
CbzHN
20
 
Synthesis of 21: 
The resin 20 (85 mg, substitution with 0.67 
mmol/g) was placed in a reaction vessel 
(volume; 8 mL) and which was swollen with 
CH2Cl2 for 30 minutes, the Boc group of the 
loaded monomer was removed by treatment 
with TFA/m-cresol (95:5), (3 mL, 2 x 4 min). 
The resin was washed with CH2Cl2 (2 x 5 mL), 
DMF (2 x 5 mL) and then treated with CH2Cl2 /DIPEA (95:5), (3 mL, 2 x 2 min). Then the 
CbzHN
N
NN
N
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resin was washed thoroughly with CH2Cl2 (2 x 5 mL). In a vial, (60.93 mg, 0.284 mmol) of 
15 PMPI in DMF (500 μL). Then in another vial, DIPEA (70 μL, 0.4 mmol, 7 eq.) with DMF 
(500 μL), add this solution of DIPEA into the resin, followed by PMPI solution and allowed 
the reaction for 12 hr at room temperature. After this the resin was filtered, washed with 
DMF (2 x 5 mL) and CH2Cl2 (2 x 5 mL) and finally dried the resin under vacuum to afford 
the corresponding supported PNA urea on resin 21 (95 mg). Kaiser Test: negative 
 
Synthesis of 22: 
Cleavage: The resin 21 (95 mg) was washed with 
TFA (2 × 100 μL) and subsequently stirred for 1 
hr with a mixture of TFA/TFMSA/thioanisole/m-
cresol [6:2:1:1 v/v] (500 μL). The reaction mixture 
was filtered, and the resin washed with TFA (2 × 
100 μL). The filtrate was concentrated under 
nitrogen flow and Et2O (5 mL) was added to 
precipitate monomer as a white solid. Centrifugation of the slurry gave the product, which 
was washed with Et2O (5 x 5 mL) and dried to afford the white coloured compound 22 (39 
mg)  
H2N
O
N
O
N
H
N
NN
N
+H3N
O
N
H
N
O
O
22
TFA-
Retention time (analytic column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
AcCN/TFA 0.1% for 30 min.) = 8.1 min and 9.2 min. 
Maldi Tof MS: found m/z: 507 [M]+ + 631, calculated for C22H23N10O5+: 507.18 
 
Methyl-N-(2-(6-(((benzyloxy)carbonyl)amino)-9H-purin-9-yl)acetyl)-N-(2-((tert 
butoxycarbonyl)amino)ethyl)glycinate (23) 
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To the stirred solution of acid 19 (100 mg, 0.189 mmol) in 
anhydrous DCM (5 mL) and methanol (0.5 mL), DMAP (23 mg, 
0.189 mmol) were added and stirred the reaction for 10 min at 0 
oC. DCC (47 mg, 0.227 mmol) was added slowly and the 
resultant solution was stirred for 3 hr at room temperature. The 
CbzHN
O
N
O
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N
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N
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progress of the reaction was monitored by TLC. Filter the reaction mixture on to the filter 
paper and evaporate all the solvent under reduced pressure. The residue were diluted with 5 
mL of Water and extracted with ethyl acetate (3×10 mL) and again washed with saturated 
solution of citric acid, then with saturated solution of NaHCO3 and brine. The organic layers 
were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to 
afford crude ester 23 which was purified by column chromatography using MeOH: DCM 
(10:90) to afford pure compound 23 (65 mg, 60%) 
Molecular formula: C25H31N7O7 
Rf: 0.6 (MeOH: DCM, 10:90) 
1H NMR (300 MHz, CDCl3): δ 1.42 (s, 9H), 3.39 (q, 2H), 3.64 (t, 2H), 3.73(s, 3H), 4.07 (d, 
2H), 5.14 (d, 2H), 5.29 (s, 2H), 5.63 (bs, 1H), 7.35-7.44 (m, 5H), 8.06 (s, 1H), 8.74 (s, 1H). 
MS (ESI) (m/z): 541 (M+Na)+ 
 
2-(2-(6-(((benzyloxy)carbonyl)amino)-9H-purin-9-yl)-N-(2-methoxy-2-
oxoethyl)acetamido)ethan-1-aminium (24) 
The compound 23 (85 mg, 0.157 mmol) was dissolved in 
minimum volume of DCM (5 mL) and TFA (1 mL) was added 
slowly at 0 oC. Reaction mixture was allowed to stir for 2 hr at 
room temperature. The progress of the reaction was monitored 
by TLC. After completion of the reaction saturated solution of 
NaHCO3 solution was added to the reaction mixture for 
neutralization and then the aqueous layer was extracted 
repeatedly with DCM (2 x 10 mL). The organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure to afford the free amine 24 (60 mg, 85%) 
which was used without further purification. 
O
O
N
O
NH3
+
N
NN
N
CbzHN
24
TFA-
Molecular formula: C20H24N7O5+ 
Rf: 0.3 (MeOH: DCM, 10:90) 
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1H NMR (300 MHz, CDCl3): δ 2.76 (t, 2H), 3.38(q, 2H), 3.60 (s, 3H), 3.79 (d, 2H), 4.30(d, 
2H), 5.10 (d, 12H), 5.30 (s, 2H), 7.31-7.34 (m, 5H), 8.18 (d, 1H), 8.73 (s, 1H). 
 
Methyl-N-(2-(6-(((benzyloxy)carbonyl)amino)-9H-purin-9-yl)acetyl)-N-(2-(3-(4-(2,5-
dioxo-2,5-dihydro-1H-pyrrol-1-yl)phenyl)ureido)ethyl)glycinate (25) 
To the stirred solution of PMPI 15 (41 mg, 0.191 
mmol) in anhydrous DCM (5 mL), compound 24 
(60 mg, 0.136 mmol) were added followed by the 
addition of DIPEA (35 µL, 0.191 mmol) at room 
temperature, and stirred the reaction for 12 hr under 
nitrogen atmosphere. The progress of the reaction 
was monitored by TLC; evaporate all the solvent 
under reduced pressure. The residue were diluted with 5 mL of Water and extracted with 
ethyl acetate (3 x 10 mL) and brine. The organic layers were dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure to afford 25. 
O
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Note: This compound 25 was not well characterized by mass as well as 1H-NMR. 
 
Synthesis of 26: 
The resin 20 (50 mg, substitution with 0.67 
mmol/g) was placed in a reaction vessel (volume; 
8 mL) and which was swollen with CH2Cl2 for 30 
minutes, the Boc group of the loaded monomer 
was removed by treatment with TFA/m-cresol 
(95:5), (2 mL, 2 x 4 min). The resin was washed 
with CH2Cl2 (2 x 5 mL), NMP (2 x 5 mL) and then 
treated with CH2Cl2 /DIPEA (95:5), (1 mL, 2 x 2 
min). Then the resin was washed thoroughly with CH2Cl2 (2 x 5 mL). In a vial, DIPEA (62 
μL, 0.354 mmol, 10 eq.) was added to a solution of PMBA 12 (40 mg, 0.184 mmol, 5.2 eq.) 
in NMP (500 μL); then, a solution of HATU (67.3 mg, 0.177 mmol, 5 eq.) in NMP (500 μL) 
N
H
O
N
O
N
H
N
NN
N
CbzHN
O
N
O
O26
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in another vial and add this solution into the acid solution, and activate the acid solution for 2 
minutes (yellow coloured solution). This mixture was then added to the neutralized resin and 
shaken for 2 hr at room temperature. After coupling step the resin was filtered, washed with 
NMP (3 x 5 mL) and CH2Cl2 (3 x 5 mL) and finally dried the resin under vacuum to afford 
the corresponding supported PNA monomer on resin 26 (61 mg). Kaiser Test: negative 
 
Synthesis of 27: 
Cleavage: The resin 26 (61 mg) was washed with 
TFA (2 × 100 μL) and subsequently stirred for 1 hr 
with a mixture of TFA/TFMSA/thioanisole/m-cresol 
[6:2:1:1 v/v] (500 μL). The reaction mixture was 
filtered, and the resin washed with TFA (2 × 100 
μL). The filtrate was concentrated under nitrogen 
flow and Et2O (5 mL) was added to  precipitate 
monomer as a white solid. Centrifugation of the 
slurry gave the product, which was washed with Et2O (5 x 5 mL) and dried to afford the 
white coloured compound 27 (7.5 mg)  
H2N
O
N
O
N
H
N
NN
N
+H3N
O
N
O
O
27
Retention time (analytic column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
AcCN/TFA 0.1% for 30 min.) = 8.8 min. 
ESI-MS: found m/z: 492.30 [M]+, calculated C22H22N9O5+: 492.17 
 
Synthesis of PNA decamer with linker (28): 
 
The resin 16 (102 mg, substitution with 0.2 mmol/g) was placed in a reaction vessel (volume; 
8 mL) and which was swollen with CH2Cl2 for 30 minutes, the Boc group of the loaded 
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monomer was removed by treatment with TFA/m-cresol (95:5), (3 mL, 2 x 4 min). The resin 
was washed with CH2Cl2 (2 x 5 mL), NMP (2 x 5 mL) and then treated with CH2Cl2 /DIPEA 
(95:5), (3 mL, 2 x 2 min). Then the resin was washed thoroughly with CH2Cl2 (2 x 5 mL). In 
a vial, DIPEA (36 μL, 0.204 mmol, 10 eq.) was added to a solution of PMBA 12 (24.36 mg, 
0.112 mmol, 5.5 eq.) in NMP (500 μL); then, a solution of HATU (38.78 mg, 0.102 mmol, 5 
eq.) in NMP (500 μL) in another vial and add this solution into the acid solution, and activate 
the acid solution for 2 minutes (yellow coloured solution). This mixture was then added to the 
neutralized resin and shaken for 2 hr at room temperature. After coupling step the resin was 
filtered, washed with NMP (3 x 5 mL) and CH2Cl2 (3 x 5 mL) and finally dried the resin 
under vacuum to afford the corresponding supported PNA decamer on resin 28 (110 mg). 
Kaiser Test: negative. 
 
Synthesis of PNA decamer with linker (9): 
 
Cleavage: The resin 28 (110 mg) was washed with TFA (2 × 100 μL) and subsequently 
2
Retention time (analytical column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
Q-TOF/MS: found m/z: 2926.00 [M+1] +, calculated C119H141N59O33: 2925.12 
 
 
stirred for 1 hr with a mixture of TFA/TFMSA/thioanisole/m-cresol [6:2:1:1 v/v] (500 μL). 
The reaction mixture was filtered, and the resin washed with TFA (2 × 100 μL). The filtrate 
was concentrated under nitrogen flow and Et O (5 mL) was added to precipitate monomer as 
a white solid. Centrifugation of the slurry gave the product, which was washed with Et2O (5 x 
5 mL) and dried to afford the white coloured PNA decamer 9 (17 mg)  
AcCN/TFA 0.1% for 60 min.) = 12.2 min. 
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Functionalisation of nanoparticles with PNA-maleimide-(MNP-DMSA-PNA: 10) 
PN
A
 
A suspension of 5 mL of Fe3O4@DMSA (0.56 mg/mL Fe = 0.77 mg Fe3O4 /ml) was added to 
a solution of 5 mg of PNA dissolved in 0.5 mL of milliQ water under inert atmosphere. The 
pH of the reaction mixture was adjusted to 7 and the reaction carried out under ultrasonic 
irradiation for 4 hr at room temperature. The nanoparticles were then collected with a 
permanent magnet, re-suspended in 5 mL water and centrifuged (3 x, 15 min at 7197 rcf). 
The isolated magnetic nanoparticles 10 were then stored under nitrogen atmosphere. 
MNP Fe3O4@DMSA:  
Elemental analysis = C 3.36% H 0.75% N NOT DETECTED;  
Total DMSA= 12.742% w/w.   
Z potential in acetone = -34.2 ± 0.3 mV 
MNP Fe3O4@DMSA + PNA maleimmide 
Elemental analysis = C 10.23% H 1.40% N 3.97% 
Total PNA =14.063% 
Z potential in acetone = -20.1 ± 1.4 mV 
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Functionalisation of nanoparticles with PNA-maleimide-(MNP-DMSA-PNA: 30) 
 
The MNP@DMSA carboxyl groups were first activated by adding 12.4 mg EDC (0.065 
mmol) and 46 mg NHS (0.4 mmol) to 5 mL of MNP8@DMSA water suspension (0.8 mg/mL 
Fe3O4). The addition of EDC apparently destabilized a lot the nanoparticle colloid, resulting 
in a visible aggregation. The suspension pH was then changed to 4.5 by careful addition of 
HCl 0.1 or 1 M and the activation reaction continued for 2 hr in an ultrasonic bath. Then the 
activated MNP were added dropwise to a solution of 5 mg PNA 18 dissolved in 0.5 mL of 
CH3CN and 1 mL of phosphate buffer (pH 8, 5 mM). The suspension pH was adjusted to 8 
by careful addition of NaOH solution. The reaction mixture was first placed in an ultrasonic 
bath and left under ultrasonic irradiation for 2 hr at room temperature and then left on a 
shaking plate overnight. The nanoparticles were then purified via centrifugation with water (3 
x, 15 min, 7550 rcf) and subsequently collected in a Schlenk flask under inert atmosphere. 
Elemental analysis: MNP Fe3O4@DMSA = C 3.36%; H 0.7%  
Elemental analysis: MNP Fe3O4@DMSA = C 8.03%; H 1.73%; N 2.16% 
Elemental analysis: PNA 18 = C 47.57%; H 5.03%; N 29.79% 
Chapter 4 Section 1…….    
 
 
 
 
 
 
 
 
Chapter 4: Design and synthesis of modified 
thymine monomer PNA and homothymine 
decamer PNA sequence with gold (I) 
complexes for cellular imaging. 
 
 
Section 1: Synthesis of modified thymine 
PNA monomer and PNA decamer 
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4.1.1. General Introduction: Gold Chemistry 
Gold is highly regarded and holds a very special position among the metals in the periodic 
table (Figure 4.1) for at least three millennia; it has been known as the most noble metal, 
referring to its resistance towards most corrosive forces. It has also been dubbed “King of the 
Metal” due to its monetary value. Gold is robust; it is mechanically ductile and soft, and has a 
attractive colour and glittering appearance. It is held to be an ideal construction material for 
objects of culture and art, for jewellery and for coin currency. In more recent periods, its high 
electrical and thermal conductivity has made gold metal also an important material: first for 
the electrical and then for the electronics industry.1 Gold is not simply a homologue of the 
other two coinage metals in the periodic table, copper and silver, but showed entirely 
different oxidation states and oxidation potentials, coordination numbers and coordination 
geometries.2 
 
Figure 4.1: Position of gold metal in the periodic table of the elements. 
Historically, gold was desirable metal because of its resistance to oxidation and excellent 
conductivity. Within the last 30 years however, chemists have had to readjust their 
perspective as a myriad of gold chemistry has emerged.3-6 As an organometallic metal centre, 
gold typically prefers the +1 or +3 oxidation state with the former being the more common. 
The overwhelming majority of neutral gold(I) complexes are two coordinate, linear species. 
This preference for linear geometry has been attributed to a small energy gap between s, p 
and d states which results in proficient s/d or s/p hybridizations.3 The linear gold(I) 
complexes are 14e- and thus electron deficient. Consequently, when sterics permit, these 
complexes have been observed to act as soft Lewis acids and can coordinate a third and 
fourth ligand.3, 7 Gold(I) complexes generally form, two coordinate species with a linear 
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geometry of two donor atoms or ligands. The ligands can be neutral (L) or anionic (X-), thus 
forming species of these general types; [L-Au-X], [L-Au-L] + or [X-Au-X]-.8 
The development of gold(I)-acetylide complexes has led to several novel compounds.9-14 
Most notably they have been investigated for their interesting photochemical properties. 
Luminescence from gold-acetylide complexes typically results from “aurophilicity” or the 
presence of weak molecular interactions between two gold centers.9, 12, 14 
The rich gold acetylide chemistry has grown to include σ 15a, 16-18 and π19, 20 bound complexes. 
LAu–C≡C–R complexes (where L is a 2e− donor, typically a tertiary phosphine) have 
classically been prepared by reaction of [Au-Cl-L] with a terminal alkyne in the presence of a 
strong base (Figure 4.2-A) 17,22,23 while ƞ2- C2R2 complexes have typically been accessible 
from complexes of [Au-X-L] where L is a volatile ligand such as SMe2 (DMS)21or 
tetrahydrothiophene (THT) as shown in (Figure 4.2-B).19 
 
Figure 4.2: Gold(I)-acetylide complexes 
4.1.2. Synthesis of gold(I)-acetylide complexes: A literature survey 
There are numerous literature reported so far with different reaction conditions for the 
conjugation of gold(I) with acetylide or a triple bond.24 In 2000 Dyson et al.25 has been 
reported the mononuclear phosphane Au(I) acetylides 1-6 were treated with the [AuCl(PR’3)] 
complex (PR3’ corresponding to the water-soluble phosphanes PTA and DAPTA) with 
terminal acetylenes in the presence of a base (KOH in methanol) (Scheme 4.1). 
 
123 
 
Chapter 4 Section 1…….    
Scheme 4.1: Synthesis of Mononuclear Alkynyl gold(I) derivatives 
In 2007 Laguna et al26 and co-workers also reported a different variety of gold(I) complexes 
containing the water-soluble phosphine ligands TPPMS, TPPDS and TPPTS (mono-, di- and 
tri-sulfonated triphenyl phosphine) were prepared by under basic condition by using NaOH 
with different gold(I) alkynyl complexes [AuC≡CR(TPPTS)] (Scheme 4.2) 
 
Scheme 4.2: Synthesis of Alkynyl gold(I) derivatives 
N-Heterocyclic carbene (NHC) gold acetylide complexes have also been reported. The first 
synthesis of these complexes by Singh et al. involved the use of ethyl magnesium chloride to 
obtain the desired product (Scheme 4.3) path I.27 This method was however, only used to 
make the terminal acetylide species. A more general approach was reported by Fujimura et 
al. who disclosed a synthetic scheme involving phosphine substitution by a stronger s-
donating NHC ligand (Scheme 4.3- (3)). More recently Gray has reported the reaction of 
[AuCl(NHC)] with sodium tert-butoxide and alkynes to form the desired gold acetylides 
complexes.28  
 
Scheme 4.3: General methods for the preparation of (NHC)AuC≡CR. 
In 2006 Barnard et al 29 reported the synthesis and structures of a family of fascinating 
dinuclear Au(I)–carbene complexes 7 and 8. These complexes have demonstrated significant 
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antimitochondrial activity and interestingly the cyclophane ligand framework allows fine 
control over the intramolecular distance between the gold atoms. Compound 7 supports a 
short Au···Au interaction of 3.0485(3) Å and is luminescent, whereas compound 8, with a 
significantly longer Au···Au distance (3.7917(4) Å), is not (Figure 4.3) 
 
Figure 4.3: N-Heterocyclic carbene (NHC) gold acetylide complexes 
Very recently in 2015 Hikisz et al30 has reported gold(I) complexes of alkynyl chromones 9, 
10 and flavone 11 were synthesized and characterized in presence of DIPEA and triphenyl 
phosphine gold chloride (Scheme 4.4) 
 
Scheme 4.4: Synthesis of gold(I)-complexes of alkynyl chromones and flavones.  
All these complexes were evaluated as anticancer and antibacterial agents against four human 
).  Gold(I) acetylide complex with an amide group has been 
 
cancer cell lines and four pathogenic bacterial strains. 
Moreover in 2012 and 2014 Chao et al31 reported synthesis of mononuclear gold(I) acetylide 
complexes with urea and with amide group by using KF as base in presence of PPh3AuCl as a 
gold precursor (Scheme 4.5
reported as an anion sensor. 
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Scheme 4.5: Synthesis of mononuclear gold(I) acetylide complexes 
4.1.3. Applications of gold(I) alkynyl systems 
Gold(I) alkynyl complexes present a growing research field with respect to their very wide 
range of applications in different areas such as luminescence, molecular recognition, optical 
switches, electronics and catalysis. Biological applications are also being developed in the 
recent years, where these complexes are used as therapeutic agents against different illnesses 
such as cancer cells or malaria. Last from 15 years, there has been a growing interest in metal 
alkynyl complexes and their potential applications in molecular electronics and materials 
science.32,33 In particular, gold(I) derivatives are especially interesting due to their rich 
luminescence properties. The preference of gold(I) for a linear coordination geometry, 
together with the linearity of the acetylide unit and its π-unsaturated nature have made the 
alkynylgold(I) complexes attractive building blocks for organometallic oligomeric and 
polymeric materials which may possess unique properties such as optical non-linearity, 
electrical conductivity, and liquid crystallinity.34  
Alkynyl gold(I) derivatives with phosphine ligands have been investigated for their 
interesting photochemical properties or rich luminescence properties due to intermolecular 
interaction between Au atoms (aurophilic interaction). 
Luminescence property: 
Luminescence is one of the most studied and denoted properties and applications of gold(I) 
alkynyl complexes. The luminescence of gold(I) acetylide was first reported by Che in 199335 
and has been extensively studied by his group and also by Yam’s group.36 More recently, 
these properties have found interest in the use of the systems in a wide range of different 
applications. In general, two different emission bands are observed between 400 and 600 nm 
whose large Stokes shifts with respect to absorption bands (250–350 nm) are used to assign a 
triplet parentage for the emissions. The heavy-atom effect induced by the introduction of the 
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AuPR3 moiety into the organic alkynyl backbone, improves the possibility to observe triplet 
emission at ambient temperature. 
Catalytic applications: 
At the beginning of the last century, organic chemists began to use transition-metal catalysts 
to form carbon-carbon and carbon-heteroatom bonds. Although gold was considered to be an 
inert metal for a long time, its ability to behave as a soft Lewis acid has been recognized 
recently.37 
Therapeutic applications: 
Throughout prehistory and ancient history, most major civilizations attributed medicinal 
character to gold.38 In fact, gold complexes have been extensively studied due to the 
clinically established antiarthritic properties of Au(I) thiolates, such as sodium 
aurothiomalate (Myocrisin), aurothioglucose (Solganal) and [(1-thio-β-D-glucopyranose-
2,3,4,6-tetraacetato-S)(triethylphosphane) gold] (Auranofin). Although rheumatoid arthritis is 
the most well known disease treated with gold derivatives, asthma, pemphigus (an 
autoimmune disease of the skin) and HIV have also been investigated in this field and more 
recently, successful results are being obtained against malaria and cancer.39 
4.1.4. Objective 
The development of gold(I) acetylide complexes has led to several novel compounds.13, 40 
most notably they have been investigated for their interesting photochemical properties or 
rich luminescence properties. Luminescence from gold-acetylide complexes typically results 
from “aurophilicity”. 
Taking all these advantages, in the present work we have planned to design and synthesize a 
gold(I) complex (Figure 4.4), which was never reported in the literature, to carry out studies 
in the field of conjugation of PNA with luminescent probes for cellular imaging. This target 
molecule can be considered a potential “dual-action” compound, composed of two specific 
parts having a different role, i.e. the PNA and the luminescent linear complex of gold.  
 
Figure 4.4: Conjugates of PNA with organometallic gold(I) complex 
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In particular, the complex of gold (I) conjugate acts as potentially luminescent probe but has 
also features as pharmacological agent and anticancer. So for this, we planned to introduce 
phosphine gold(I) chloride 12 onto PNA decamer 13 containing the triple bond at the 
terminal position (Figure 4.5) 
 
Figure 4.5: Phosphine gold(I) chloride 12 and PNA decamer 13 
4.1.5. Results and discussion 
We decided to start our synthesis from single thymine PNA monomer in solution. 
4.1.5.1. Synthesis of thymine monomer PNA gold(I)-acetylene 
The synthesis started from the thymine monomer precursor 14 (for preparation refer chapter 
2, section 1). This thymine monomer 14 was subjected to TFA in dichloromethane for the 
deprotection of Boc group to afford 15, which was used for the next reaction without 
purification. The crude compound 15 was then treated with DIPEA followed by the addition 
of succinic anhydride in DMF to afford acid 16 which was purified by methanol. Its 1H-NMR 
spectrum showed peaks as multiplets at δ 2.27 to 2.43 for four protons and one singlet at δ 
12.05 for one proton and peaks at δ 171.66 and 173.84 in its 13C-NMR spectrum 
corresponded to amide and acid carbonyl group. Further peak at m/z 398 [M+1] + in its mass 
spectrum confirmed the formation of acid 16. The acid 16 was reacted with DIPEA and 
propargyl amine in the presence of EDC.HCl as a coupling agent in DMF to furnish 
compound 17 in 77% yield after chromatographic purification. Its 1H-NMR spectrum showed 
peak as singlet at δ 3.08 for one proton corresponding to terminal alkyne and peaks at δ 3.81 
to 3.84 for two protons and peaks at δ 73.00 and 81.38 in its 13C-NMR spectrum 
corresponding to alkyne. Further peak at m/z 435 [M+1] + in its mass spectrum confirmed the 
formation of 17 compound. The compound 17 was then reacted with different bases in 
presence of phosphine gold chloride 12 for the formation of compound 18 (Scheme 4.6) 
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Scheme 4.6: Reagents and conditions: a) 20% TFA, DCM, 0 oC - rt, 12 hr, 96%; b) succinic 
anhydride, DIPEA, DMF, 0 oC - rt, 12 hr, 70%; c) propargyl amine, EDC.HCl, DMF, rt., 12 
hr, 82% ; d) Phosphine gold chloride (12), base, rt. (Table 4.1) 
 
In order to introduce the phosphine gold moiety under basic conditions on to the acetylene 
compound 17, several different conditions were screened, as shown in Table 4.1. In almost all 
conditions reported in Table 4.1, entry 1-3, we do not get the desired product 18, instead we 
recovered the starting compound 17. It was observed that treatment of compound 17 with 5 
eq. of sodium acetate at ambient temperature, gave the gold complex in only 10% (Table 4.1, 
entry 4).  
Whereas, 17 on treatment with strong base (KOtBu) at room temperature led to the formation 
of gold complex 18 in 24% yield (Table 4.1, entry 5). 1H NMR spectrum showed absence of 
signal that appeared at δ 3.06 (t, 1 H), as a triplet integrating for one protons (acetylene 
proton) and the downfield shifting of the multiplet at δ 7.45-7.55 for the fifteen protons 
indicating the presence of a phosphine group (-PPh3). 13C NMR spectra of compound 18 
displayed downfield signals at δ 128.39 to 134.30 indicating the presence of a phosphine 
group (-PPh3). Further peak at m/z 893 [M+Na]+; in its mass spectrum confirmed the 
formation of 18 compound. 
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Table 4.1: bases and solvents for the formation of Compound 18 
 
Entry Base Solvent Result (18) % Analysis 
1 NaOMe (1.5 eq.) MeOH - starting recovered 
2 NEt3 (1.5 eq.) DCM/MeOH - starting recovered 
3 NaOAc (1.5 eq.) DCM/MeOH - starting recovered 
4 NaOAc (5 eq.) DCM/MeOH 10%  - 
5 KOtBu (4 eq.) MeOH 24% (after purification) 1H/13C-NMR, ESI 
We also designed and synthesized 18 by another alternative strategy (Scheme 4.7) 
 
Scheme 4.7: Reagents and conditions: a) (Boc)2O, THF:H2O, 0 oC – rt, 2 hr, 34%; b) n-BuLi, 
TMSCl, THF, -78 oC, 2 hr, 58%; c) 20% TFA, DCM, rt, 1 hr, quant. 
For the synthesis of thymine PNA monomer gold complex 18, we started our synthesis from 
commercially available propargyl amine 19 which was protected with Boc anhydride to 
afford compound 20 in 34%. The alkyne functionality of compound 20 was protected with 
TMS by using trimethyl silyl chloride in presence of n-BuLi to afford 21 in 57% yield. 
Compound 22 was subjected to N-Boc deprotection by TFA in dichloromethane at room 
temperature to get product 22 in quantitative yield. This compound 22 were used as coupling 
partner for the next reaction. (Scheme 4.8) 
 
Scheme 4.8: Reagents and conditions: a) 22, EDC.HCl, HOBt, DIPEA, DMF, rt, 12 hr, 48%; 
b) PPh3AuCl 12, KF, DCM/MeOH, rt, 12 hr, 54%. 
The thymine monomer of acid 16 were coupled with amine salt 22, in presence of DIPEA, 
EDC.HCl and HOBt as coupling reagent in DMF as solvent to afford 23 in 48% yield. Its 1H-
NMR spectrum showed peak as singlet at δ 0.15 for nine proton corresponds to trimethylsilyl 
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group and peak at δ -0.37 in its 13C-NMR spectrum corresponds to the TMS group, while 
peaks at δ 88.01 and 101.22 corresponded to alkyne. Further peak at m/z 507 [M+1] + in its 
mass spectrum confirmed the formation of 23 compound. 
The structure of compound 23 was fully assigned by using 2D NMR experiments like COSY 
and HSQC. Partial COSY indicating correlation between the protons only; which was 
suggested confirmation of compound 23. (Figure 4.6) 
Figure 4.6: COSY-NMR spectrum of compound 23 in CDCl3. 
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While in the HSQC spectrum, indicating correlation between the protons and carbons; Its 1H-
NMR spectrum showed peak as singlet at δ 0.15 for nine proton corresponds to trimethylsilyl 
group and peak at δ -0.37 in its 13C-NMR spectrum corresponds to the TMS group; and 1H-
NMR spectrum showed peak as multiplets at δ 3.98-4.05 for four protons which corresponds 
to –CH2 (g) protons and which correlates with its 13C carbon at δ 30.09. 
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Figure 4.7: HSQC-NMR spectrum of compound 23 in CDCl3 
The 2D-NMR experimental study strongly supported the structure of compound 23. 
The compound 23 was subjected with KF and phosphine gold chloride 12 in methanol at 
room temperature to furnish gold(I) acetylene thymine PNA monomer 18 in 54% yield. 
(Scheme 4.8) 1H NMR spectrum showed absence of signal that appeared at δ 0.15 for nine 
proton corresponds to trimethylsilyl group and the downfield shifting of the multiplet at δ 
7.45-7.55 for fifteen protons indicating the presence of a phosphine group (-PPh3). 13C NMR 
spectra of compound 18 displayed downfield signals at δ 128.39 to 134.30 indicating the 
presence of a phosphine group (-PPh3). Further peak at m/z 893 [M+Na]+; in its mass 
spectrum confirmed the formation of 18 compound. 
We also tried another alternative strategy for the synthesis of gold(I) acetylene thymine PNA 
monomer 18. As we have compound 21 in our hand, which was subjected with KF and 
phosphine gold chloride 12 in methanol at room temperature to furnish gold(I) acetylene 
compound 24 in 73% yield (Scheme 4.9).  
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Scheme 4.9: Reagents and conditions: a) PPh3AuCl 12, KF, DCM/MeOH, rt, 12 hr, 73%; b) 
The Boc group of compound 24 was removed by TFA in dichloromethane at room 
sting photoluminescence emission properties 
4.1.5.2. Optical characterization and photoluminescence emission of compound 18 
The gold complex 18 appears as a white microcrystalline solid, soluble in most organic 
Figure 4.6 reports the quantitative absorption spectrum of 18 measured in a dichloromethane 
20% TFA, DCM, rt, 1 hr, quant.; c) 25, EDC.HCl, HOBt, DIPEA, DMF, rt.  
temperature but failed to obtain compound 25.  
The compound 18 shows some good and intere
on its solid state than in solution state. 
solvents, like DCM, THF and DMSO and less soluble in water or buffer solutions. The 
spectroscopic and photo physical data of the Au(I)-acetylide complex are reported in figures 
4.6 to 4.8 and Table 4.2  
solution at 10-5 M concentration. Up to 300 nm the spectra accounts for optical transitions 
characterized by extinction coefficient over 104 M-1cm-1,which are typical of almost pure  π- 
π* excitations of the conjugated framework.  
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Figure 4.6: Absorption spectra of 18 in DCM solution (10-5 M). 
Sample 18 is not emissive in diluted solution at room temperature or at low temperature in 77 
K rigid matrix of 2MeTHF or MeOH/EtOH 1:1 v/v mixture. 
On the contrary, according to literature41 in aggregate form as a neat microcrystalline solid, 
sample 18 displays at room temperature, a clear orange-red emission as shown in Figure 4.7. 
The solid sample was excited both at 250 nm and 300 nm and in both cases it displays an 
full width half maxima) of 
5200 cm . The excitation spectra of the sample, green line in figure 4.7 (inserted figure), 
be ascribed to the absorption of 
the aggregated form of sample 18 and tentative attributed to a transition deriving from Au(I)-
emission with maximum at 655 nm (Figure 4.7) and FWHM (
-1
shows a sharp peak at 310 nm and absorption onset at 370 nm. Compared to the solution 
room temperature analysis this new low energy band could 
Au(I) interactions. The sample, in the solid state is characterized by a quite high emission 
quantum efficiency (QY). A luminescence QY of 5% is measured by means of absolute 
methods and the emission is characterized by a microsecond, bi-exponential, decay rate with 
a short lifetime component of 1.9 µs (33% relative contribution) and a longer one of 14.0 µs 
(67% relative contribution). The microsecond lifetime regime is typical of heavy metal 
perturbed phosphorescence emissions.  
450 500 550 600 650 700 750 800
0.0
2.0x105
4.0x105
 PT112 (ex 250)
 Quartz tube (ex 250)
 PT112 (ex 300)
 Quartz tube (ex 300)
 Excitation spectra
 
 
 
Em
is
si
on
 In
te
ns
ity
 (a
.u
.)
655nm
λ (nm) 
300 400 500 600 700 800
0
1x105
2x105
3x105
4x105
5x105
λ (nm)
 
Figure 4.7: Emission spectrum of 18 solid sample at two different excitations, black line at 
250 nm and deep red one at 300 nm. For comparison the baselines observed for the quartz 
sample holder, excited at the same wavelength (red and blue lines), are reported. Inset reposts 
the excitation spectra of the solid sample. 
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Moreover by considering (i) the structure of sample 18 (and the absence of significant 
chromogenic moieties other than the phenyl groups of PPh3 and the Au(I)-acetylide)42, (ii) the 
lack of emission in fluid solution (indeed consequence of the previous consideration), (iii) the 
broad, featureless emission and its large Stocks shift from the excitation maximum; (iv) the 
relatively long radiative lifetime; we can confidently attribute the emission reported in figure 
4.7 to a phosphorescent process involving metal-metal Au(I)-Au(I) interactions in the solid 
state. It means that upon aggregation staking can take place between molecules providing 
new Metal-Metal “d” states which are responsible for the 655 nm emission. 
The fact that in the solid state of the sample 18 Au complex emits with good quantum 
ious literature studies43, we investigate the 
L; hence the 
concentrations of 56 µM (similar to literature reported value43) were studied. Figure 4.8 
efficiency is, by itself, interesting because it means that the complex can be used as a 
luminescent “off-on” probe. In fact the complex evolve from a non emissive species (isolated 
molecules) to a red emissive one (aggregate) upon careful induced aggregation from its 
homogeneous solution. Similarly to prev
aggregation induced emission of sample 18 in a mixed solvent system. Due to the poor 
solubility in water we engineered the experiment and studied the aggregation phenomena in a 
DMSO (good solvent for sample 18) / water solvent system. DMSO represents also a good 
solvent choice since it has good biocompatibility with cells and is suitable for with in vitro 
experiments.44  
We prepared a mother solution of sample 18 in DMSO (CM=1.12 mM). 0.1 mL of the mother 
solution was diluted during the experiment to a final volume of 2 m
reports the aggregation induced luminescence enhancement of sample 18 at different 
DMSO/H2O ratio (range 40/60 up to 5/95). 
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Figure 4.8: Emission spectra of sample 18 (56 µM) in DMSO/H2O mixture between 400 nm 
and 840 nm (with excitation at 300 nm).  
The Au(I)-acetylide complex is as expected, non emissive in pure DMSO solution and 
analogously no emission is detected up to a water content of 80%. In figure 4.8 is clearly 
evident the raise of a broad band peaking around 655 nm at the 15/85 DMSO/H2O mixture; 
this signal becomes more intense increasing the water content (see 5/95). In the inset of 
Figure 4.8 is reported, together with the titration curves, the emission spectra of the Au(I) 
complex as neat solid which nicely match the emission detected in solution. 
The lifetime of the emission signal in the 5/95 DMSO/H2O mixture shows a bi-exponential 
character with a short decay component of 2.0 µs (38%) and a longer one of 15.4 µs (62%). It 
is interesting to note that these photo physical data perfectly match with those measured for 
the pure solid sample 18; therefore indicating that the signal recorded in solution belongs to a 
gold self-aggregate analogue to the solid aggregate previously described in figure 4.7 
O/H2O solvent mixture. Both at 10/90 and 15/85 
 sample and the 
In table 4.2 are reported the photophysical data measured for sample 18 microcrystalline solid 
sample and those measured in the DMS
DMSO/H2O solvent ratio the measured lifetimes are in good agreement with those of the 
parent solid aggregate indicating the same origin. To note that even though an emission 
signal is not clearly perceivable in figure 4.83 at the 20/80 ratio, nonetheless a decay lifetime 
of about 3.9 µs can be measured indicating probably the incipient formation of micro 
aggregates that later evolve to give the broad orange-red emission. 
Table 4.2: Photophysical data measured for sample 18 microcrystalline solid
DMSO/H2O solvent mixtures. 
 
Expt. 
 
Quantum yield (φ)
 
 
Τ (%) [µS] (ex.300 nm to ex.600 nm) 
Sample 18 [Au(I) complex] 
 
0.05 1.9 (33); 14.0 (67) 
DMSO/H O system -  2
5/95 - 2.0 (38); 15.6 (62) 
10/90 - 1.62 (41); 13.50 (59) 
15/85 - 0.47 (50); 7.26 (50) 
20/80 - 3.9 (100) 
30/70 - - 
40/60 - - 
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So in conclusion, we used a physical media (solvent/non-solvent) to induce aggregation and 
we proved that this interaction cause the formation of a new emissive system. In principle any 
conditions that m
Au(I) syste
a “off-on” probe or shows photoluminesecent property and can be applicable for cellular 
imaging. 
We have successfully synthesized thym  monomer gold(I)-acetylene 18 
phosphine ligand (PPh3 ted triphenylphosphane (TPPTS) as 
a lig w route for the nthesis of gold(I)-acetylene c mplex 31 (Scheme 
4.10) 
ay allow for the same type of metal-metal interaction (formation of Au(I)-
m) may lead to the same red emission and therefore the molecule 18 can behave as 
ine with triphenyl 
). So we planned to use trisulfona
and and designed a ne  sy o
 
Scheme 4.10: Reagents and conditions: a) 27, AcCN, H2O, rt, 2 hr, quant.; b) propargyl 
amine, rt, 12 hr; c) NHS, EDC.HCl, DIPEA, DMF, rt, 12 hr, 85%; d) 29, DMF, rt. 
ompound 28 was subjected with propargyl amine and KOH under degassed 
MeOH:DMF solvent system at room temperature, but failed to obtained compound 29. The 
thymine monomer of acid 16 was also reacted with NHS in presence of DIPEA and EDC.HCl 
as coupling reagent in DMF as solvent to afford 30 in 85% yield.  
We tried the same reaction condition and did the reaction two times for the formation of 
compound 29; which was reported in literature43; but we failed to obtained compound 29. 
We started our synthesis from commercially available m-trisulfonated-triphenylphosphane 
(TPPTS) 26 with chloro(tetrahydrothiophene)gold(I) complex 27 (which is prepared in lab) 
under degassed solvent system AcCN:H2O to afford gold(I) complex 28 in quantitative yield. 
The c
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We decided to change to our protocol for the formation of compound 31, as we already 
synthesized the thymine monomer 18 by using TMS strategy, we applied the same conditions 
for the synthesis of compound 31 (Scheme 4.11) 
 
Scheme 4.11: Reagents and conditions: a) 28: ClAu(TPPTS), KF, DCM/MeOH, rt, 12 hr, 
quant. 
mine monomer in solution 
e 4.12).  
The compound 23 was subjected with KF and m-trisulfonated-triphenylphosphane gold 
chloride 28 in methanol at room temperature to furnish gold(I) acetylene thymine PNA 
monomer 31 in quantitative yield. 1H NMR spectrum showed absence of signal that appeared 
at δ 0.15 for nine proton corresponds to trimethylsilyl group. Further peak at m/z 1199 
[M+K]+; in its mass spectrum confirmed the formation of 31 compound. 
After successful synthesis of gold(I) complexes 18 and 31 with thy
phase; we planned to introduce the same strategy with homothymine PNA oligomer on solid 
phase. 
4.1.5.3. Synthesis of gold complex with homothymine PNA decamer on solid support 
The synthesis was performed with standard manual Boc-based chemistry using MBHA resin 
32, firstly loaded with Thymine monomer 33 by using HBTU as a coupling reagent in order 
to obtain functionalized resin 34 with loading 0.2 mmol/g (Schem
 
Scheme 4.12: Reagents and conditions: a) CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; b) 33, HBTU, 
DIPEA, NMP, 24 hr, rt; c) Ac2O/Pyridine/NMP 1:25:25, 2 × 1 min, rt. 
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Then the tert-butyloxycarbonyl (Boc) group of the loaded monomer 34 was removed by 
treatment with 5% m-cresol in TFA to get an amine TFA salt which was neutralized by 5% 
DIPEA in dichloromethane. Then the free amine on resin was coupled with next thymine 
monomer 33 with DIPEA and HATU in NMP as a solvent. After coupling step resin were 
washed with NMP, and then treated with a solution of Ac2O/pyridine/NMP (1:25:25, v/v). 
The cycles were repeated eight more times by using the thymine monomer only with the 
ixture of TFA/TFMSA/thioanisole/m-cresol (6:2:1:1 v/v) to get 
ed 
same protocol to afford the corresponding supported homothymine PNA decamer on resin 35 
(Scheme 4.13). Then the resin 35 (5 mg) were cleaved by washing with TFA, and 
subsequently stirred with a m
35’ and characterized by analytical HPLC with retention time 11.84 min. and also confirm
by Q-Tof mass analysis m/z C110H144N41O40+: 2680.00 
 
Scheme 4.13: Reagents and conditions: a) TFA/m-cresol, 95:5, 2 × 4 min, rt; b) 
CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; c) 33: thymine monomer, HATU, DIPEA, NMP, 2 hr, rt; 
d) Ac2O/Pyridine/NMP 1:25:25, 2 ×  1 min, rt.; e) TFA/TFMSA/thioanisole/m-cresol 6:2:1:1 
(v/v), 1 hr, rt. 
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4.1.5.4. Analytical HPLC and Q-Tof mass: Homothymine PNA decamer (35’) 
 
Figure 4.9: Analytical HPLC of homothymine PNA decamer 35’, retention time 11.84 min. 
 
Figure 4.10: Q-Tof/Mass analysis of homothymine decamer 35’, C110H144N41O40+: 2680.00 
thesizing homothymine decamer 35, Boc group were removed by 
treatment with 5% m-cresol in TFA to get an amine TFA salt which was neutralized by 5% 
yl acid 36 
with DIPEA and HATU in NMP as a solvent for 2 hr at room temperature. After coupling 
step, the resin was washed with NMP and DCM for several times to afford the corresponding 
resin 37 (Scheme 4.14).Then the resin was cleaved by washing with TFA, and subsequently 
stirred with a mixture of TFA/TFMSA/thioanisole/m-cresol (6:2:1:1 v/v). The reaction 
mixture was filtered, and the filtrate were concentrated to by the addition of diethyl ether to 
afford white coloured crude PNA decamer 38, which was analyzed by mass and HPLC. 
After successfully syn
DIPEA in dichloromethane. Then the free amine on resin was coupled with proparg
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Scheme 4.14: Reagents and conditions: a) TFA/m-cresol, 95:5, 2 × 4 min, rt; b) 
CH2Cl2/DIPEA, 95:5, 2 × 2 min, rt; c) 36, HATU, DIPEA, NMP, 2 hr, rt; d) 
TFA/TFMSA/thioanisole/m-cresol 6:2:1:1 (v/v), 1 hr, rt. 
4.1.5.5. Analytical HPLC and Q-Tof mass: PNA decamer (38) 
 
Figure 4.11: Analytical HPLC of PNA decamer 38, retention time 12.80 min. 
 
mer 38, C HFigure 4.12: Q-Tof/Mass analysis of PNA deca 117 150N42O42: 2855 [M+K]+ 
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The PNA decamer 38 was subjected to KOtBu and phosphine gold chloride 12 in methanol at 
room temperature; however, in these conditions the formation of gold(I) acetylene PNA 
decamer 39 was not observed, as revealed by the MALDI-Tof analysis (Scheme 4.15) 
 
Scheme 4.15: Reagents and conditions: a) PPh3AuCl 12, KOtBu, DCM/MeOH, rt, 12 hr. 
MALDI-TOF: m/z: C135H164AuN42O42P calculated 3273.14; found 1657.39 and 2837.8 
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4.2.1. Experimental Section 
4.2.1.1. General Materials and Methods 
The monomers containing the nucleobases C, G and A were purchased from ASM Research 
Chemicals and were used for the synthesis of PNA decamer, as such without further 
purification. The thymine monomer aeg-(T) PNA-COOH was synthesized in lab. (Chapter 2, 
section 2). 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxidhexafluoro phosphate (HATU), trifluoroacetic acid (TFA), trifluoromethanesulfonic acid 
(TFMSA), m-cresol, phosphine gold chloride and Triphenylphosphine-3,3′,3′′-trisulfonic acid 
trisodium salt (TPPTS) were purchased from Aldrich. N-methyl-2-pyrrolidone (NMP), N, N-
diisopropylethylamine (DIPEA) and thioanisole were purchased from Fluorochem. 
Polystyrene bead carrying 4-methylbenzhydrylamine hydrochloride salt groups (MBHA 
resin, 0.63 mmol/g) was purchased from VWR International. 
4.2.1.2. Experimental Techniques 
1H, 13C and 31P NMR spectra were recorded on Bruker 300 MHz and 70 MHz respectively. 
Chemical shifts (δ) are reported in parts per million relative to solvent peak. Many of the 
compounds described below showed many rotamers and consequently exhibit complex 1H 
NMR patterns. Some of the signals in the 1H NMR are therefore described as major (ma.) and 
minor (mi.) components; however, in many cases, some minor signals were obscured by the 
major signal of another proton. In such cases, only the major signal is reported or a range 
containing two or more CH2. In some cases, the 13C spectrum shows many peaks that cannot 
be distinguished in a small range: ov. Means ‘overlapped’. Melting points of samples were 
determined in open capillary tubes with a Büchi Melting Point B-540 apparatus and (dec) 
indicates decomposition. The IR spectra were recorded on a Perkin-Elmer FTIR 4100. Mass 
spectra were obtained by LCMS techniques (a Thermo Scientific LCQ Advantage). TLC was 
performed using TLC glass plates pre-coated with silica gel (Merck). TLCs were visualized 
with UV light and/or either by charring in Ninhydrine solution or developing in I2 chamber. 
Silica gel 60-120 and 100-200 mesh was used for column chromatography using ethyl 
acetate/hexane and dichloromethane/methanol mixture as elution solvent depending upon the 
compound polarity and chemical nature. Commercial reagents were generally used as 
received. Solvents used in organic reactions were distilled under an inert atmosphere. 
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Unless otherwise noted, all reactions were carried out at room temperature. Oligomers were 
characterized by RP HPLC, using C18 column and MALDI-TOF mass spectrometry. 
All weightings of reagents were carried out with analytical balance Mettler Toledo AB135- 
S/FACT. Vials ALLTECH of 1.5 ml, 4 ml and 8 ml with frits of PTFE were used as reactor 
for manual solid phase synthesis. 
HPLC of PNA oligomers were performed with a HPLC AGILENT 1100 Series, using an 
analytical column Phenomenex Luna (15 cm x 4.6 mm, 5 μm) and a semi preparative column 
Phenomenex Luna C18 (25 cm x 10 mm, 10 μm). 
MALDI-TOF spectra were recorded with a Bruker Daltonics Omniflex. Pulsed nitrogen 
lasers (337 nm) were used to generate ions that have been accelerated in a 20 kV field. The 
instrument was calibrated in the range from 0 to 20 kDa. Generally, Sinapinic acid and 2, 5- 
dihydroxybenzoic acid (DHB) matrixes were used. 
A lyophilizer Telstar Cryodos were used to isolate pure PNA oligomers from aqueous 
solutions. 
4.2.1.3. Experimental Procedures 
2-(N-(2-methoxy-2-oxoethyl)-2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)acetamido)ethan-1-aminium salt (15) 
The compound 14 (1 gm, 2.509 mmol) was dissolved in 
DCM (10 mL) and 20% TFA (2 mL) was added slowly at 
0 oC. Reaction mixture was allowed to stir for 2 hr at room 
temperature. The progress of the reaction was monitored 
by TLC. After completion of the reaction; reaction mixture 
were evaporated on rota vapour to afford pale yellowish 
white residue of free amine salt 15 in quantitative yield; 
which was used without further purification. 
O
O
N
NH3+
O
N
NH
O
O
CF3COO
-
15
Molecular formula: C12H19N4O5+ 
Rf: 0.2 (MeOH: DCM, 50:50) 
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1H NMR (300 MHz, MeOD-d4 mix of rotamers): δ 1.88 (s, 3H); 3.15-3.31 (m, 4H); 3.70-
3.76 (m, 4H); 3.83 (s, 3H); 4.18mi - 4.39ma (d, 2H); 4.60ma - 4.75mi (d, 2H); 7.29ma - 7.37mi (s, 
1H) 
 
4-((2-(N-(2-methoxy-2-oxoethyl)-2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)acetamido)ethyl)amino)-4-oxobutanoic acid (16) 
A mixture of succinic anhydride (2.42 gm, 24.18 
mmol) and DIPEA (4.2 mL, 24.18 mmol) was added 
to a solution of 15 (1 gm, 2.42 mmol) in dry DMF (20 
mL) at 0 °C. The reaction mixture was kept at room 
temperature and stirred it for overnight. Then, the 
solvent (dark brown colour) was evaporated at 
reduced pressure and the crude product was 
precipitated from MeOH and recovered by filtration to afford 16 (0.680 gm, 71%) as white 
solid. M.P.: 216 °C. 
O
O
N
N
H
O
N
NH
O
O
O
OH
O
16
Molecular formula: C16H22N4O8 
Rf: 0.2 (ethyl acetate: methanol, 80:20) 
FT-IR (Nujol): νmax/cm-1 3316, 2925, 1698, 1662, 1556, 1463, 1375 
1H NMR (300 MHz, DMSO-d6: mix of rotamers): δ 1.75 (s, 3H), 2.27-2.43 (m, 4H), 3.14-
3.41 (m, 4H), 3.31 (s, 3H), 3.63ma - 3.72mi (d, 2H), 4.07ma - 4.31mi (d, 2H), 4.47mi - 4.64ma (d, 
2H), 7.27mi - 7.33ma (d, 1H), 7.80mi - 7.95ma (t, 1H), 11.26 (s, 1H), 12.05 (s, 1H, -COOH) 
13C NMR (75 MHz, DMSO-d6: mix of rotamers): δ 11.87, 28.90, 29.84, 36.92, 46.69, 47.70, 
48.70, 51.75, 52.24, 108.01, 142.17, 150.97, 164.36, 167.39, 169.55, 171.66, 173.84 
MS (ESI) (m/z): 398 [M+1]+ and [M+Na]+ 
  
Methyl-N-(2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)acetyl)-N-(2-(4-oxo-4-
(prop-2-yn-1-ylamino)butanamido)ethyl)glycinate (17) 
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EDC.HCl (216 mg, 1.13 mmol) and propargyl 
amine (42 μL, 1.13 mmol) were added to a 
solution of compound 16 (150 mg, 0.37 mmol) 
in dry DMF (5 mL). The mixture was stirred at 
room temperature for overnight. The solvent 
were removed under vacuum and the crude 
product was purified by column 
chromatography on silica gel (ethyl acetate/MeOH 8:2) yielding 17 (135 mg, 82%) as white 
solid. M.P.: 192 °C. 
O
O
N
N
H
O
N
NH
O
O
O H
N
O
17
Molecular formula: C19H25N5O7 
Rf: 0.6 (ethyl acetate: methanol, 80:20) 
FT-IR (Nujol): νmax/cm-1 3294, 2936, 2724, 1716, 1674, 1643, 1536, 1213. 
1H NMR (300 MHz, DMSO-d6 mix of rotamers): δ 1.75 (s, 3H); 2.29 - 2.34 (m, 4H); 3.04 - 
3.28 (m, 4H); 3.62ma - 3.71mi (d, 2H); 3.81- 3.83 (m, 2H); 4.06ma - 4.30mi (d, 2H); 4.47mi - 
4.64ma (d, 2H); 7.27mi - 7.36ma (d, 1H); 7.78mi - 7.93ma (t, 1H); 8.25 (s, 1H); 11.27 (s, 1H) 
13C NMR (75 MHz, DMSO-d6 mix of rotamers): δ 12.05, 27.93, 30.20, 30.42, 37.00, 46.81, 
47.90, 51.97, 52.43, 73.00, 81.38, 108.25, 142.43, 151.17, 164.64, 167.59, 169.78, 171.38, 
172.22 
MS (ESI) (m/z): 435 [M+1]+ and [M+Na]+ 
 
Tert-butyl prop-2-yn-1-ylcarbamate (20) 
A solution of propargyl amine 19 (0.4 gm, 7.26 mmol) in 25% 
THF-H20 (20 mL) was treated with aq. saturated NaHCO3 (0.4 
mL) followed by the dropwise addition of di-tertbutyl dicarbonate 
(1.47 gm, 7.99 mmol) and the mixture was stirred at room 
temperature for 5 hr. The progress of the reaction was moniterd by TLC. The reaction 
mixture was concentrated, extracted with ethyl acetate (3 x 10 mL) and washed with brine (5 
mL). The combined organic extracts were dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure to afford crude compound 20, which was purified on 
H
NO
O 20
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flash column chromatography (SiO2) using EtOAc: Hexane (20:80) as a eluent to afford 
compound 20 as a white solid (0.395 gm, 35% yield) or Recrystallization in hexane to 
afforded 20. 
Molecular formula: C8H13NO2 
Rf: 0.4 (EtOAc: Hexane; 30:70) 
FT-IR (Nujol): νmax/cm-1 3461, 2359, 1725, 1556 
1H NMR (300 MHz, CDCl3): δ 1.46 (s, 9H); 2.22 (t, 1H); 3.92 (s, 2H), 4.70 (bs, 1H) 
13C NMR (75 MHz, CDCl3): δ 28.23, 30.25, 71.13, 79.94, 80.04, 155.23 
 
Tert-butyl (3-(trimethyl silyl)prop-2-yn-1-yl) carbamate (21) 
A solution of n-BuLi in hexane (1.6 M, 1.2 mL) was added to 
a solution of N-t-butoxycarbonylprop-2-ynylamine 20 (150 
mg, 0.1 mmol) in THF (5 mL) at -78 oC. After 15 minutes a 
solution of Trimethyl silyl chloride (0.25 mL, 1.93 mmol) in 
THF (5 mL) was added dropwise. The mixture was stirred for an additional 1 hr at room 
temperature, the progress of the reaction was monitored by TLC after which a solution of 
AcOH (2 mL, 0.25M) was added and stirred the reaction for additional l hr at room 
temperature, the solution was concentrated under reduced pressure and extracted with ethyl 
acetate (3 x 10 mL). The combined organic extracts were dried over anhydrous Na2SO4, 
filtered and concentrated under reduced pressure to afford crude compound 21, which was 
purified on flash column chromatography (SiO2) using EtOAc: Hexane (20:80) as a eluent to 
afford compound 21 as a white solid (125 mg, 58% yield) or Recrystallization in hexane to 
afforded 21. 
H
NO
O
TMS
21
Molecular formula: C11H21NO2Si 
Rf: 0.5 (EtOAc: Hexane; 20:80) 
FT-IR (Nujol): νmax/cm-1 3431, 2360, 1719, 1645 
1H NMR (300 MHz, CDCl3): δ 0.15 (s, 9H); 1.44 (s, 9H); 3.93 (s, 2H); 4.73 (bs, 1H) 
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13C NMR (75 MHz, CDCl3): δ -0.23, 28.31, 31.40, 79.89, 87.94, 101.80, 155.15 
MS (ESI) (m/z): 227 [M+Na]+  
 
3-(trimethylsilyl)prop-2-yn-1-aminium 2,2,2-trifluoroacetate (22) 
The compound 21 (50 mg, 0.219 mmol) was dissolved in 
DCM (5 mL) and 20% TFA (0.4 mL) was added slowly at 
room temperature reaction mixture was allowed to stir for 1 hr. 
The progress of the reaction was monitored by TLC. After 
completion of the reaction; reaction mixture were evaporated on rota vapour to afford pale 
yellowish residue of free amine salt 22 in quantitative yield; which was used without further 
purification. 
+H3N
TMS
22
CF3COO-
Molecular formula: C8H14F3NO2Si 
Rf: 0.02 (EtOAc: Hexane; 30:70) 
1H NMR (300 MHz, CDCl3): δ 0.16 (s, 9H); 3.78 (s, 2H); 8.19 (bs, 2H) 
 
Methyl-2,2-dimethyl-14-(2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetyl)-
7,10-dioxo-6,11,14-triaza-2-silahexadec-3-yn-16-oate (23) 
To a stirred solution of the compound 16 
(102 mg, 0.256 mmol) in anhydrous DMF (5 
mL), HOBt (47 mg, 0.307 mmol) and 
EDC.HCl (76 mg, 0.385 mmol) were added 
at 0 oC. Then a solution of compound 22 (62 
mg, 0.256 mmol) in DMF (1 mL) was added 
dropwise followed by addition of DIPEA (30 
µL, 1.28 mmol). The reaction mixture was stirred for an additional 12 hr at room 
temperature, the progress of the reaction was monitored by TLC. The solution was 
concentrated under reduced pressure and extracted with ethyl acetate (3 x 10 mL). The 
combined organic extracts were dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure to afford crude compound 23, which was purified on flash column 
O
O
N N
H
O
N
NH
O
O
O H
N
O
TMS
23
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chromatography (SiO2) using DCM: MeOH (90:10) as a eluent to afford compound 23 as a 
white solid (52 mg, 48% yield) 
Molecular formula: C22H33N5O7Si 
Rf: 0.4 (DCM: MeOH: 90:10) 
1H NMR (300 MHz, CDCl3 mix of rotamers): δ 0.15 (s, 9H); 1.89 (s, 3H); 2.53-2.60 (m, 
4H); 3.46-3.57 (m, 4H); 3.74ma-3.80mi (s, 3H); 3.98-4.05 (m, 4H); 4.07ma-4.23mi (d, 2H); 
4.47mi-4.62ma (d, 2H); 6.59 (bs, 1H); 7.09mi-7.19ma (s, 1H); 7.44 (s, 1H); 9.44 (bs, 1H) 
13C NMR (75 MHz, CDCl3 mix of rotamers): δ -0.31, 12.15, 30.09, 30.70, 30.97, 37.35, 
47.89, 48.11, 48.29, 52.40, 88.01, 101.22, 110.24, 117.23, 141.75, 151.44, 164.68, 167.72, 
170.12, 172.08, 173.32 
MS (ESI) (m/z): 507 [M+1]+ and [M+Na]+ 
 
Synthesis of Thymine monomer PNA with gold complex (18) 
O
O
N
N
H
O
N
NH
O
O
O H
N
O
Au
PPh3
18
To a stirred solution of the compound 17 (50 
mg, 0.114 mmol) in anhydrous methanol (5 
mL) with a foil covered round bottomed 
flask. KOtBu (26 mg, 0.23 mmol) and 
[AuCl(PPh3)] 12 (68.2 mg, 0.14 mmol) were 
added under nitrogen atmosphere for 12 hr at 
room temperature. The progress of reaction 
was monitored by TLC. After completion of reaction solvent were removed under reduced 
pressure, to afford an yellow coloured residue which was purified on flash column 
chromatography (SiO2) using DCM/MeOH (95:05) as a eluent to afford compound 18 as a 
white solid (23 mg, 24% yield)  
Or 
To a mixture of Ph3PAuCl 12 (48 mg, 0.098 mmol) and compound 23 (50 mg, 0.098 mmol) 
in anhydrous CH2Cl2 was added KF. 2H2O (12 mg, 0.196 mmol) in methanol (1 mL) 
dropwise. The mixture was stirred overnight in the dark. After completion of reaction, solvent 
were removed under reduced pressure, to afford an yellow coloured residue which was 
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purified on flash column chromatography (SiO2) using DCM/MeOH (95:05) as a eluent to 
afford compound 18 as a white solid (48 mg, 54% yield)  
Molecular formula: C37H39AuN5O7P 
Rf: 0.5 (DCM: Methanol, 95: 05) 
1H NMR (300 MHz, CDCl3 mix of rotamers): δ 1.86 (s, 3H); 2.46 – 2.56 (m, 4H); 3.44 - 
3.54 (m, 4H); 3.74ma - 3.76mi (s, 3H); 4.04ma - 4.06mi (d, 2H); 4.11ma - 4.22mi (m, 2H); 4.48mi 
– 4.65ma (d, 2H); 6.41 (s, 1H); 7.05mi - 7.19ma (s, 1H); 7.42 – 7.55 (m, 15H); 9.03 (bs, 1H) 
13C NMR (75 MHz, CDCl3 mix of rotamers): δ 12.30, 29.65, 30.64, 31.05, 31.54, 37.23, 
48.41, 52.56, 53.39, 83.43, 99.25, 110.42, 128.39, 128.56, 129.10, 129.24, 131.68, 134.12, 
134.30, 141.56, 151.29, 164.00, 167.70, 170.40, 171.52,172.84 
31P[1H] NMR (CDCl3): δP = +43.23 ppm 
MS (ESI) (m/z): 893 [M+Na]+; 721.71 [PPh3AuPPh3] 
 
Synthesis of gold(I) acetylene complex (24) 
To a stirred solution of the compound 21 (50 mg, 0.219 
mmol) in anhydrous DCM (5 mL), [AuCl(PPh3)] 12 (108 
mg, 0.219 mmol) were added under nitrogen atmosphere 
and a solution of KF (25 mg, 0.439 mmol) in 1 mL of 
methanol were added dropwise and stirred it for 12 hr at room temperature. The progress of 
reaction was monitored by TLC. After completion of reaction solvent were removed under 
reduced pressure to afford an yellow coloured residue which was purified on flash column 
chromatography (SiO2) using EtOAc: Hexane (30:70) as a eluent to afford compound 18 as a 
white solid (101 mg, 73% yield) 
H
NO
O
Au
PPh3
24
Molecular formula: C26H27AuNO2P 
Rf: 0.4 (EtOAc: Hexane (30:70) 
1H NMR (300 MHz, CDCl3 mix of rotamers): δ 1.46 (s, 9H); 4.11 (d, 2H); 4.72 (bs, 1H); 
7.45-7.56 (m, 15H) 
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MS (ESI) (m/z): 613 [M+Na]+ 
 
Chloro(tetrahydrothiophene)gold(I) complex (27) 
Potassium tetrachloroaurate(III) (0.4 gm, 0.0105 mmol) was 
dissolved in water (5 mL) at 0 oC. To this solution 
tetrahydrothiophene (0.3 mL, 0.0317 mmol) was added dropwise. 
After stirring for 0.5 hr, the pale-white solid was filtrated off, washed 
with water and diethyl ether, and dried under vacuum. The resulting 
chloro(tetrahydrothiophene)gold(I) complex 27 was used for the next step without further 
purification. 
S Au Cl
27
Molecular formula: C4H8AuClS 
1H NMR (300 MHz, CDCl3): δ 2.23 (bs, 2H); 3.40 (bs, 2H) 
 
Synthesis of (PPh3)AuCl Complex (12) 
To a stirred solution of chloro(tetrahydrothiophene)gold(I) 27 (100 
mg, 0.31 mmol) in CH2Cl2 (5 mL) was added dropwise a solution of 
the triphenyl phosphine (PPh3) (82 mg, 0.31 mmol) in CH2Cl2 (3 mL) 
at room temperature for overnight, the solvent was removed under 
reduced pressure to give (PPh3)AuCl complex 12 as a white solid in quantitative yield. 
12
PPh3-Au-Cl
Molecular formula: C18H15AuClP 
1H NMR (300 MHz, CDCl3): δ 7.48- 7.57 (m, 15H) 
31P[1H] NMR (CDCl3): δP = +35.19 ppm 
 
Synthesis of (TPPTS)AuCl Complex (28) 
To a solution of ClAu(THT) 27 (40 mg, 0.124 mmol) in 6 mL 
degassed CH3CN, was added m-trisulfonated-triphenylphosphane 
P
SO3Na
Cl
Au
NaO3S
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(TPPTS) (71 mg, 0.124 mmol) under an argon atmosphere. 6 mL of degassed H2O were 
added to dissolve the TPPTS completely. After stirring for 2 hr at room temperature under 
argon, CH3CN and tetrahydrothiophene were removed on the rota vapour. The aqueous 
solution was then lyophilised on the freeze dryer to obtain a white solid 28 in quantitative 
yield. 
Molecular formula: C18H12AuClNa3O9PS3 
1H NMR (300 MHz, DMSO-d6): δ 7.42 - 7.61 (m, 3H); 7.62 – 7.79 (m, 3H); 7.83 – 7.86 (m, 
6H) 
31P[1H] NMR (DMSO-d6): δP = +35.20 ppm 
MS (ESI) (m/z): 823 [M+Na]+ 
 
2, 5-dioxopyrrolidin-1-yl 4-((2-(N-(2-methoxy-2-oxoethyl)-2-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)acetamido)ethyl)amino)-4-oxobutanoate (30) 
To a stirred solution of the compound 16 (100 
mg, 0.251 mmol) in anhydrous DMF (5 mL), 
EDC.HCl (105 mg, 0.627 mmol) and DIPEA 
(0.13 mL, 0.753 mmol) were added at room 
temperature. N-Hydroxy succinimide (72 mg, 
0.627 mmol) was added onto the reaction 
mixture and stirred it for 12 hr at room 
temperature, the progress of the reaction was monitored by TLC. The solution was 
concentrated under reduced pressure to afford crude compound 30, which was directly 
purified on flash column chromatography (SiO2) using DCM: MeOH (90:10) as a eluent to 
afford compound 30 as a white solid (106 mg, 85% yield) 
O
O
O
O
N
O
N
H
NH
N
O
O
O
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O
O
30
Molecular formula: C20H25N5O10 
Rf: 0.4 (MeOH: DCM; 10:90) 
1H NMR (300 MHz, CDCl3 mix of rotamers): δ 1.89 (s, 3H); 2.64 (s, 2H); 2.80 (s, 2H); 2.88 
(s, 3H); 2.95 (s, 3H); 3.63 (t, 2H); 3.73 (s, 3H); 3.80 (s, 2H); 4.14ma – 4.16mi (d, 2H); 4.35mi – 
4.46ma (d, 2H); 6.96 (s, 1H); 8.02 (s, 1H); 8.76 (bs, 1H)  
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Synthesis of Complex (31) 
To a mixture of (TPPTS)AuCl 28 
(17.65 mg, 0.022 mmol) and 
compound 23 (11.20 mg, 0.022 
mmol) in anhydrous CH2Cl2 was 
added KF. 2H2O (3 mg, 0.044 mmol) 
in methanol (0.5 mL) dropwise. The 
mixture was stirred at room 
temperature for overnight in the dark. After completion of reaction, solvent were removed 
under reduced pressure, to afford an yellow coloured residue which was then lyophilised on 
the freeze dryer to obtain a light organge solid 31 in quantitative yield. 
O
O
O
N
O
N
H
NH
N
O
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AuH
N
P SO3Na
NaO3S
SO3Na
31
Molecular formula: C37H36AuN5Na3O16PS3 
1H NMR (300 MHz, DMSO-d6 mix of rotamers): δ 1.75 (s, 3H); 2.27 – 2.41 (m, 4H); 2.74 
– 2.99 (m, 4H); 3.62 (s, 3H); 3.69 - 3.87 (d, 2H); 4.05ma – 4.32mi (d, 2H); 4.55mi – 4.70ma (d, 
2H); 6.53 (s, 1H); 7.37 – 7.42 (m, 16H); 11.25 (bs, 1H)  
MS (ESI) (m/z): Q-Tof: calculated: 1199.04; found 1238.39 [M+K] + 
 
4-oxo-4-(prop-2-yn-1-ylamino)butanoic acid 
A solution of succinic anhydride (300 mg, 2.99 mmol), 
propargylamine (29 µL, 4.49 mmol) and 4-DMAP (330 mg, 
2.69 mmol) in CH2Cl2 (10 mL) was stirred for 3 hr at room 
temperature. Then, the mixture was washed with a solution of 
5% Na2CO3 (10 mL). The aqueous layer was acidified with a 1 N HCl solution and then 
extracted with ethyl acetate (3 X 10 mL). The combined organic extracts were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure to afford compound XX 
(465 mg, 88%). 
HO
O H
N
O
Molecular formula: C7H9NO3 
Rf: 0.5 (CH2Cl2/MeOH/AcOH) 
FT-IR (Nujol): νmax/cm-1 3293, 2724, 1698, 1634, 1555, 
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1H NMR (300 MHz, CDCl3): δ 2.31- 2.32 (m, 2 H); 2.40-2.42 (m, 2H), 3.08 (s, 1H); 3.82 (s, 
2H); 8.29 (s, 1H); 12.07 (s, 1H) 
13C NMR (75 MHz, CDCl3): δ 27.84, 28.92, 29.71, 72.99, 81.26, 170.76, 173.80 
MS (ESI) (m/z): 155 [M+Na] +  
 
Loading (0.2 mmol/gm) of thymine monomer 33 on MBHA resin (34) 
The MBHA resin 32 (0.2 gm) was washed with CH2Cl2 (2 
x 5 mL) and activated by treatment with 5% DIPEA in 
CH2Cl2 for 5 min for 3 times; and then washed with 
CH2Cl2 (2 x 5 mL). In a vial, DIPEA (14 μL, 0.08 mmol) 
was added to a solution of thymine monomer 33 (15.38 
mg, 0.04 mmol) in NMP (1 mL); then, a solution of HBTU 
(15.17 mg, 0.04 mmol) in NMP (1 mL) in another vial and add this solution into the 
monomer solution, and activate the monomer solution for 2 minutes. This mixture was then 
added to the neutralized resin and shakes it on orbital shaker for 12 hr. The resin was washed 
with NMP (3 x 5 mL). A solution of Ac2O/Py/NMP 1:2:2 (5 mL) was added to the resin 
(capping of unreacted amino groups) and left under stirring at rt for 1 hr. After this time, the 
resin was washed with NMP (3 x 5 mL), CH2Cl2 (4 x 5 mL), 5% DIPEA in CH2Cl2 (2 x 5 
mL) and again with CH2Cl2 (4 x 5 mL); and finally dried in vacuum to afford the MBHA 
resin downloaded with thymine monomer 34 (0.242 gm); Kaiser Test: negative. 
34
N
H
O
N
O
N
NH
NHBoc
O
O
 
Synthesis of homo-thymine decamer (35) on solid phase 
 
The resin 34 (100 mg, substitution with 0.2 mmol/g) was placed in a reaction vessel (volume; 
8 mL) and which was swollen with CH2Cl2 for 30 minutes, the Boc group of the loaded 
monomer was removed by treatment with TFA/m-cresol (95:5), (3 mL, 2 x 4 min). The resin 
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was washed with CH2Cl2 (2 x 5 mL) and then treated with CH2Cl2/DIPEA (95:5), (3 mL, 2 x 
2 min). Then the resin was washed thoroughly with CH2Cl2 (2 x 5 mL). In a vial, DIPEA (35 
μL, 0.2 mmol, 10 eq.) was added to a solution of Thymine monomer 33 (40.7 mg, 0.106 
mmol, 5.3 eq.) in NMP (500 μL); then, a solution of HATU (38 mg, 0.1 mmol, 5 eq.) in NMP 
(500 μL) in another vial and add this solution into the monomer solution, and activate the 
monomer solution for 2 minutes. This mixture was then added to the neutralized resin and 
shaken for 2 hr at room temperature. After coupling step the resin was filtered, washed with 
NMP (3 x 5 mL) and CH2Cl2 (3 x 5 mL). Then resin treated with Ac2O/Py/NMP; 1:25:25 
capping solution twice for 1 min. and again washed the resin with CH2Cl2 (3 x 5 mL), NMP 
(3 x 5 mL) and CH2Cl2 (3 x 5 mL). The cycle was repeated using thymine monomer 33 with 
the same protocol and after the last coupling and capping the resin was washed with several 
times with NMP and CH2Cl2 and finally dried the resin under vacuum to afford the 
corresponding supported PNA homothymine decamer on resin 35 (138 mg). 
Short cleavage: The resin 35 (5 mg) was washed with TFA (2 × 100 μL) and subsequently 
stirred for 1 hr with a mixture of TFA/TFMSA/thioanisole/m-cresol [6:2:1:1 v/v] (300 μL). 
The reaction mixture was filtered, and the resin washed with TFA (4 × 100 μL). The filtrate 
was concentrated under nitrogen flow and Et2O (5 mL) was added to precipitate PNA as a 
white solid. Centrifugation of the slurry gave the product, which was washed with Et2O (8 x 5 
mL) and dried to afford the crude homothymine decamer 35’ as a white solid. 
Retention time (analytic column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
AcCN/TFA 0.1%) = 11.84 min. 
Maldi Tof MS: found m/z: 2680.00 [M] +, calculated for C110H144N41O40+: 2679.05 
 
Synthesis of homo-thymine decamer with terminal alkyne (37) on solid phase 
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The resin 35 (50.5 mg) was placed in a reaction vessel (volume; 8 mL) and which was 
swollen with CH2Cl2 for 30 minutes, the Boc group of the loaded homothymine decamer was 
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removed by treatment with TFA/m-cresol (95:5), (2 mL, 2 x 4 min). The resin was washed 
with CH2Cl2 (2 x 5 mL) and then treated with CH2Cl2/DIPEA (95:5), (2 mL, 2 x 2 min). Then 
the resin was washed thoroughly with CH2Cl2 (2 x 5 mL). In a vial, DIPEA (18 μL, 0.101 
mmol, 10 eq.) was added to a solution of propargyl acid 36 (8.6 mg, 0.055 mmol, 5.5 eq.) in 
NMP (500 μL); then, a solution of HATU (19.20 mg, 0.055 mmol, 5 eq.) in NMP (500 μL) in 
another vial and add this solution into the monomer solution (propargyl acid), and activate 
the monomer solution for 2 minutes. This mixture was then added to the neutralized resin and 
shaken for 2 hr at room temperature. After coupling step the resin was filtered, washed with 
NMP (3 x 5 mL) and CH2Cl2 (3 x 5 mL) and finally dried the resin under vacuum to afford 
the corresponding supported resin of PNA homothymine decamer 37 (58 mg). 
 
Synthesis of homo-thymine decamer with terminal alkyne (38) 
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Cleavage: The resin 37 (58 mg) was washed with TFA (2 × 200 μL) and subsequently stirred 
for 1 hr with a mixture of TFA/TFMSA/thioanisole/m-cresol [6:2:1:1 v/v] (500 μL). The 
reaction mixture was filtered, and the resin washed with TFA (4 × 200 μL). The filtrate was 
concentrated under nitrogen flow and Et2O (5 mL) was added to precipitate PNA as a white 
solid. Centrifugation of the slurry gave the product, which was washed with Et2O (8 x 5 mL) 
and dried to afford the crude homothymine decamer 38 (14.5 mg). Purification of the crude 
PNA by RP-HPLC afforded the homothymine decamer 38 as a white solid. 
Retention time (analytic column 15 cm); gradient from 95% of H2O/TFA 0.1% to 100% of 
AcCN/TFA 0.1%) = 12.80 min. 
Maldi Tof MS: found m/z: 2816.09 [M] +, calculated for C117H150N42O42: 2855 [M+K] + 
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